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Abstract 
Invasive mould infections are global contributors to morbidity and mortality in 
immunocompromised patient populations. There are increasing reports of pathogenic 
fungi that confer both acquired and intrinsic resistance to current antifungal 
therapies. The development of novel antifungal agents is essential to broaden the 
therapeutic options for invasive fungal disease. A knowledge of the 
pharmacokinetics and the pharmacodynamics of a drug can facilitate an 
understanding of the optimal exposures required for efficacy. The relationship 
between dose-exposure and response can be defined from experimental data using 
PK-PD modelling. 
Experimental work was completed using static and dynamic in vitro cellular models 
of invasive fungal infections. Drugs were measured using high performance liquid 
chromatography and mass spectrometry. Fungal specific antigens were detected 
using enzyme-linked immunosorbent assays. PK and PD datasets were linked using 
a PK-PD nonparametric modelling program. 
Static studies demonstrated clear dose-response relationships for isavuconazole 
(ISA), voriconazole (VRC) and novel agent, F901318 against pathogenic fungi. 
Exposure-response relationships were defined for these agents in dynamic models. 
Mathematical models demonstrated satisfactory fits to each dataset. PD indexes 
associated with maximal antifungal effect, in terms of AUC:MIC were determined 
from model outputs for each agent against isolates of Aspergillus (ISA), S. 
apiospermum and F. solani (VRC and F901318). 
The treatment options available for invasive fungal infections are not ideal. Rising 
resistance to current antifungal therapies warrant a better understanding of the 
- 12 - 
 
optimal exposures that will treat an invasive disease effectively. This thesis describes 
the development and use of in vitro models of invasive fungal disease for the 
delineation of these key relationships. These analyses may provide decision support 
for clinicians when determining an effective dosing regimen in the clinic. The 
datasets generated may also provide information on dosages that may be suitable to 
take into Phase III clinical trial for novel agents. 
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CHAPTER I 
Introduction 
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1.1 INVASIVE FUNGAL INFECTIONS  
Invasive fungal infections (IFI) are an ever-present clinical concern for patients with 
a compromised immune system. Patients undergoing transplantation or receiving 
chemotherapy are most at risk of invasive disease (Galimberti, Torre et al. 2012). The 
most common IFI are caused by Candida spp. closely followed by Aspergillus spp. 
However, the widespread use of chemotherapy and immunosuppressive agents has 
seen an evolution in the spectrum of organisms that can cause invasive infection 
(Kontoyiannis and Lewis 2006). Species of Scedosporium and Fusarium have been 
increasingly recognised as emerging fungal pathogens. Invasive infections with these 
organisms are often associated with devastating clinical outcomes (Nucci 2003). Due 
to the increasing frequency of reported cases and their innate resistance to first-line 
agents, Scedosporium and Fusarium species now represent two of the most clinically 
important moulds contributing to 16% and 22% of non- Aspergillus mould infections 
worldwide, respectively (Figure 1.1) (Park, Pappas et al. 2011, Smith and Kauffman 
2012, Slavin, van Hal et al. 2015). 
Aspergillus
31%
Candida
45%
Other Moulds
15%
Cryptococcus
4%
Endemic fungi
3%
PCP
2%
Figure 1. 1 
The contribution of specific fungal pathogens to global invasive fungal infections. Data 
taken form Park et al. 2011 (Park, Pappas et al. 2011)  
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The discovery and development of novel antifungal drugs is essential to broaden 
the spectrum of therapeutic options available for the treatment of IFI. An 
understanding of how both new and existing antifungal regimens can be designed in 
order to treat organisms appropriately is central to combatting resistance. The 
pharmacokinetics (PK) of a drug can be described as what happens to an agent as it 
passes through the human body. The pharmacodynamics (PD) of a drug is how the 
agent exerts its desired effect within the human body. The target in the case of 
antimicrobial agents is a specific organism causing an infection. A knowledge of the 
relationship between the pharmacokinetics and pharmacodynamics (PK-PD) of a drug 
against specific organisms may facilitate our understanding of the optimal dose and 
subsequent exposure that will treat a disease effectively. This may, in turn, provide 
decision support when determining an effective therapeutic course. 
Aspergillus spp. are ubiquitous filamentous fungi commonly found in soil or in 
areas where decomposition is in progress such as compost heaps. Aspergillus is a 
thermotolerant organism and can therefore thrive in a broad range of environments, 
from tropical to polar conditions (Galimberti, Torre et al. 2012). The majority of 
human infections are caused by A. fumigatus, A. terreus, A. flavus and A. niger 
(Dimopoulos, Frantzeskaki et al. 2012). The rise in frequency of infection with 
Aspergillus spp. is closely correlated with the increased use of immunosuppressant 
therapy for the treatment of various conditions. Corticosteroids have been shown to be 
in use in around 30% of patients with Aspergillus infection, 63% of whom developed 
invasive disease (Perfect, Cox et al. 2001). The incidence and mortality of infection is 
relative to the degree of immunosuppression and the underlying illness. In patients 
with acute leukaemia, the incidence of invasive infection is around 13% with an 
attributable mortality rate (AMR) of around 12%.(Pagano, Caira et al. 2007). A multi-
- 16 - 
 
centre study of patients receiving haematopoietic stem cell transplants (HSCT) 
observed a frequency of infection with Aspergillus spp. in around 7-10% of patients. 
In this study mortality rates reached around 60% (Marr, Carter et al. 2002). In solid 
organ transplant patients, a similar mortality rate is observed with a slightly higher 
incidence of 11%-14% (Segal 2009). Consequently, Aspergillus species have become 
an increasingly recognised human pathogen in immunocompromised hosts and 
infections with this organism have become a recurring clinical complication in patients 
receiving immunosuppressive drugs.  
 
 
 
 
  
Underlying disease or 
characteristic 
No. (%) of 
patients 
(n=1209) 
Pulmonary disorder 477(40) 
Corticosteroid use 381(32) 
Neutropenia 61 (5) 
Haematopoietic stem cell 
transplant 
39 (3) 
Solid-organ transplant 100 (8) 
Cystic Fibrosis 127 (11) 
HIV infection 138 (11) 
Table 1. 1 
A summary of risk factors for Aspergillus infection. Data from 24 centres and 
1209 patients over a one year time period was obtained for the formations of the 
Aspergillosis Case Surveillance Form. (Perfect, Cox et al. 2001) 
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Scedosporium spp. and related organisms within the Scedosporium- 
Pseudallescheria species complex are ubiquitous filamentous moulds that can be 
found in temperate climates and areas of extensive pollution (Cortez, Roilides et al. 
2008). These organisms are often described as rare and emerging fungal pathogens as 
an increase in the frequency of infection has been observed over recent years.  S. 
apiospermum is the predominant species causative of human infections followed by 
S. prolificans (Lamaris, Chamilos et al. 2006, Heath, Slavin et al. 2009). Their 
emergence as a pathogenic species may be correlated with the increased use of 
antifungal prophylaxis (Park, Pappas et al. 2011, Auberger, Lass-Flörl et al. 2012). S. 
apiospermum has previously been described as the asexual reproductive form 
(anamorph) of P.boydii. More recently, these organisms have been reclassified as 
separate species although very closely related on both a morphological and molecular 
level  (Gilgado, Cano et al. 2008). Infections caused by these organisms are not 
transmitted between individuals (Campa-Thompson, West et al. 2014). Disease states 
may range from cutaneous and sub-cutaneous tissue infections to invasive, 
disseminated disease (Troke, Aguirrebengoa et al. 2008). Although disseminated 
infection has been reported in immunocompetent patients in the case of near drowning 
incidents, immunocompromised individuals are the predominant population at risk for 
developing invasive scedosporiosis (Smith and Kauffman 2012).  
Fusarium spp. are important plant pathogens that grow on a wide range of 
substrates including soil, plant debris and in water. These ubiquitous saprophytes are 
able to persist in water reservoirs in the form of water-structure biofilms. Fusarium 
species are recognised as a significant contributor to water-borne infections in hospital 
patients (Nucci and Anaissie 2007). Hyaline hyphae are formed in tissue and as for 
Scedosporium spp. can often be mistaken for those formed by Aspergillus spp. 
- 18 - 
 
(Esnakula, Summers et al. 2013). Human infection with Fusarium spp. can present as 
a range of clinical manifestations from superficial to locally invasive and disseminated 
infection. A review of the literature of 300 cases of Fusarium infection revealed that 
approximately 12 species of Fusarium spp. are associated with human infection. F. 
solani is the most common human pathogen accounting for approximately 50% of 
cases, followed by F. oxysporum which is responsible for approximately 20% of cases 
overall and almost all cases of fusarial onchomycosis. F. verticilloidis and F. 
moniliforme accounted for approximately 10% of cases individually. In a multicentre 
review of patients with haematological malignancy and invasive fusariosis, 83% of 
patients were persistently neutropenic and around 39% had undergone a 
haematopoietic stem cell transplant (HCST). Mortality rates of up to 80% have been 
observed in these groups of patients. Prolonged neutropenia and the use of high dose 
corticosteroids were predictive of poor outcome (Nucci, Anaissie et al. 2003). These 
findings were confirmed in a second multi-centre investigation in HSCT recipients 
with fusariosis. In this study persistent neutropenia was also observed to be the single 
prognostic factor relating to death (Nucci, Marr et al. 2004) 
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1.11 Pathophysiology 
The pathophysiology of invasive mould disease is similar for Aspergillus, 
Scedosporium and Fusarium species. 
The development of an invasive infection is dependent on the underlying state 
of the host immune system (Table 1.1). The production of pro-inflammatory cytokines 
and phagocytosis of conidia by alveolar macrophages is a first-line defence for the 
clearance of inhaled conidia (Segal 2009). The subsequent prevention of conidial 
germination and hyphal damage via neutrophilic aggregation and the formation of 
NADPH oxidase are principal clearing mechanisms in place for invading pathogenic 
fungi (Dagenais and Keller 2009). In the presence of steroids such as in chemotherapy 
patient populations, the secretion of inflammatory mediators is diminished 
(Alekseeva, Huet et al. 2009, Bellanger, Millon et al. 2009).  
In the absence of these key pulmonary defence mechanisms microscopic 
fungal spores may be inhaled into the lung which can then colonise to cause a primary 
infection (Figure 1.2 A). With minimal clearance by the host immune system, the 
conidia swell and begin to germinate into hyphae (Kwon-Chung and Sugui 2013). The 
process of angioinvasion by the hyphae then begins (Kousha, Tadi et al. 2011), 
eventually leading to dissemination of the fungi and fungaemia (Denning 1991) 
(Figure 1.2 B). 
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A 
B  
 
 
 
  
 Figure 1. 2 
 (A) Pathophysiology of a primary fungal lung infection and (B) 
Pathophysiology of an invasive and disseminated infection fungal infection. 
Taken from Dagenais et al. (2009) and Richardson et al. (2009). 
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Specific virulence factors involved in the pathophysiology of S. apiospermum 
and F. solani infections have not been extensively studied. Several factors have been 
well characterised for Aspergillus species which may contribute towards an overall 
understanding of how a primary infection is contracted and how this may develop into 
an invasive and disseminated disease. 
Sialic acid residues are present on the surface of the conidia of several 
pathogenic species of Aspergillus  and are particularly abundant on those produced by 
A. fumigatus (Wasylnka, Simmer et al. 2001). These residues may facilitate the 
binding of conidia to the basal lamina of the alveolar epithelium and may play a role 
in the establishment of primary lung disease. Conidia then produce toxins that can 
inhibit the mucociliary clearance mechanism. This may inhibit the  expulsion of  
pathogens from the lung and facilitate the entry of additional conidia into the lower 
airways (Margalit and Kavanagh 2015). 
The production of reactive oxygen species (ROS) by the alveolar macrophages 
is an important antimicrobial defence against respiratory pathogens (Jahn, Koch et al. 
1997).  Dihydroxynaphthalene (DHN)-melanin is a pigment present in the cell walls 
of Aspergillus species. This pigment has a protective role against ultra-violet light, 
enzymatic lysis and oxidation, including that induced by ROS (Chotirmall, Mirkovic 
et al. 2014). More recently, DHN-melanin has demonstrated the ability to inhibit the 
acidification of Aspergillus containing phagolysomes post engulfment by the alveolar 
macrophages (Thywiben et al. 2011).  Superoxide dismutase enzymes (SOD), 
responsible for the detoxification of superoxide, have been implicated as  virulence 
factors for several pathogenic fungi including A. fumigatus, Candida  spp. and some 
species of Cryptococcus (Fréalle, Noël et al. 2005). Lima et al. (2007) investigated 
production of SOD by the hyphae of S. apiospermum and it was suggested that the 
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production of SOD may play a protective, immuno-evasive role in the 
pathophysiology of S. apiospermum infection (Lima, Larcher et al. 2007).  
In order for the hyphae of Aspergillus spp. to invade through the surrounding 
blood vessels the organism secretes a range of proteolytic enzymes for the destruction 
of host tissue and nutrient acquisition (Hohl and Feldmesser 2007). Elastin is an 
important component of the lung tissue. Clinical isolates from patients with invasive 
disease have demonstrated increased elastase activity in comparison to environmental 
isolates, suggesting a key role for elastase in the pathogenicity of invasion (Blanco, 
Hontecillas et al. 2002)  Silva et al. investigated peptidase release for isolates of P. 
boydii and S. apiospermum. This investigation established that peptidase enzymes 
were extracellularly released by the mycelium of these fungi. IgM and IgG are 
involved in the activation of complement cascades and play a significant role in the 
host antimicrobial response (Horton and Vidarsson 2013). Lima et al. demonstrated 
that metallopeptidase enzymes extracted from P. boydii were able to cleave the IgG 
molecules in vitro and may contribute towards the pathogenesis of invasion. 
Fibronectin is implicated in the activation of alveolar macrophages and monocytes 
(Lackner and Guarro 2013). Laminin represents a key component of the basement 
membranes of the lung. The release of metallopeptidases by P. boydii was 
demonstrated to be associated with the break-down of these proteins. This may allow 
the fungi to suppress the activation of macrophages by fibronectin and may also 
contribute towards angioinvasion of P. boydii. 
The virulence factors associated with the pathogenesis of Fusarium spp. in 
humans are understudied. Fusarium species inherently produce mycotoxins such as 
the trichothecenes. These compounds have been demonstrated to decrease the 
proliferation and production of both lymphocytes and macrophages. They also inhibit 
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neutrophilic aggregation. This suppression of humoral and cellular immunity may play 
a key role in the pathophysiology of invasive disease (Nelson, Dignani et al. 1994).  
 
1.12 Diagnosis 
1.121 Imaging 
The use of computed tomography (CT) is amongst the most conventional 
forms of diagnoses for invasive mould disease. The earliest radiological manifestation 
is a nodule however in the case of an aspergilloma the fungal mass may be separated 
from the wall of the lung producing a crescent- shaped airspace known as the “air 
crescent sign” (Franquet, Muller et al. 2001, Smith and Kauffman 2012). The mass 
usually moves around within the lung as the patient changes position known as the 
“Monod sign”. Invasive disease may present on a CT scan as a “halo” sign (HS) that 
can be seen as an opaque area surrounded by a halo, ground-glass like attenuation 
which represents an area of alveolar haemorrhage. The frequency of observation very 
much depends on the immune status of the individual and the progression of the 
disease. This is a good indication of IFI in at risk patient populations and is thought to 
be present in around 50-90% of cases. However, lower frequencies of HS can be 
observed in the later stages of disease (Georgiadou, Sipsas et al. 2011). Imaging is not 
species specific and similar signs may be observed in patients infected with a range of 
respiratory pathogens. This may result in a delay in diagnosis. Therefore, alongside 
imaging other diagnostic techniques must be used to determine the disease- causing 
pathogen (Morrissey, Chen et al. 2013). 
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1.122 Microbiology and histopathology 
The culture and identification of sputum, bronchoalveolar lavage (BAL) and 
serum samples are traditional methods of diagnosis for invasive aspergillosis. Samples 
are cultured in a suitable medium such as Sabouraud dextrose medium (SAB) and are 
then identified by microscopy.  Microscopic examination allows for the identification 
of a specific pathogen, an advantage over imaging alone.  
Microscopic visualisation of fungi in a sample may also be used to confirm the 
presence of an infection where there is uncertainty of the results obtained from other 
tests. Direct microscopic examination is time-efficient and results can be obtained in 
1-2 hours (Schelenz, Barnes et al. 2015). The morphological characteristics and 
microscopic markers of IFI are similar between clinically important moulds (Table 
1.2). The patient may also be infected with more than one pathogen. Training and 
expertise for medical mycologists is essential for the determination of organism and 
species. It is therefore suggested that microscopy is used in parallel to other diagnostic 
tests to obtain a definitive diagnosis (McClenny 2005). As Aspergillus species are 
ubiquitous in nature they can often contaminate specimens and culture medium which 
may produce false-positive results. The sensitivity of culture and microscopic 
identification is increased in patients with an advanced disease. However this may be 
hampered if only a small sample is obtained from the patient. This can be improved 
by repeat sampling however is often difficult in critically ill patients (Hayes and 
Denning 2013).  
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Organism(s) Microscopic markers 
Hyphae Other features 
A. fumigatus 2.5-8 µm wide, septate, 
hyaline, acute angle 
branching, tree or fan-like 
branching. Stipes may 
resemble those of 
zygomycetes. 
Conidial head uniseriate, 
columnar, conidia in chains 
or detached and dispersed. 
Single or paired conidia may 
resemble yeast cells 
A. niger See A. fumigatus Conidial head biseriate, 
radiate, conidia in chains or 
detached and dispersed. 
Single or paired conidia may 
resemble yeast cells 
A. terreus See A. fumigatus Small, round, hyaline conidia 
(‘accessory’ conidia) 
attached to the vegetative 
hyphae 
Accremonium, 
Fusarium, 
Paecilomyces spp. 
See A. fumigatus Phialides and phialoconidia, 
specific to the genus, may be 
found in closed tissue 
Scedosporium 
apiospermum 
See A. fumigatus Typical annelloconidia and 
annellides may be found in 
closed tissue 
Zygomycetes 10–30 µm wide, aseptate, 
non-radiating, 90° angle 
branching. Folds in hyphae 
may simulate septae 
N/A 
Dermateaceous 
moulds 
Hyphae with brown 
pigmentation; walls often not 
parallel; may appear 
moniliform (like a ‘string of 
beads’) 
Brown pigment seen in KOH 
exam with brightfield 
illumination; stained with 
Fontana—Masson and often 
with Hematoxylin and Eosin 
Table 1. 2  
Microscopic markers of clinically relevant pathogenic mould species (McClenny 
2005) 
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Histopathological staining of biopsy samples may also be used in order to 
diagnose an IFI. A panel of stains may be used in order to both identify and exclude 
the presence of specific organisms. The Grocott methenamine silver (GMS) stain or 
Periodic Acid Schiff (PAS) are used for the assessment of fungi and are recommended 
in patients with a suspected fungal infection (Schelenz, Barnes et al. 2015). Both 
Scedosporium and Fusarium species demonstrate the ability to sporulate in tissue 
(adventitial sporulation), which may be a key indicator of scedosporiosis or fusariosis 
in biopsy samples or blood cultures. Fusarium species may be identified by the 
presence of characteristic ‘banana-shaped’ macroconidia. However, these structures 
may often be confused with yeasts (Lackner and Guarro 2013). Although 
histopathology is a useful tool in the determination of invasive infection, it may be 
difficult to determine the presence of a specific fungal pathogen due to the 
morphological similarities in septated fungi (Thornton, Johnson et al. 2012). 
Obtaining a biopsy sample for histopathological analysis may also be complicated and 
in some cases fatal for patients who are critically ill. 
  
Figure 1. 3 
Histological images of tissue infected with A) S. apiospermum and B) F. solani. Arrows 
highlight the septated, branching hyphae associated with invasion. Adapted from A) 
Agatha et al. (2014) and B) Galimberti et al. (2012). 
. 
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1.123 Serological and molecular testing 
The development of molecular based techniques and serological assays for the 
diagnosis of IFI has been a major advancement. Molecular based diagnostics such as 
PCR or a galactomannan assay may be performed on bronchoalveolar lavage fluid 
(BAL) and blood samples. The diagnostic strategy associated with a molecular 
platform is detailed in Figure 1.3.  
The detection of circulatory biomarkers that are indicative of disease has been 
particularly useful in the diagnosis of aspergillosis (Verdaguer, Walsh et al. 2006, 
Galimberti, Torre et al. 2012). Galactomannan is an exo-antigen that is a key 
component of the fungal cell wall. It is released by Aspergillus species during cell 
growth and has been demonstrated to be a relatively specific biomarker for 
aspergillosis. The double sandwich enzyme immunoassay (ELISA) for the detection 
of galactomannan has been clinically available in Europe and the USA for over a 
decade. This assay now provides the gold standard for the diagnosis of aspergillosis 
and may also be indicative of disease progression. The Platelia Aspergillus kit 
marketed by Bio-Rad laboratories utilises a galacatofuranose- specific rat 
monocolonal antibody in order to detect galactomannan at varying concentrations in 
blood and BAL cultures. A cut off absorbance value (450nm) of 1.5 was originally 
recommended by the manufacturer for the classification of a positive result. However 
further research has demonstrated the reduction of this to the FDA approved value of 
0.5 significantly boosts the assay sensitivity to 97.4%. It is important to note that in 
this study an increase in sensitivity was at the expense of specificity which was 
reduced from 97.5% to 90.4% (Maertens, Klont et al. 2007). The accuracy of the 
galactomannan assay is very much dependent on disease progression and has a rate of 
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misdiagnosis in itself. A recent multicentre study of European ICU patients observed 
an 87% accurate diagnosis in patients with definitive invasive aspergillosis compared 
to a positive galactomannan culture seen in only 18% of patients in the early stages of 
disease (Taccone, Van den Abeele et al. 2015). Although galactomannan has been 
clinically validated as a relatively accurate biomarker of both early and late-stage 
aspergillosis (Marr, Balajee et al. 2004), there are limitations to its use in 
pharmacodynamic studies. Firstly, the assay read-outs demonstrate a relatively limited 
dynamic range. False negative results have also been reported. These may be due to 
the requirement of a heat pre-treatment step that denatures potential reactive serum 
proteins however may also denature protein-bound galactofuranose antigens (Verweij 
and Mennink-Kersten 2006). Studies have also suggested that prior exposure to 
antifungals may reduce the sensitivity of the Platelia Aspergillus assay (Marr, 
Laverdiere et al. 2005). This has a direct implication on the diagnosis of patients 
receiving prophylactic antifungal therapy using this assay. 
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Figure 1. 4 
Diagnostic strategy using molecular based techniques as the primary diagnostic 
platform . Figure taken from Morrissey et al. (2013) 
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More recently, Thornton et al. have described the generation of an Aspergillus-
specific monoclonal antibody (JF5). This has been incorporated into a point-of-care 
diagnostic immuno-chromatographic lateral flow device for the detection of 
circulating antigens released by Aspergillus spp. (Thornton 2008). The use of this 
device has been validated in patient sera and BAL samples (Thornton, Johnson et al. 
2012). Studies suggest that antigens bound by JF5 may be used as a surrogate marker 
for the diagnosis of invasive aspergillosis (Thornton 2008) (Figure 1.4). 
 
 
 
Figure 1. 5 
Control lines and test lines from patient serum and BAL samples using the lateral 
flow device produced by Thornton et al. Figure taken from Thornton et al. (2008)  
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Scedosporium and Fusarium spp. are galactomannan negative therefore no 
serological assays for their detection are clinically available. Recently Thornton et al. 
have utilised in-house developed immunoglobulin (IgM) and IgG1 k-light chain 
monoclonal antibodies (MAbs) in a double antibody sandwich enzyme-linked 
immunosorbent assay (DAS-ELISA) in order to detect P. boydii and its related 
species. The MAbs are specific to P. boydii and S. apiospermum and do not react with 
S. prolificans, A. fumigatus and many other clinically relevant pathogenic fungi 
(Thornton 2009). Similarly, a single antibody ELISA utilising mouse-derived 
monoclonal antibodies is also under development for the detection of Fusarium 
species. ED-7 is an IgM specific monoclonal antibody and binds to an extracellular 
200kDa heat stable glycoprotein antigen specific for Fusarium spp. The detection of 
ED-7 in both hospital and sink biofilms has allowed for the tracking of environmental 
isolates of Fusarium species (Thornton and Wills 2015, Al-Maqtoofi and Thornton 
2016). Despite the relatively limited dynamic ranges these assays currently provide, 
the detection of these antigens in a clinical setting may provide a potential platform 
for the molecular diagnosis of infection with S. apiospermum and Fusarium species.  
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1.13 Clinical Presentation 
Relatively few specific clinical symptoms are typically seen in the early stages 
of pulmonary aspergillosis (Taccone, Van den Abeele et al. 2015). Fever, cough, 
sputum production and dyspnoea are common symptoms however these are 
nonspecific (Soubani and Chandrasekar 2002). Upon vascular invasion patients may 
present with significant pleuritic chest pain due to the development of pulmonary 
infarcts. In late stage disseminated disease the nervous system may be implicated, 
manifesting with seizures, focal neurological signs, cerebral infarctions and 
intracranial haemorrhage (Denning 1998). Deterioration may occur extremely rapidly. 
The clinical spectrum in immunocompetent hosts spans keratitis, endopthalmitis, 
sinusitis, soft tissue infections and lung infection. CNS involvement in healthy 
individuals is generally a result of an invasive and disseminated sinus or lung 
infection. In immunosuppressed hosts the spectrum of infection is similar, however 
invasive and disseminated disease may affect several organs (Tortorano, Richardson 
et al. 2014). The clinical presentation of invasive scedosporiosis is generally non-
specific and similar to that of aspergillosis. Disseminated S. apiospermum infection 
often involves the central nervous system and the brain is also a common primary site 
of infection (Castiglioni, Sutton et al. 2002). Symptoms of CNS involvement can 
include headaches, incontinence, drowsiness and vomiting (Park, Pappas et al. 2011). 
The clinical manifestation of invasive infection with Fusarium spp. is very similar to 
that of invasive aspergillosis and scedosporiosis and is often non symptomatic. 
Invasive infection can present as skin, lung or sinus lesions. As with Aspergillus spp., 
patients with a lung infection may present with a cough, fever and pleuritic chest pain 
(Marom, Holmes et al. 2008, Tortorano, Richardson et al. 2014).   
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1.2 ANTIFUNGAL AGENTS FOR THE TREATMENT OF INVASIVE 
FUNGAL INFECTIONS  
The treatment of IFI may be challenging for several reasons. The continuous 
emergence of resistant strains of pathogenic fungi represents a major clinical issue 
when determining an effective treatment regimen. Contributing to this, many isolates 
of Fusarium and Scedosporium may demonstrate innate resistance to clinically used 
antifungals (Nucci and Anaissie 2007, Cuenca-Estrella, Alastruey-Izquierdo et al. 
2008). The patient populations these infections most commonly affect often have 
underlying conditions and may already be taking a significant amount of medication 
including antifungal prophylaxis. This may reduce the safe therapeutic options 
available to patients due to altered pharmacokinetic profiles in these populations and 
potential drug interactions. As discussed, the species- specific diagnosis of invasive 
mould infections may be a lengthy process. Empirical decisions on therapy may have 
been made during this time, driving resistance and limiting the effective therapeutic 
options available for the patient. 
The use of higher dosages or combination therapy for the treatment of invasive 
fungal infections represent alternative therapeutic options for patients (Cuenca-
Estrella, Alastruey-Izquierdo et al. 2008). Importantly, the development of novel 
antifungal agents will allow for a greater diversity in treatment options. There are four 
main classes of drugs currently available for the treatment of IFI. These include the 
echinocandins, the triazoles, polyene classes of agents and flucytosine (Figure 1.7). 
More recently, the discovery of novel classes such as the orotomides may broaden the 
spectrum of antifungals for the treatment of IFI.  
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1.21 Pharmacokinetics and Pharmacodynamics (PK-PD) of Antifungal Agents  
 Pharmacokinetics and pharmacodynamics (PK-PD) data for antifungal agents 
can provide a valuable insight into the optimal exposures of drug associated with 
antifungal activity against an organism. 
1.211 The assessment of antifungal resistance and determination of susceptibility 
breakpoints 
With the diversity of pathogenic mould species increasing, it is necessary for 
clinicians to have a knowledge of how effective an antifungal agent may be against a 
specific organism. The epidemiological cut off value (ECOFF) for an organism 
defines the concentration at which a drug is no longer effective against a population 
of isolates. They are derived from large epidemiological studies wherein extensive 
determination of the minimum inhibitory concentrations (MIC) against large numbers 
of strains is conducted in order to delineate concentrations at which strains have a high 
probability of resistance (Howard, Lass-Flörl et al. 2013). ECOFF values may then be 
used alongside PK-PD data obtained from several preclinical and clinical studies in 
order to define the clinical susceptibility breakpoint for an agent. Clinical 
susceptibility breakpoints are used to differentiate concentrations at which an agent 
may demonstrate therapeutic success (susceptible strains) from those where treatment 
failure is likely (resistant strains) (Martinez, Coque et al. 2015). The use of 
standardised methodologies for MIC testing and the determination of both ECOFF and 
clinical breakpoints has proven invaluable to clinicians worldwide (Espinel-Ingroff, 
Chowdhary et al. 2013). When an antimicrobial agent has been in use for an extended 
period of time breakpoints are often revised in order to compensate for the emergence 
and evolution of resistant strains. Large surveillance studies are key to the revision of 
breakpoints for various antifungal agents as they allow for the identification of trends 
- 35 - 
 
in pathogen incidence and resistance profiling (Masterton 2008). Active since 1997, 
the SENTRY Antimicrobial Surveillance Program is one of the largest programs to 
date. SENTRY provides comprehensive information on the frequency of pathogen 
emergence and their susceptibilities to antifungal agents that is central to the 
establishment of susceptibility breakpoints for antimicrobial agents (Pfaller, Messer et 
al. 2013).  
 The relationship between the concentration-time profile for an agent and its 
clinical efficacy is key for the revision and setting of clinical susceptibility 
breakpoints. This can be termed the exposure-response relationship between an 
organism and a drug. The exposure- response relationships of an agent and the MIC 
are often linked together to derive indices that best correlate to clinical efficacy. These 
are termed PK-PD indices as they incorporate both the pharmacokinetics of an agents 
and its pharmacodynamics against an organism. For many agents the clinical outcome 
is well correlated with the ratio between the area under the concentration time curve 
(AUC) and the MIC of the organism (AUC:MIC). For other agents outcome may be 
better related to the proportion of a dosing interval that the concentration of drug 
exceeds the MIC (%T>MIC) or the maximal concentration of drug reached (Cmax) over 
the MIC (Cmax:MIC) (Mouton, Brown et al. 2012). The determination of these 
parameters requires analysis of the antimicrobial kill kinetics and is largely dependent 
on whether an agent exhibits concentration or time-dependent killing (Tam and 
Nikolaou 2011).   
A prior knowledge of the pharmacokinetics and pharmacodynamics of a drug 
may mean that no more information than the MIC is needed in order to determine an 
appropriate dosage. However, many find that the interpretation of PK-PD data via 
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clinical breakpoints is extremely useful when determining if a treatment regimen will 
be successful (Turnidge and Paterson 2007).  
1.212 Current models for the analysis of antifungal PK-PD  
In vivo 
Several in vivo models of invasive aspergillosis have been developed and 
utilised for the delineation of exposure-response relationships. Murine models of 
fungaemia using a tail-vein route of infection have been used to define the efficacy of 
posaconazole, fluconazole, itraconazole, (Gonzalez, Tijerina et al. 2003),  AmB 
formulations (Capilla, Mayayo et al. 2004) and voriconazole (Capilla, Serena et al. 
2003) against isolates of P. boydii and S. apiospermum. 
Inhalational murine models of invasive aspergillosis have been used to define 
the PK-PD of several antifungal agents against isolates of Aspergillus spp. (Mavridou, 
Bruggemann et al. 2010, Lepak, Marchillo et al. 2013, Seyedmousavi, Mouton et al. 
2014).  Similar to humans, invasive and disseminated infections cannot be established 
in the presence of a competent immune system. The use of immunosuppressive agents 
may increase the complexity of a model however plays an essential role in the 
establishment of a suitable pulmonary infection. Severe and persistent neutropenia is 
most commonly achieved using a combination of cyclophosphamide and 
corticosteroids in order to mimic the immune status of an individual at risk of infection 
(Paulussen, Boulet et al. 2014).   
A limitation of these murine models is the differences in expression of key 
drug metabolising enzymes between mice and humans such as those implicated in the 
cytochrome P450 pathway (Muruganandan and Sinal 2008). For antifungal agents 
cleared via these pathways it may be difficult to obtain accurate pharmacokinetic data. 
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This is particularly apparent in the case of triazole agents voriconazole and 
isavuconazole where the clear differences in clearance can be seen between mice and 
humans (Warn, Sharp et al. 2006, Goddard, Stevens et al. 2010, Calvo, Pastor et al. 
2012, Lepak, Marchillo et al. 2013, Seyedmousavi, Bruggemann et al. 2015). Mice 
also exhibit significantly different levels of plasma esterase enzymes to humans which 
may present challenges in the development of models of agents that are administered 
as prodrugs, such as isavuconazonium sulphate, the prodrug of isavuconazole (Bahar, 
Ohura et al. 2012). Mouse models are generally cost effective as the use of a lower 
order species requires less technical expertise. Murine studies are also high throughput 
however are terminal and numerous samples cannot be taken. 
Rabbit models of invasive aspergillosis are also well validated for the study of 
PK-PD. Similar to murine studies these models generally induce immunosuppression 
for the establishment of disease. This may differ depending on whether a neutropenic 
or a non-neutropenic model is preferred. A neutropenic model is associated with a 
more severe infection that may be due to the ability of the hyphae to elongate and 
invade more efficiently in the absence of neutrophils (Petraitiene, Petraitis et al. 2015). 
Non neutropenic studies are less severe and may be used for the analysis of an early-
stage infection. The route of infection is usually by endotracheal instillation of conidia 
(Felton, Baxter et al. 2010, Al-Nakeeb, Petraitis et al. 2015, Petraitiene, Petraitis et al. 
2015). These models have defined the PK-PD relationships for several antifungals 
including amphotericin B formulations (Al-Nakeeb, Petraitis et al. 2015), micafungin 
(Petraitis, Petraitiene et al. 2002) and the triazole agents. A non-linear 
pharmacokinetic profile for voriconazole is also seen in the rabbit model. As in mice, 
this is thought to be due to saturation of the cytochrome P450 enzymes used for 
metabolism (Roffey, Cole et al. 2003).  
- 38 - 
 
The guinea pig may be a more reliable model for the determination of PK-PD 
for such agents against Aspergillus spp. and has been validated (Roffey, Cole et al. 
2003). However this model is not widely available and is costly. 
Current models of infection for invasive infection with P. boydii and S. 
apiospermum are mainly murine and use a tail-vein route of infection. For a significant 
infection to be established severe and persistent neutropenia is essential. A guinea pig 
model has previously been used to investigate the PK-PD of voriconazole in vivo, 
although this model is not widely available (Capilla and Guarro 2004). 
Models of fusariosis have been utilised in order to evaluate the use of PCR 
versus colony forming unit (CFU) measurement as an estimate of fungal burden 
(González, Márquez et al. 2013). A neutropenic model has also been used to compare 
the efficacy of AmB and caspofungin in the prophylaxis and treatment of invasive 
fusariosis with F. solani (Spellberg, Schwartz et al. 2006). A similar model evaluated 
the efficacy of pentamidine as a potential prophylactic and therapeutic agent for the 
treatment of F. oxysporum infection (Lionakis, Chamilos et al. 2006). 
In vitro 
There are several in vitro models of infection used in the determination of 
exposure response relationships for antimicrobial agents. These may be static or 
dynamic in nature. A time-kill static methodology is often used in the early evaluation 
of antibacterial pharmacodynamics. This is consists of a timed incubation of the 
organism in the presence of a concentration of an agent. Samples are taken at various 
time-points in order to distinguish the kill kinetics of the agent. For the assessment of 
antifungal agents against mould species, this methodology is less commonly used. In 
the case of an invasive pulmonary infection, hyphae are the morphological structures 
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present. As conidia are usually absent in infected tissue, it is important that the 
antifungal efficacy is determined against actively growing hyphae as opposed to 
conidia (Krishnan, Manavathu et al. 2005). In vitro models of invasive aspergillosis 
using cellular bilayers as a model of the human alveolus have defined the PK-PD 
relationships of voriconazole (Al-Saigh, Elefanti et al. 2012, Jeans, Howard et al. 
2012, Jeans, Howard et al. 2012), itraconazole (Al-Nakeeb, Sudan et al. 2012) and 
posaconazole (Howard, Lestner et al. 2011) against isolates of A. fumigatus. Cellular 
bilayers consisting of airway epithelial cells on the top layer and human pulmonary 
endothelial cells on the bottom layer are inoculated with Aspergillus conidia which 
may then germinate into hyphae. The hyphae then begin to invade through the cellular 
bilayer to simulate the invasion of the pulmonary artery seen in humans. Upon 
exposure to varying concentrations of drug in a static environment, the concentration 
at which maximal antifungal efficacy is achieved can be determined. 
The use of kinetic models of infection can allow for the simulation of 
pharmacokinetic profiles that are representative of human clearances and exposures of 
drug, whilst determining the antimicrobial effect over the time course. The use of 
hollow-fibre infection models (HFIM) to examine the PK-PD relationships of 
antibacterial agents has been well validated. The models typically comprise of two 
parallel circuits. A central reservoir is ‘dosed’ with the antibacterial agent. Drug 
containing media is then pumped out into a waste reservoir and is replaced with fresh 
media at a rate proportional to the relevant clearance seen in humans. Simultaneously, 
the drug containing media is circulated through a hollow fibre cartridge containing the 
bacteria of interest. The cartridge consists of thousands of tubular filters. Pores on the 
fibres allows for the free diffusion of drugs whilst retaining the bacteria in the cartridge 
to prevent bacterial elimination (Gloede, Scheerans et al. 2010). These models have 
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been central to the determination of key PD indices for several antibacterial agents and 
have informed the dosage selection for both preclinical animal studies and clinical 
trials (Gloede, Scheerans et al. 2010, Felton, Goodwin et al. 2013, Docobo-Perez, 
Drusano et al. 2015). 
As with a time-kill methodology the applicability of these models to represent 
an invasive mould infection is questionable. Jeans et al. further developed the static 
cellular model of invasive aspergillosis for use in a kinetic model using a similar 
circuitry to that of the HFIM.  In replacement of the hollow fibre cartridge was the 
cellular bilayer model described earlier, housed in a custom made bioreactor that 
allowed for the continuous flow of media and the direct exposure of fungal hyphae to 
drug. This model has been particularly useful in the assessment of the efficacy of 
voriconazole at current dosages in the treatment of triazole resistant Aspergillus 
isolates. As voriconazole demonstrates nonlinear PK and a rapid clearance in mice this 
model allowed for exposures seen in the clinical to be achieved and was able to define 
accurate pharmacodynamic target exposures that may be best associated with 
antifungal efficacy against isolates with an elevated MIC (Jeans, Howard et al. 2012).  
1.214 Mathematical modelling for the bridging of in vitro PK-PD data to humans 
The use of pharmacokinetic and pharmacodynamic modelling and simulation 
in order to extrapolate experimental findings to human populations has the potential 
to revolutionise the drug development process and may be a step towards the 
individualisation of antimicrobial therapy. The establishment of an in vitro- in vivo 
correlation is essential for the translation of experimental data into a clinical setting.  
Pmetrics, short for pharmacometrics, is a library package for R developed for 
the non- parametric and parametric modelling of PK-PD datasets. This software can 
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be used in order to establish a link between PK and PD datasets to explore the 
relationship between dose- exposure and the resultant pharmacodynamic effect 
(Neely, van Guilder et al. 2012). The model can allow for the prediction of key 
pharmacokinetic parameters and the elucidation of target PD indices that would 
otherwise be unobtainable from raw datasets (Kovanda, Petraitiene et al. 2016). Once 
the PK-PD model has been assessed and validated, the predicted data may then be 
used in further PK-PD simulations in order to explore the clinical implications of the 
experimental findings (Felton, Goodwin et al. 2013). Monte- Carlo simulation utilises 
large clinical pharmacokinetic datasets that are either obtained from patient 
populations and/ or clinical studies in order to construct a population model. Individual 
exposures of drug using a defined dosing regimen can then be predicted from datasets 
obtained either clinically or experimentally for the determination of response to 
therapy (Neely, Margol et al. 2015, Huurneman, Neely et al. 2016, Rhodes, Kuti et al. 
2016).  Key limitations in in vitro datasets such as differences in protein binding may 
be accounted for and incorporated into the model design using this methodology. In 
the bridging of in vitro data obtained from infection models to human populations  the 
pharmacokinetic parameter values and variance for each “individual” obtained from 
PK-PD models may be used in simulations in order to determine what proportion of 
patients in a population are likely achieve the PD target recommended by the 
experimental data when given a dose of drug (Jeans, Howard et al. 2012). It is 
therefore possible to elucidate whether clinical success is likely to be achieved using 
a certain dosing regimen or if a dosage adjustment is necessary. This approach has 
been used to predict the likelihood of PD target attainment for several agents on the 
basis of preclinical in vivo and in vitro data.  Jeans et al. successfully defined target 
AUC:MIC values for the treatment of azole- resistant aspergillosis. When placed in a 
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clinical context via Monte- Carlo simulation it was clear that target exposures could 
not be achieved using current dosing recommendations and that a dosage escalation 
would be necessary for the treatment of resistant isolates (Jeans, Howard et al. 2012). 
Using a similar methodology, Felton et al. examined the impact of bolus dosing versus 
extended infusion of piperacillin/ tazobactam on the emergence of resistance in a 
model of Pseudomonas aeruginosa. In this case, it was concluded that bolus doses of 
drug were equivalent in both antibacterial effect and in suppressing the emergence of 
resistance (Felton, Goodwin et al. 2013).  
 
 
1.213 The use of PK-PD analyses in drug development 
The interest of large pharmaceutical companies in the discovery and 
development of novel antifungal agents has diminished in the past years. This is 
largely due to a lack of financial incentive and the challenges associated with 
demonstrating efficacy and safety. Clinical trials for novel antimicrobial agents are 
notoriously difficult as patient populations are refined to those who have exhausted 
alternative therapies. There is also a high risk in the use of an experimental agent in 
at-risk patient populations due to underlying illness and the complex physiological 
state of the patient.  In this case, the analysis of data may be complicated and prevent 
the determination of an endpoint to describe success or failure. These trials may 
therefore fail due to lack of evidence to prove the safety and efficacy of the agent. This 
may lead to late- stage withdrawal of a candidate drug. Regulatory bodies are then 
presented with the question of whether to withdraw a drug from the market based on 
a failed trial, the consequences of which for patients with no alternative options may 
be fatal. These reasons collectively present an unfeasible development pathway for the 
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development of novel antimicrobial agents and owe to the lack of interest in the 
antimicrobial field from the pharma industry (Rex, Eisenstein et al. 2013).  More 
recently, it has been suggested that, if necessary, regulatory approval should exist in 
stages. Termed “adaptive licensing”, clinical access to agents may be granted earlier 
on in development for orphan diseases based on a portfolio of smaller studies and 
clinical trials. This evidence based approach would allow access to the agent under 
restricted circumstances as more evidence to further its development accumulates. It 
is thought that lowering the barriers associated with the development of novel agents 
and using a benefit-risk approach to approval may increase financial incentive and 
allow for the progression of candidate drugs that would otherwise be terminated 
(Woodcock 2012). 
The use of PK-PD analysis has now been incorporated into the drug 
development pipeline for agents focussed upon the treatment of orphan diseases. It has 
been recognised that in the setting of an unmet medical need where it is essential that 
novel agents be introduced into the clinic more rapidly, a framework of one Phase III 
study and several smaller studies may be sufficient in order to grant an agent orphan 
drug status by the Food and Drug Administration (FDA). PK-PD analysis forms the 
basis of these smaller studies and allows for the definition of an appropriate dosage 
that has been demonstrated as safe (Phase I studies) and effective to be taken into 
Phase III studies. It is suggested that the late-stage failure of antimicrobial agents is 
uncommon when the clinical dosages are guided by PK-PD analysis (Rex, Eisenstein 
et al. 2013) (Figure 1.7). 
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Figure 1. 6 
The use of PK-PD studies in the drug development process. The balance between 
quantity of clinical efficacy data and unmet medical need. Taken from Rex et al. 
2013. 
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1.22 Amphotericin B (AmB) 
Formerly, amphotericin B deoxycholate (DAmB) has been standard antifungal therapy 
for the treatment of many invasive fungal infections. AmB binds directly and 
irreversibly to ergosterol, a key component of the fungal cell membrane. This results 
in the disruption of the cell membrane and ultimately, cell death (Gray, Palacios et al. 
2012). AmB demonstrates activity against an extensive range of fungal pathogens 
including Aspergillus, Candida, Scedosporium, Fusarium spp. and several of the 
zygomycetes (Gomez-Lopez, Cuenca-Estrella et al. 2001, Diekema, Messer et al. 
2003, Lewis, Wiederhold et al. 2005, Torres-Narbona, Guinea et al. 2007, 
Rudramurthy, Jatana et al. 2013).  Although conventional DAmB is an effective agent 
in treating these infections, its routine use presents serious safety concerns. Adverse 
drug reactions associated with DAmB include infusion-related side effects such as 
pyrexia and chills, and neprotoxicity (Petrikkos 2009). Further to this it is only 
available in i.v. formulation and demonstrates poor penetration of the blood brain 
barrier (Dupont 2002). Due to these limitations, alternative lipid formulations of AmB 
have now been developed. Three formulations are available in most countries:  
liposomal amphotericin B (L-AmB, AmBisome; Gilead Sciences Inc., Foster city, CA, 
USA), amphotericin B lipid complex (ABLC; Enzon Pharmaceuticals Inc., 
Bridgewater, NJ, USA;  Cephalon Limited, Welwin Garden City, UK), and 
amphotericin B colloidal dispersion (ABCD; Three River Pharmaceuticals Inc., 
Cranberry Township, PA, USA). These formulations demonstrate activity against 
most yeast and mould species comparable to that of conventional AmB. Despite 
similar activities, their structures and pharmacokinetics differ significantly (Adler-
Moore and Proffitt 2008, Lestner, Howard et al. 2010). Lipid formulations of AmB 
allow for a superior drug delivery system and improved safety profiles. This can, 
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therefore, overcome the safety reservations that clinicians often harbour when using 
AmB therapy  (Vyas and Gupta 2006). 
1.221 Pharmacokinetics and Pharmacodynamics 
ABCD has been demonstrated to be less nephrotoxic than DAmB (Choi, 
Brummer et al. 2004, Chandrasekar and Sobel 2006). However, there are still toxicity 
concerns with ABCD. This was demonstrated in a clinical trial carried out by Timmers 
et al. This open-label randomised trial to compare ABCD with fluconazole for 
antifungal prophylaxis in neutropenic patients demonstrated a high rate of infusion 
related toxic events (94%) in patients receiving 4mg/kg/day of ABCD. It was 
concluded that ABCD was not a suitable prophylactic agent for neutropenic patients 
(Joseph, Jain et al. 2007). 
A recent in vitro study demonstrated the effectiveness of L-AmB against 
mould isolates in comparison to DAmB, voriconazole, itraconazole and fluconazole. 
This study found that L-AmB has in vitro activity against Aspergillus, Fusarium and 
species of Zygomycetes comparable to, if not superior, to that of both conventional 
AmB and the triazole agents (Rudramurthy, Jatana et al. 2013). A clinical trial by 
Walsh et al. evaluating the safety and tolerability of high-dose L-AmB in the treatment 
of infections with Aspergillus spp. and other filamentous fungi further validated these 
findings. Dosages of up to 15mg/kg were observed to be effective in treating infections 
whilst also demonstrating good tolerability and safety (Garcia-Effron, Park et al. 
2009). 
Despite upstanding pre-clinical and clinical data to support the use of higher 
dosages of L-AmB, several recent clinical trials have demonstrated similar efficacy of 
low-dose regimens when compared to standard dose in the treatment of IFI 
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(Kassamali, Danziger et al. , Cornely, Maertens et al. 2007, Bal 2010). The most recent 
of these trials observed comparable survival rates and clinical improvement in 
treatment groups receiving low-dose L-AmB (1mg/kg/day) and standard dosages 
(>2mg/kg/day) (Kassamali, Danziger et al.). A second trial comparing a high-loading 
dose regimen with standard dosing for the treatment of invasive aspergillosis in 
severely immunocompromised patients also demonstrated that the use of 10mg/kg/day 
for 14 days offered little superiority in treatment outcome and an increased frequency 
of nephrotoxicity compared to patients receiving 3mg/kg/day (Cornely, Maertens et 
al. 2007). Collectively these studies suggest that the use of higher dosages of L-AmB 
may increase the incidence of adverse events with no additional antifungal benefit. 
Similar antifungal efficacies between formulations were also observed in an in 
vitro model of invasive pulmonary aspergillosis which described the PK-PD 
relationship of DAmB, L-AmB and ABLC against a green fluorescent protein (GFP) 
modified isolate of A. fumigatus. However, despite similar MIC values, concentrations 
at which 50% antifungal activity was observed (EC50) estimated from AUC- response 
relationships for both L-AmB and ABLC were significantly higher than those for 
DAmB (67.73, 210.2 and 6.4 respectively) (Lestner, Howard et al. 2010).  
Animal studies suggest that the use of higher dosages of L-AmB may be more 
effective in reducing fungal burden in rats and mice (Clemons, Espiritu et al. 2005, 
Gavalda, Martin et al. 2005, Olson, Adler-Moore et al. 2006, Takemoto, Yamamoto 
et al. 2010). In a murine model of invasive scedosporiosis with S. prolificans, dosage 
escalation up to 10mg/kg and 20mg/kg observed a significant improvement in survival 
(70% and 80% survival respectively) compared to control mice (10% survival). 
However when escalated to 30mg/kg a decreased survival was seen suggesting 
toxicity at this dosage (around 30% survival) (Bocanegra, Najvar et al. 2005). In an 
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immunosuppressed murine model of IPA Olsen et al. validated the safe use of higher 
dosages compared to high-dose ABLC. Survival of mice was significantly prolonged 
in groups receiving 12mg/kg of both drugs. Mice receiving even higher dosages of 15 
and 20mg/kg showed a further increase in survival of 80-90% compared to 12mg/kg 
dosing (57% survival). ABLC demonstrated decreased survival and nephrotoxicity at 
dosages higher than 12mg/kg suggesting that dosage escalation may be unsafe. The 
reduced nephrotoxicity seen in mice receiving L-AmB compared to those which 
received ABLC may provide evidence for the use of L-AmB at higher dosages of 15 
or 20 mg/kg (Olson, Adler-Moore et al. 2006). The safety of L-AmB at higher dosages 
of 10mg/kg was also demonstrated in a murine model of six species of Zygomycetes 
with efficacy equal to or superior to DAmB. Efficacy of L-AmB at clinical dosages 
(3mg/kg) was also observed in this study (50-100% survival) (Takemoto, Yamamoto 
et al. 2010).  
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1.23 Echinocandins 
The echinocandins represent the latest class of antifungal agent to be 
developed and include caspofungin, micafungin and anidulafungin. Their mechanism 
of action targets FKS1, a 1,3-β-D glucan synthase enzyme that is responsible for the 
transcription of 1,3-β-D glucan, an essential component of the fungal cell wall. The 
susceptibility of an organism to the echinocandins is dependent on the amount of 
glucan present in the cell wall. This varies between species. With nephrotoxicity 
concerns for amphotericin B and emerging limitations of azole drugs, the 
echinocandins have proved to be a favourable treatment option for IFI. Their 
advantages include desirable safety profiles, broad spectrum efficacy and minimal 
drug-drug interactions (Vazquez 2005).   
The echinocandins are compounds of high molecular weight and have limited 
oral bioavailability. They are, therefore, administered intravenously (i.v). They are 
generally metabolised in the liver and metabolism does not implicate the Cytochrome 
P450 metabolising enzymes. Therefore few drug-drug interactions can be seen with 
this class of drugs (Chandrasekar and Sobel 2006). Plasma concentrations are dose-
proportional, indicating linear pharmacokinetic (PK) profiles after single and multiple 
dose intravenous administration of the echinocandins (Chandrasekar and Sobel 2006). 
As efficacy of the echinocandins has been demonstrated to be related to both 
overall exposure and the achievement of high peak concentrations of drug it is 
debatable whether AUC/MIC or Cmax/MIC is the PK-PD predictive parameter best 
associated with efficacy (Sinnollareddy, Peake et al. 2012). 
The echinocandins are approved for the treatment of aspergillosis as a salvage 
therapy only when other antifungal strategies have been unsuccessful (Bal 2010). 
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Determination of pharmacodynamic properties for the echinocandins against 
Aspergillus spp. is challenging. The MIC is often hard to interpret due to the 
fungistatic nature of the echinocandins. Therefore the minimum effective 
concentration (MEC50) is determined as a potential pharmacodynamic target. The 
MEC50 values for all the echinocandins range between 0.007 and 0.12 mg/L for 
isolates of A. fumigatus, A. terreus, A. niger and A. flavus (Pfaller, Boyken et al. 2009).  
In terms of monotherapy the echinocandins have little to poor effectiveness in the 
treatment of infections with Scedosporium spp. or Fusarium  spp. and are therefore 
not recommended for the treatment of these infections (Chen, Slavin et al. 2011). 
There are however some studies where the use of an echinocandin in combination with 
amphotericin B or triazole agents has demonstrated a synergistic effect in treating 
fusariosis (Philip, Odabasi et al. 2005, Ruiz-Cendoya, Rodriguez et al. 2008, Shalit, 
Shadkchan et al. 2009). 
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1.24 Triazole Agents 
The triazole class of antifungal drugs are first-line agents for the treatment and 
prophylaxis of several invasive and superficial fungal infections.  Their mechanism of 
action targets the cytochrome P-450- dependent 14-α-demethylase enzyme that is 
necessary for the conversion of lanosterol to ergosterol. Inhibition of this biosynthetic 
pathway results in an accumulation of toxic methylsterol compounds leading to cell 
death and inhibition of fungal growth. Depletion of ergosterol also compromises the 
integrity of the fungal cell membrane contributing to further cell death (Sharma and 
Bhatia 2011). 
Triazoles routinely used in a clinical setting include first generation triazoles 
itraconazole and fluconazole, and second generation agents, voriconazole, 
posaconazole and more recently, isavuconazole (Fera, La Camera et al. 2009). As a 
class they are generally well tolerated. However, drug interactions are a concern to 
clinicians when prescribing these drugs. Their spectrum of activity spans across a 
broad range of fungal pathogens including A. fumigatus, S. apiospermum and F. 
solani. The activity, mechanisms of resistance and susceptibility breakpoints of the 
triazoles against isolates of Aspergillus spp. have been extensively studied and defined 
(Howard, Webster et al. 2006, Howard, Cerar et al. 2009). However, variable in vitro 
and clinical susceptibilities of these agents is seen against species of Scedosporium 
and Fusarium (Alastruey-Izquierdo, Cuenca-Estrella et al. 2008, Cuenca-Estrella, 
Alastruey-Izquierdo et al. 2008). Therefore susceptibility testing is essential in these 
cases. The PK-PD properties of the triazoles differ between drugs (Stevens 2012). 
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 1.241 Itraconazole 
Itraconazole is a lipophilic triazole with high plasma protein binding of >99% 
yielding low concentrations in parts of the body such as cerebrospinal fluid (CSF) and 
eye fluid (Willems, van der Geest et al. 2001). As a result, fungal infections of the 
central nervous system may require dosage adjustments or alternative antifungal 
therapy for successful treatment. Itraconazole exhibits a wide tissue distribution 
(Heykants, Van Peer et al. 1989). This allows concentrations at infection sites to 
remain high even after drug has been cleared from the plasma. Itraconazole undergoes 
extensive metabolism in the liver mainly by CYP3A4 to produce its major metabolite, 
hydroxy-itraconazole. This metabolite also possesses potent antifungal activity and 
similar PK-PD to the parent compound (Mino, Naito et al. 2013).  Itraconazole was 
originally marketed in a capsule formulation. However there is a marked variability in 
intestinal absorption using this formulation. To overcome this, an oral solution and i.v 
formulation with the incorporation of cyclodextrin were later developed (Zhang, Zhou 
et al. 2011). The pharmacokinetic profile for itraconazole is non-linear and the 
metabolism is saturated at clinical dosages leading to a long plasma half-life of around 
30 hours (Willems, van der Geest et al. 2001). 
1.242 Posaconazole 
Posaconazole was approved in 2005 and 2006 in the US and Europe 
respectively for the treatment and prophylaxis of IFIs in immunocompromised 
patients. It is also approved for the treatment of oropharyngeal candidiasis, 
aspergillosis, fusariosis, chromoblastomycosis and coccidioidomycosis in patients 
refractory to or intolerant of first-line agents. Posaconazole has a spectrum of activity 
comparable to that of voriconazole with the exception of zygomycetes for which 
superior activity is demonstrated (Torres, Hachem et al. 2005).  In vitro data evaluating 
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the activity of posaconazole against 55 clinical isolates of S. prolificans demonstrated 
an MIC range of 2-8 mg/L suggesting dosage escalation may be necessary for a 
successful treatment outcome in patients with scedosporiosis (Meletiadis, Meis et al. 
2002, Wiederhold, Kontoyiannis et al. 2004).  
For the treatment of fusariosis, posaconazole is currently recommended as 
salvage therapy and may be an effective treatment option in some cases (Nucci 2003, 
Raad, Hachem et al. 2006, Tortorano, Richardson et al. 2014). Isolates of F. solani 
demonstrate varying susceptibilities to posaconazole and can be greater than 8 mg/L 
(Espinel-Ingroff 2001, Paphitou, Ostrosky-Zeichner et al. 2002, Espinel-Ingroff 2003) 
 
1.243 Voriconazole 
Voriconazole is the first of the second generation triazoles to be developed. It 
gained FDA approval in May 2002 for the treatment of invasive aspergillosis. It is also 
indicated for fusariosis and scedosporiosis in patients refractory to or intolerant of 
other antifungal medications (Ader, Bienvenu et al. 2009). This licence was then 
extended in 2004 for the treatment of candidemia in non-neutropenic patients, 
disseminated candidiasis and Candida infections of the abdomen, kidney, bladder wall 
and wounds (Peman, Salavert et al. 2006). 
Pharmacokinetics and Pharmacodynamics 
The recommended dosing regimen of voriconazole consists of 6 mg/mg q12hr 
for the first day followed by a 4mg/kg twice daily maintenance dose. Voriconazole is 
available in both oral and i.v formulations and has a non- linear saturable 
pharmacokinetic profile in adults. Comparative to this, a linear pharmacokinetic 
profile has been demonstrated in children with doses of 4 mg/kg correlating to 
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exposures similar to that of 3 mg/kg in adults (Walsh, Teppler et al. 2004). Steady 
state plasma concentrations are usually reached around 5 days after oral and 
intravenous administration. With the use of a loading dose steady state may be 
achieved within 24 hours (Purkins, Wood et al. 2002, Theuretzbacher, Ihle et al. 2006). 
Voriconazole demonstrates an oral bioavailability of around 96% when taken after 
food. When administered orally, maximum plasma concentrations are achieved within 
2 hours post administration. The plasma elimination half-life of voriconazole is around 
6-7 hours. This is dose dependent and dose escalation can result in a non-proportional 
accumulation of drug. It is metabolised primarily by CYP2C19 with some contribution 
from CYP2C9 and CYP3A4.  Due to the polymorphic nature of CYP2C19 there can 
be a high variability in plasma concentrations between individuals (up to 100-fold) as 
voriconazole clearance may be significantly reduced in patients with a CYP2C19 
deficient phenotype (Denning, Ribaud et al. 2002). Inducers and substrates of 
CYP3A4, CYP2C19 and CYP2C9 may also contribute to a variation in the PK of 
voriconazole and present a considerable risk of drug-drug interactions between 
voriconazole and other drugs which interfere with these enzymes (Dolton, Ray et al. 
2012). This has previously been seen with rifabutin (CYP3A4 inducer) and efavirenz 
(CYP3A4 inhibitor and substrate) (Pfizer 2011). A study in critically ill patients with 
renal impairment demonstrated sub-optimal concentrations of drug when administered 
the recommended dosage of 3-4mg/kg. This suggests that dosage escalation may be 
beneficial in these patients. Further studies in the critically ill are necessary to confirm 
these findings (Myrianthefs, Markantonis et al. 2010). 
Voriconazole demonstrates excellent in vitro and in vivo antifungal activity 
against clinically important Aspergillus species. In an in vitro dynamic model of 
pulmonary invasive aspergillosis, the PK-PD relationships of voriconazole against 
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wildtype and resistant isolates of A. fumigatus were established. When bridged to 
humans using a nonparametric mathematical model and Monte-Carlo simulation, this 
study suggested that increased drug exposures may allow for the successful treatment 
of infections with resistant strains of Aspergillus spp. (Jeans, Howard et al. 2012). 
A similar study describing the PK-PD of voriconazole against three clinical 
strains of A. fumigatus, A. flavus and A. terreus suggests that higher drug exposures 
are necessary in order to effectively inhibit A. terreus (Al-Saigh, Elefanti et al. 2012). 
Both studies suggest that an increased dosage may be an option for clinicians when 
treating patients suffering from resistant infections. 
For the treatment of infections with Scedosporium spp. numerous cases have 
reported successful treatment outcomes. In an analysis of 101 patients suffering from 
scedosporiosis treated with voriconazole, 61% patients responded to therapy with a 
33% recovery rate. A 63% success rate was observed in patients infected with S. 
apiospermum compared to a 44% success rate in those with S. prolificans infection 
suggesting an increased dosage or combination therapy may be a more appropriate 
option for patients infected with S. prolificans (Troke, Aguirrebengoa et al. 2008). 
Voriconazole exhibits varying in vitro activity against species of Fusarium 
with MICs ranging from 1 mg/L -16 mg/L (Espinel-Ingroff, Johnson et al. 2008). 
Several retrospective analyses observe voriconazole to be the most commonly used 
agent in the treatment of disseminated fusariosis (Lortholary, Obenga et al. 2010, 
Horn, Freifeld et al. 2014). Lorthorlary et al. saw a survival rate of 42% in patients 
with haematological malignancies who had been treated with voriconazole 
(Lortholary, Obenga et al. 2010). Similar figures were obtained by  Horn et al. where 
survival was 44% (Horn, Freifeld et al. 2014) and Nucci et al. reported a survival rate 
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of 43% (Nucci, Marr et al. 2014). These analyses suggested that voriconazole is a 
potential treatment option for fusariosis, however the exposures necessary to improve 
response rates are yet to be defined. 
Numerous clinical studies have investigated the relationship between plasma 
concentrations of voriconazole and antifungal efficacy (Ally, Schurmann et al. 2001, 
Denning, Ribaud et al. 2002, Perfect, Marr et al. 2003, Dolton, Ray et al. 2012, Jacobs, 
Selleslag et al. 2012). An analysis of samples obtained from 10 clinical trials found no 
correlation between plasma concentration of voriconazole and efficacy against 
Aspergillus spp. (Lutsar, Hodges et al. 2003). However, further PK-PD analysis of 
data suggested that a decrease in dosage may lead to a reduction in efficacy in patients 
with plasma concentrations <5ug/ml. This was further studied in 28 patients receiving 
voriconazole where a correlation between plasma concentrations of <2.05 mg/L and a 
reduced clinical response was observed, suggesting that a dosage escalation may be 
necessary in patients who do not achieve plasma levels >2.05 mg/L (Smith, Safdar et 
al. 2006).  
Walsh et al. carried out the largest evaluation to date of the safety and efficacy 
of voriconazole in comparison to liposomal amphotericin B for empirical antifungal 
therapy in a cohort of 837 febrile neutropenic patients. The superiority of voriconazole 
in reducing fungal breakthrough infections and adverse events such as infusion- 
related reactions and nephrotoxicity was demonstrated in patients receiving a 6mg/kg 
loading dose q12h for two doses followed by a 3mg/kg q12h loading dose. Plasma 
concentrations far exceeding the MIC for the majority of fungal pathogens were 
detected between dosing intervals. This may suggest that a regimen using lower 
dosages of voriconazole may be indicated in neutropenic patients and could reduce the 
risk of toxicity (Walsh, Pappas et al. 2002).  
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An observational study investigating the relationship between plasma 
concentrations of voriconazole and clinical response analysed PK-PD data from 825 
patients from nine phase II and III clinical trials. A clear relationship between patients 
who had a higher Cavg/MIC value and increased clinical response to voriconazole 
therapy was seen. Although the use of trough concentration as a PD parameter has its 
limitations, the trough/MIC concentrations at which clinical efficacy is most likely to 
occur was demonstrated to be around 2-5 which may help to guide dosing of 
voriconazole (Troke, Hockey et al. 2011). 
Though studies have demonstrated a relationship between the 
pharmacokinetics and antifungal efficacy of voriconazole, due to its nonlinear PK 
profile a small change in dosage may have dramatic effects on the resultant plasma 
levels.  It is therefore hard to suggest a dosage that may reach exposures within the 
therapeutic range. Therapeutic drug monitoring is recommended for patients receiving 
voriconazole therapy in order to determine appropriate dosage adjustments. Studies 
have reported that nonparametric population models may be able to predict 
voriconazole AUC from clinical trough levels. There is the potential here to predict 
target exposures from as little as one pharmacokinetic sample, for the individualisation 
of therapy (Hope, VanGuilder et al. 2013, Neely, Margol et al. 2015, Huurneman, 
Neely et al. 2016) 
In vitro and in vivo preclinical data for the treatment of invasive pulmonary 
aspergillosis using a dynamic in vitro model and an inhalational neutropenic murine 
model suggests that an AUC:MIC ratio of 166.9 is required to achieve 50% antifungal 
effect. The study also estimates that for Aspergillus species with MIC values >0.125 
mg/L the current dosing regimen of 800 mg/ day may be sub-optimal (Howard, 
Lestner et al. 2011). In a recent investigation to determine a pharmacodynamic target 
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for posaconazole against wild-type and resistant isolates of A. fumigatus, the highest 
MIC for which the existing dosing regimen would produce a 1-log kill was 0.25 mg/L. 
This also suggests that the current dosing regimen may be ineffective for the treatment 
of infections with resistant isolates for which MIC values are 1-8 mg/L (Lepak, 
Marchillo et al. 2013).  
.  
1.534 Isavuconazole 
Isavuconazole is a novel triazole agent that is approved in the USA for the 
treatment of aspergillosis, mucormycoses and candidiasis. Isavuconazole exhibits a 
broad spectrum of activity against several clinically important fungal pathogens 
including Candida spp., Aspergillus spp., Cryptococcus neoformans and perhaps some 
species of the Zygomycetes (Thompson and Wiederhold 2010). The incorporation of 
a side arm into the molecular structure of isavuconazole allows for a higher binding 
potency for the CYP51 binding pocket. Isavuconazole therefore demonstrates a 
broader antifungal activity compared to that of other triazole agents (Livermore and 
Hope 2012).  
Pharmacokinetics and Pharmacodynamics 
  Isavuconazole is administered either orally or intravenously as a water-soluble 
pro-drug, BAL8557. Therefore the use of potentially nephrotoxic excipients such as 
cyclodextrin can be avoided. Cleavage into the active compound, BAL4815 via 
esterase enzymes in the plasma is near complete (around 98%) as negligible amount 
of pro-drug can be found in the urine post administration (Livermore and Hope 2012). 
Single and multiple dose studies in healthy volunteers demonstrated isavuconazole to 
be well tolerated. Isavuconazole exhibits an extensive half-life of 76-100hr with a low 
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systemic clearance (2.80-5.03 L/h). It is highly protein bound (around 98%) and has a 
large volume of distribution. Single dose studies suggest a non-linear pharmacokinetic 
profile however multiple dose studies suggest linearity (Schmitt-Hoffmann, Roos et 
al. 2006, Schmitt-Hoffmann, Roos et al. 2006) 
Isavuconazole possesses potent antifungal activity against Aspergillus spp. 
with MIC values ranging from 0.06-4 mg/L (Guinea, Pelaez et al. 2008, Perkhofer, 
Lechner et al. 2009, Rudramurthy, Chakrabarti et al. 2011). However it’s in vitro 
activity against Fusarium spp. and Scedosporium spp. is dependent on strain as many 
isolates of these organisms exhibit resistance to isavuconazole and have MICs 
exceeding 8 mg/L (MIC range of 2->16 for S. apiospermum and S. prolicans, 4->16 
for Fusarium spp.) (Guinea, Pelaez et al. 2008, Thompson and Wiederhold 2010).   A 
Phase III randomised, comparative study (SECURE) demonstrated the non-inferiority 
of isavuconazole to voriconazole for the treatment of invasive aspergillosis. Patients 
received dosages of isavuconazium sulphate comparable to 4 mg/kg i.v twice-daily or 
200 mg orally twice- daily. Isavuconazole demonstrated a 50% success rate and 62% 
clinical response rate in this trial and also exhibited an overall comparable safety 
profile to voriconazole in this patient population (Ullmann A 2014). 
 
1.25 The Orotomides  
The discovery and development of novel classes of antifungal agents has been 
a great challenge over the past decades. The interest from big pharma in the 
development of antimicrobials with novel targets has diminished due to lack of 
financial incentive. Therefore, small biotechnology companies have become the main 
contributors towards the discovery of novel antimicrobial agents. The orotomide class 
of agents are a novel class of antifungals. F901318 is the first and most advanced agent 
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of the orotomides and is currently in Phase I of clinical development with F2G Ltd. 
F901318 was discovered via the screening of a 370,000 compound library for 
antifungal activity against A. fumigatus. Its primary target was determined to be the 
dihydroorotate dehydrogenase (DHODH) enzyme. The role of DHODH in the de novo 
biosynthesis of pyrimidines is well characterised in both humans and fungi. It is 
responsible for the conversion of dihydroorotate to orotate. As fungi such as 
Aspergillus spp. cannot salvage pyrimidines from their environment, the de novo 
biosynthesis pathway is the sole source of pyrimidines for these pathogens (Figure 
1.7). Specificity of F901318 for fungal DHODH has been demonstrated and the agent 
exhibits a very poor inhibition of the human enzyme. The mechanism of F901318 is 
reversed in the presence of pyrimidine compounds however this is only at high 
concentrations of >5mM of which only a small fraction is present in human serum 
(Oliver, Law et al. 2015). F901318 also demonstrates in vitro activity against S. 
apiospermum and other species within its species complex (Fothergill, Wiederhold et 
al. 2015). Phase I data also suggests F901318 is safe and well tolerated at the dosages 
given in its first single ascending dose study in humans (Kennedy, Allen et al. 2015) 
An understanding of the pharmacokinetic and pharmacodynamic (PK-PD) 
relationships of new and currently used agents against S. apiospermum can provide an 
insight into the optimal dosages that may be effective in treating these infections 
(Fothergill, Wiederhold et al. 2015, Oliver, Law et al. 2015). 
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Figure 1. 7 
Flow diagram to describe the de novo pyrimidine biosynthesis pathway used in fungi 
emphasising the mechanism of action of novel agent, F901318. 
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1.3 AIMS 
The general aims of this thesis are comprised of two key components. Firstly, 
to develop in vitro models of invasive fungal infections that can successfully mimic 
the human PK of antifungal agents. Secondly, to refine these models for the 
establishment of key PK-PD relationships of new and existing agents that may guide 
the use of antifungal therapy in the clinic. 
Aim 1 is to use the existing in vitro cellular models of invasive aspergillosis 
described by Jeans et al. to define the exposure response relationships between the 
novel triazole agent, isavuconazole, and both wild-type and triazole resistant isolates 
of Aspergillus fumigatus. These PK and PD datasets will then be bridged together 
using a one compartmental, non-parametric PK-PD model to establish the 
importance of key pharmacodynamic indices, such as the AUC and AUC:MIC in the 
case of triazole agents. This model will then be further developed for isolates of 
Aspergillus terreus in order to provide pre-clinical evidence for the suitability of 
isavuconazole in treating this species. 
Aim 2 is to develop in vitro cellular models of scedosporiosis and fusariosis, 
specific for isolates of Scedosporium apiospermum and Fusarium solani. These 
models will first be validated using voriconazole. The study will use novel ELISA 
methodologies for the tracking of S. apiospermum and F. solani to define the 
exposure- response relationships for novel orotomide agent, F901318, against wild-
type isolates of these organisms. Pharmacodynamic analysis will be performed using 
PK-PD modelling software to predict the PD indices best associated with maximal 
antifungal effect in these models.   
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CHAPTER II 
The Pharmacokinetics and 
Pharmacodynamics of Isavuconazole 
against isolates of Aspergillus fumigatus 
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2.1 INTRODUCTION 
Invasive pulmonary aspergillosis (IPA) predominantly affects individuals with 
a significantly impaired immune system.  A. fumigatus is the most common 
Aspergillus species associated with opportunistic human infection and is a leading 
cause of infection in immunocompromised patients (Hope, Kruhlak et al. 2007). 
 The triazole class of agents target the fungal cytochrome P-450- dependent 
14-α-demethylase enzyme responsible for the biosynthesis for key fungal cell wall 
components. It has been widely demonstrated that mutations within this target enzyme 
confer towards resistance to the triazoles (Parker, Warrilow et al. 2014).  As the 
triazoles form the basis of many antifungal treatment regimens, the increasing 
emergence of triazole resistance in Aspergillus spp. is of growing clinical concern.  
Therefore research into the development of new and broader spectrum antifungals is 
necessary in order to combat this problem. 
Isavuconazonium sulfate (BAL8557) is a water soluble prodrug that is cleaved 
by plasma esterase enzymes to form the active triazole moiety, isavuconazole (ISA; 
BAL4815), plus an inactive compound (BAL8728). ISA has recently been approved 
for the treatment of invasive aspergillosis and invasive mucormycosis in the United 
States (Livermore and Hope 2012). ISA demonstrates in vitro antifungal activity 
against the majority of A. fumigatus. (Gregson, Goodwin et al. 2013). The safety and 
efficacy of ISA for the treatment of aspergillosis have been demonstrated in Phase I 
and III clinical trials (Schmitt-Hoffmann, Roos et al. 2006, Schmitt-Hoffmann, Roos 
et al. 2006, Desai 2014). ISA has a safety profile comparable to that of voriconazole 
with fewer adverse events recorded during Phase III trials. An alteration in structure 
to include a branch side chain allows ISA to exhibit a broader spectrum of activity 
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compared to voriconazole that is inclusive of the mucorales (Thompson and 
Wiederhold 2010).  The pharmacokinetics and pharmacodynamics (PK-PD) of ISA 
against isolates of Aspergillus spp. have been studied in murine models of 
disseminated aspergillosis (Warn, Sharp et al. 2009, Lepak, Marchillo et al. 2013, 
Seyedmousavi, Bruggemann et al. 2015). However, there are significant differences 
in the clearance of ISA between mice and humans.  The terminal half-life in these 
studies was seen to be approximately 1-2 hours comparable to that of 100 hours in 
humans (Warn, Sharp et al. 2006, Majithiya JB 2008, Warn PA 2008).  These 
differences in the PK of ISA may be a potential roadblock in the bridging of PK-PD 
data from mice to humans.   
A greater understanding of the pharmacokinetics and pharmacodynamics of 
new and existing agents against Aspergillus spp. can provide valuable insight into the 
optimal dosages required to treat these infections. 
In this thesis in vitro static model of the human alveolus was used in order to 
establish the PK-PD of ISA against one strain of A. fumigatus in order to establish 
both effective and sub optimal concentrations for dynamic studies. The activity of ISA 
against A. fumigatus was then studied further in a dynamic of the human alveolus were 
also used to define the PK-PD relationships of ISA against two wild-type and two 
mutant strains of A. fumigatus.  
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2.2 METHODS 
2.21 Organism preparation 
2.211 Isolates 
All isolates of A. fumigatus were gifted from the Regional Mycology Reference 
Laboratory, University Hospital of South Manchester and are detailed in Table 3.1. 
Species Isolate CYP51 mutation 
A. fumigatus GFP- transformant Widtype 
NIH4215 Wildtype 
F16216 L98H substitution 
F11628 G138C substitution 
 
 
2.212 Culture 
Isolates of A. fumigatus were obtained from Wynthenshawe stored at -80⁰C using the 
Microbank ™ preservation system (Pro-lab, Merseyside, UK). Isolates were sub-
cultured onto a potato dextrose agar (PDA) flask (Sigma-Aldrich, Poole, UK), at 37⁰C, 
5 days prior to each experiment.   
2.213 Inoculum preparation 
Conidial suspensions were prepared by flooding with 20 ml phosphate buffered saline 
(PBS) (Invitrogen, Paisley, UK) whilst carefully disturbing the surface of the growth 
using a sterile swab.  The resultant suspension was then filtered through sterile gauze 
(Medisave Ltd., Dorset, UK). Washing was performed twice by centrifuging the 
Table 2. 1 Isolates of A. fumigatus used for static and dynamic studies. 
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filtrate for 10 minutes at 2500rpm and re suspending the pellet in 20ml PBS. 
Endothelial basal medium (EBM-2) (Promocell, Heidelberg, Germany) was used for 
the preparation of the final inoculum.  A conidial suspension of 1-3 x 104 was prepared 
using a haemocytometer and was confirmed by quantitative cultures on Sabouraud 
dextrose agar with chloramphenicol (SAB-C) (Oxoid, Hampshire, UK). 
2.22 In vitro susceptibility testing 
Minimum inhibitory concentrations (MIC) for isavuconazole (ISA) against A. 
fumigatus and A. terreus isolates were determined in 5 independent experiments using 
both the European Committee for Antimicrobial Testing (EUCAST) and Clinical 
Laboratories Standards Institute (CLSI) methodologies. ISA concentrations for MIC 
testing ranged from 0.03 mg/L- 8 mg/L. 
2.23 Tissue culture 
A cell culture model of the human alveolus using 24- well cell culture plate inserts 
(Appleton Woods, Birmingham, UK) for a static in vitro model and 12-well cell 
culture plate inserts (Greiner Bio-One, Stonehouse, UK) for a dynamic in vitro model 
was used. A cellular bilayer consisting of human pulmonary arterial endothelial cells 
(HPAECs) (Promocell, Heidelberg, Germany) and human alveolar epithelial cells 
(A549s) (LGC Standards, Middlesex, UK) was constructed.  
HPAECs were cultured using endothelial growth medium (EGM-2) (Promocell, 
Heidelberg, Germany). This was prepared in accordance with instructions provided by 
the manufacturer. EBM-2 was supplemented with 2% foetal bovine serum (FBS) 
(Invitrogen, Paisley, UK), ascorbic acid, heparin, hydrocortisone, human endothelial 
growth factor, vascular endothelial growth factor 165, human fibroblast factor B and 
R-3-insulinlike growth factor 1.   
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A549 cells were cultured using EBM-2 medium containing 10% FBS.  Once 70-80% 
confluency was achieved, cells were washed using Hanks Balanced Salt Solution 
(HBSS) (Sigma-Aldrich, Poole, UK) and harvested with 6 mL of 0.25% trypsin–
ethylenediaminetetraacetic solution (Sigma-Aldrich, Poole, UK). Cells were then 
centrifuged for 5 minutes at 2000 rpm and re-suspended in the appropriate media to 
achieve final densities of 1 x 106 and 5.5 x 105 for HPAECs and A549s respectively. 
24-well cell culture inserts (static model) and ThinCert cell culture inserts for 12- well 
plates (dynamic and histopathology models) were used for the construction of the 
cellular bilayer.  Cell culture inserts were aseptically inverted and placed in a sterile 
plate. For the construction of the endothelial cell layer 100 uL and 400 µL of HPEAC 
cell suspension was pipetted onto the underside of the membrane for static and 
dynamic/histopathology models respectively.  Inserts were then incubated (37⁰C, 5% 
C02) for 2 hours to ensure cellular adhesion to the membrane.  Inserts were then 
transferred to their corresponding 24 (static) and 12 (dynamic and histopathology)-
well plates containing 0.6 mL and 1.5 mL of EGM-2 media. 100 µL and 400 µL of 
EBM-2 containing 10% FBS were then added to the top compartment (alveolar) for 
static and dynamic/ histopathology models respectively.  The cell culture plates were 
then incubated (37⁰C, 5% C02) for 24 hours. After 24 hours, media in the alveolar 
compartments was removed and inserts were transferred to new plates containing the 
relevant amounts of fresh EGM-2 media.  At this time, 100 µL for static models and 
400 µL for dynamic/histopathology models of A549 cell suspension was added to the 
top compartment of each insert and incubated.  After 2 hours, media in the alveolar 
compartment was removed to create an air-liquid interface.  EGM-2 media in the 
bottom compartment was replaced every 48 hours and any media present in the 
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alveolar compartments was also removed. Inserts were used for experiments 5 days 
after construction. 
2.24 Static in vitro models of invasive aspergillosis 
Cell culture inserts were transferred to a 24 well plate containing 0.6 mL of EBM-2 
media supplemented with 2% FBS. A conidial suspension of 1-2 x 104 for Aspergillus 
spp. and 4-8 x 105 for Scedosporium spp. and Fusarium spp. was prepared as described 
earlier and warmed to 37⁰C for 20 minutes. 100 µL of conidial suspension was 
pipetted into the top compartment for each cell culture insert and incubated at 37⁰C, 
5% CO2 for 6 and 12 hours for Aspergillus spp. and Scedosporium/ Fusarium spp. 
respectively. 
Pure isavuconazole, F901318 and voriconazole powders were dissolved in DMSO 
(Sigma- Aldrich, Poole) to produce stock solutions. Stocks were then serially diluted 
in EBM-2 media supplemented with 2% FBS in order to achieve the desired 
concentrations of each drug. These can be seen in Figures 3.2, 4.2 and 5.2. After 6 
hours of incubation for experiments using Aspergillus spp. and a 12 hour incubation 
period for experiments using Scedosporium spp. and Fusarium spp., the inoculum was 
removed from cell culture inserts which were then placed into 24 well plates 
containing relevant drug concentrations. Plates were then then incubated at 37°C, 5% 
CO2 for 48 hrs. Samples from the endothelial and alveolar compartments were 
obtained and stored at −80⁰C for measurement of drug concentrations and fungal 
burden. 
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2.25 Dynamic in vitro models of invasive aspergillosis 
2.251 Bioreactors and Construction 
Cell culture inserts were housed in custom-designed stainless steel bioreactors for the 
duration of the experiment. Bioreactors were specifically engineered to house cell 
culture inserts whilst allowing media to flow past the endothelial layer of cells. Each 
bioreactor was connected to the circuit using Marprene® thermoplastic elastometer 
tubing (Watson Marlow, Cornwall, UK). Silastic®, 1.6 mm bore tubing (Dow 
Corning) was used to construct the remainder of the circuit. All connections were 
made using polypropylene barbed luer adapters (Cole Palmer, London UK; West 
Group, Hants, UK).  A central reservoir containing 200 mL of warmed media was 
connected to the circuit using 1.5-mm bore polytetrafluoroethylene (PTFE) semi-rigid 
tubing (Diba Labware, Kinesis Ltd., Cambridge, UK) fitted into Omni-Fit Q-series 
bottle caps (Diba Labware, Kinesis Ltd., Cambridge, UK). All central reservoirs 
contained magnetic stirring bars and were placed on a stirring plate to create a vortex, 
thereby ensuring continuous mixing of media components and drug. Duran bottles 
containing fresh media and empty bottles for the removal of waste were also connected 
to the circuit in a similar manner. ISA was administered directly to the central 
compartment. Two 205-U multichannel cassette peristaltic pumps fitted with 1.52 mm 
bore Marprene manifold tubing (Watson Marlow, Cornwall, UK) were used, ensuring 
flow of media round the system and allowing for multiple circuits to be run 
simultaneously. 
All components of the model were sterilised by autoclave before use and circuits were 
assembled in a class II safety cabinet. Once assembled, circuits were transferred to a 
37⁰C incubator for the remainder of the experiment. Dulbecco’s modified Eagle 
medium (DMEM) containing 4500 mg/L D-Glucose, L-Glutamine and HEPES buffer 
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(Invitrogen, Paisley, UK) was supplemented with 2% FBS and penicillin- 
streptomycin solution (Sigma-Aldrich, Poole) to give a final concentration of 100 
U/mL penicillin and 0.1 mg/mL streptomycin. This media was used for all 
experiments. The circuits were primed overnight at a pump speed of 0.5rpm with this 
media. The bioreactors were then connected to the circuit. The pump responsible for 
media flow through the bioreactor was run at 1.9 rpm as described by Jeans et al. 
(Jeans, Howard et al. 2012).  
2.252 Inoculation 
Cell culture inserts were transferred to a 12 well plate containing 1.5 mL EBM-2 media 
supplemented with 2% FBS per well. A conidial suspension of 1-2 x 104 was prepared 
as previously described in the literature (Jeans, Howard et al. 2012) and incubated at 
37⁰C for 20 minutes. Four hundred µL of this suspension was then pipetted into the 
top compartment of each cell culture insert and incubated at 37⁰C, 5% CO2 for 12 
hours.  
2.253 Treatment with antifungal agents and sampling 
For each experiment the PK and PD of antifungal agents against each isolate of A. 
fumigatus were determined in three individual circuits. Each circuit was treated with 
a different dosage of drug.  A fourth untreated circuit was used as a control. Bolus 
dosages of 0mg, 0.3mg, 0.5mg and 1.5mg were administered to separate circuits at 
time 0. These dosages were chosen on the basis of static in vitro data in order to 
achieve concentrations of drug in the system that correlated to sub-optimal, optimal 
and levels of drug exceeding the effective antifungal dose (Figure xxx). The 
relationship between dose and concentration within the system was first tested in 
control pharmacokinetic experiments, i.e. drug alone in un-infected circuits. ISA was 
administered directly to the central compartment. Samples for PK and PD were taken 
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from the same sampling port situated after the bioreactor every 6 hours up to 48 hours 
post-treatment. A pump speed of 0.5rpm was used to set a clearance rate of ISA of 
0.043 mL/min- clearance of ISA in L/h reference. After sampling, media taken out of 
the system during sampling was replaced with an equal volume of complete DMEM.  
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Figure 2. 1  Set-up of the dynamic in vitro model of the human alveolus for ISA 
against A. fumigatus. 
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2.26 High performance liquid chromatography 
High performance liquid chromatography (HPLC) for pharmacokinetic analysis was 
performed by Joanne Goodwin and Sarah Whalley at the University of Liverpool. 
Isavuconazole concentrations in media were measured using HPLC with a Shimadzu 
Prominence (Shimadzu).  The isavuconazole method used a Kinetex 2.6u C18 New 
Column 75 x 4.6 mm (Phenomenex) and a 40 µL injection volume.  A standard curve 
encompassing 0.005–20 mg/L was constructed from stock solutions of isavuconazole 
1000 mg/L in DMSO further diluted in methanol (Fisher Scientific, Loughborough, 
UK).  The internal standard was itraconazole (Sigma-Aldrich, Poole, UK).  The mobile 
phase was 60% 0.1% trifluoroacetic acid (TFA) in water 40% acetonitrile with 0.1% 
TFA (v/v) with a gradient profile changing to 40% and 60% respectively over 4 
minutes with an overall run time of 6 minutes and flow rate of 1 mL/min.  
Isavuconazole was detected using fluorescence with Ex 250nm, Em 380nm; they 
eluted after 3.2 and 4.5 mins, respectively. The CV% was <6.4% over the 
concentration range 0.005 – 20 mg/L. The limit of detection was 0.005 mg/L. The intra 
and inter-day variation was <6.6%. 
2.27 Platelia Aspergillus assay 
Galactomannan (GM) was used as a quantitative biomarker in order to evaluate the 
antifungal efficacy of isavuconazole. Galactomannan levels were measured using a 
double-sandwich enzyme linked immunosorbent assay (Platelia Aspergillus; Bio-
Rad). The protocol provided by the manufacturer, was followed with one 
modification. Due to the relatively small volume of sample that can be obtained using 
this model, 25 µL of sample treatment solution was added to 75 µL of sample as 
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opposed to the recommended volume of 100 µL of sample treatment solution to 300 
µL of sample. 
2.28 Mathematical modelling 
A population methodology was used in order to fit a mathematical model to 
the data from each isolate. A one compartmental model was chosen to represent the 
number of compartments present in the dynamic model. In order to account for the 
varying susceptibilities of the isolates used in this study and to improve the fit of the 
pharmacodynamic model, the MIC was incorporated into equation 2b. Version 1.2.9 
of Pmetrics PK-PD analytical software was used.  The structural mathematical model 
consisted of the following two inhomogeneous ordinary differential equations: 
dX1/dt=B(1)-(SCL/Vc)*X1     Equation 1 
dN/dt=Kgmax*(1-(N/POPMAX))*N    Equation 2a 
*(1-(X1/Vc)Hg/(X1/Vc)Hg+C50gHg))     Equation 2b 
Where: B(1) is the bolus input of isavuconazole, SCL is the clearance of 
isavuconazole from the circuit, Vc  is the volume of the circuit, N is the galactomannan 
concentration, Kgmax is the maximal rate of growth; POPMAX is the theoretical 
maximal density within the circuit; Hg is the slope function for the suppression of 
growth; and, C50g is the concentration of ISA in the circuit where there is half-
maximal suppression of growth multiplied by the MIC.  
Equation 1 describes the rate of change of ISA concentrations in the circuit.  
Equation 2 describes the rate of change of galactomannan in the circuit and contains 
terms that describe fungal growth in the absence of ISA (Equation 2a) and the ISA 
induced suppression of growth in relation to the MIC (Equation 2b). 
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The model was fitted to the dataset of untreated and treated circuits obtained 
from each isolate.  Each circuit was treated as an “individual”.  The Bayesian posterior 
estimates for each of the parameters in the model were then used to define the 
concentration-time profile of ISA and the resultant effect on galactomannan 
concentrations.  
As the AUC:MIC has consistently been demonstrated as the pharmacodynamic 
indices best associated with the antifungal efficacy of ISA (Lepak, Marchillo et al. 
2013) the parameter estimates from the model were used to estimate the AUC that 
developed in each circuit, and consequently the AUC:MIC ratio for each isolate and 
experimental condition. A sigmoid inhibitory maximal effect (Emax) model was used 
in order to establish the relationship between AUC and AUC:MIC and antifungal 
efficacy. The model consisted of the following structure: 
Effect = Baseline- (Emax* XH)/(EC50
H* XH),  
Where Baseline is the fungal burden in the absence of drug, Emax is the 
asymptotic reduction in fungal burden induced by antifungal drug exposure, X 
is a measure of drug exposure (i.e., the AUC or AUC/MIC ratio), EC50 is the 
concentration resulting in half-maximal effect, and H is the slope (or Hill) function. 
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2.3 RESULTS 
2.31 Minimum Inhibitory Concentrations 
Minimum inhibitory concentrations (MIC) (mode, range and geometric 
means) for ISA against isolates of A. fumigatus using EUCAST and CLSI 
methodologies are summarised in Table 2.3.  For isolates of A. fumigatus, the MIC 
was higher in those isolates with amino acid substitutions in the Cyp51 protein using 
both methodologies.
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EUCAST CLSI 
Species Isolate Cyp51A mutation Mode Range Mean Mode Range Mean 
A. fumigatus GFP Wild-type 1 0.5-2.0 1 1 0.5-1 0.81 
A. fumigatus 4215 Wild-type 1 0.5-2.0  1 1 1-4 1.62 
A. fumigatus  16216 L98H 2 2-4  2.64 4 1-4 2.63 
A. fumigatus 11628 G138C 4 4-8  4.92 4 1-8 2.82 
         
         
Table 2. 2 
Minimum inhibitory concentrations were determined in 10 independent experiments. Means displayed above are geometric means. 
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2.32 Pharmacokinetics and pharmacodynamics of A. fumigatus in static models 
of invasive aspergillosis 
The exposure-response relationship of ISA against a wild-type GFP-
transformant of A. fumigatus is demonstrated in Figure 3.2. Consistent with previous 
findings using this model concentrations of ISA required to achieve suppression of 
galactomannan release were higher for the alveolar compartment than the endothelial 
compartment. A dose-dependent decline in galactomannan index was observed. 
Maximal suppression of galactomannan for this isolate was achieved at a 
concentration of around 0.4 mg/L. This result was comparable to the MIC obtained 
for this isolate (Table 3.1). 
Figure 2. 2 
Pharmacokinetics and pharmacodynamics of ISA in a static model against A. 
fumigatus GFP transformant. Error bars represent the standard deviation of three 
separate transwells. Measured concentrations were all within 10% of 
administered dosage. 
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2.33 Pharmacokinetics and pharmacodynamics of ISA against isolates of A. 
fumigatus in dynamic models of invasive aspergillosis 
Human-like plasma concentration-time profiles for ISA were generated using 
the dynamic in vitro model (Figures 2.3- 2.6).  
The kinetics of galactomannan release was different between isolates. Levels 
of galactomannan in all untreated circuits started to increase at around 18-24 hours 
post treatment (Figures 2.3-2.6). A maximum galactomannan index was observed at 
approximately 24 hours for the GFP transformant, F/11628 and NIH 4215. The strain 
F/16216 appeared to grow more slowly and maximal galactomannan concentrations 
were reached at around 36 hours post inoculation (Figure 2.5).  The maximum 
galactomannan concentrations ranged from an index of approximately 6-9.  
Clearly defined exposure-response relationships for ISA against each of the 
isolates were demonstrated. Consistent with results from the static model, a trough 
concentration of approximately 0.2-0.5 mg/L resulted in near maximal suppression of 
galactomannan release for the wild-type GFP transformant. Similar results were 
observed for the wild-type organism NIH 4215.   For the two CYP51A variant isolates 
the exposure-response relationships were different.  Only a dosage of 1.5mg ISA 
against F/16216 resulted in a considerable suppression of galactomannan production.  
None of the ISA concentrations were able to suppress the release of galactomannan 
for strain F/11628.  Thus the MIC and genotype seemed to be a significant influence 
on the variation in the observed exposure-response relationships. 
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Figure 2.3 Pharmacokinetics and pharmacodynamics of ISA against the GFP 
transformant of A. fumigatus.   
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Figure 2.4 Pharmacokinetics and pharmacodynamics of ISA against wild-type 
isolate NIH4215 of A. fumigatus.   
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Figure 2.5 Pharmacokinetics and pharmacodynamics of ISA against L98H 
expressing isolate F/16216 of A. fumigatus.   
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Figure 2.6 Pharmacokinetics and pharmacodynamics of ISA against G138C 
expressing isolate F/11628.   
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3.34 Mathematical Modelling of A. fumigatus pharmacokinetics and 
pharmacodynamics 
 The fit of the mathematical model to the data was highly acceptable.  The fit 
of the Bayesian posterior estimates for each circuit is shown in Figures 2.3-2.6.
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Figure 2.7 
Observed vs predicted graphs after the Bayesian step, generated using Pmetrics for (A) pharmacokinetics data from 16 individual 
circuits and (B) pharmacodynamics data as measured by absorbance obtained from the Platelia Aspergillus assay from 16 individual 
circuits. 
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Isolate 
Dosage 
(mg) 
MIC 
(mg/L) Cl (L/hr( V (L) F Kgmax POPMAX C50 Hg IC1 
GFP 0.0 1 0.003 0.17 0.10 0.32 7.67 0.13 1.53 0.00 
GFP 0.3 1 0.0008 0.16 0.10 0.18 7.73 0.06 1.45 0.07 
GFP 0.5 1 0.003 0.14 0.10 0.16 8.13 0.00 1.99 0.10 
GFP 1.5 1 0.003 0.14 0.10 0.16 8.12 0.00 1.99 0.10 
4215 0.0 1 0.0005 0.49 0.01 0.51 7.67 0.00 1.99 0.00 
4215 0.3 1 0.003 0.11 0.09 0.88 9.97 0.06 1.99 0.00 
4215 0.5 1 0.003 0.23 0.10 0.24 7.11 0.08 1.49 0.02 
4215 1.5 1 0.003 0.23 0.10 0.24 7.11 0.08 1.49 0.02 
16216 0.0 2 0.003 0.17 0.10 0.32 7.66 0.13 1.52 0.00 
16216 0.3 2 0.003 0.17 0.10 0.32 7.67 0.13 1.53 0.00 
16216 0.5 2 0.002 0.13 0.09 0.80 9.98 0.06 1.83 0.00 
16216 1.5 2 0.001 0.11 0.06 0.10 5.03 0.00 0.96 0.41 
11628 0.0 4 0.003 0.23 0.10 0.24 7.13 0.08 1.50 0.02 
11628 0.3 4 0.003 0.24 0.10 0.42 6.83 0.06 0.97 0.00 
11628 0.5 4 0.003 0.17 0.10 0.32 7.67 0.13 1.53 0.00 
11628 1.5 4 0.004 0.18 0.07 1.00 7.63 0.03 1.06 0.00 
Table 2. 3 
The median posterior parameter estimates from the mathematical model using data from 12 individual circuits. Cl represents the estimated 
clearance of ISA from the ciruit; V; the estimated volume of the central compartment; Kgmax, the predicted rate of growth of A. fumigatus in 
the circuit; POPMAX, the maxima obtained from the Platelia Aspergillus assay; C50, the concentration of ISA that 50% suppression of 
galactomannan is obtained; Hg, the slope function to describe A. fumigatus growth in both absence and presence of drug; IC1, the initial 
conditions for the pharmacodynamic dataset, representing background noise of the assay. 
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Strain Dose (mg/ q12) Predicted AUC0-48 
isavuconazole(mg.hr/L) 
Predicted AUC0-
48 galactomannan 
A. fumigatus GFP 0 
0.00 187.59 
0.3 
4.03 8.35 
0.5 
6.36 4.70 
1.5 
19.06 4.72 
A. fumigatus 4215 0 
0.00 254.40 
0.3 
4.30 38.29 
0.5 
4.27 5.47 
1.5 
12.83 1.22 
A. fumigatus 16216 0 
0.00 192.17 
0.3 
3.47 120.96 
0.5 
6.68 72.87 
1.5 
19.28 19.86 
A. fumigatus 11628 0 
0.00 166.92 
0.3 
2.55 152.18 
0.5 
5.79 135.52 
1.5 
10.14 118.81 
 
 
 
 
Table 2. 4 
Model predicted isavuconazole AUC0-48 and galactomannan absorbance values 
for isolates of A. fumigatus for individual circuits achieved using the dynamic 
model. 
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2.35 Sigmoid Emax analysis 
 The fit of the sigmoidal curve demonstrated an association between the AUC0-
48 for galatomannan release and the AUC0-48 of ISA (Figure 3.8, R
2= 0.701). This link 
was improved upon the incorporation of the MIC as a pharamcodynamic predictor of 
response (Figure 3.9, R2= 0.888). 
  
Figure 2.8 
Area under the galactomannan curves (0-48hrs) for A. fumigatus versus area 
under the concentration- time curves (mg.hr/L) (0-28). R2 = 0.709. 
 
- 90 - 
 
  
Figure 2.9 
Area under the galactomannan curves (0-48hrs) for A. fumigatus versus AUC0-
48:MIC. R2 = 0.911 
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2.4 CONCLUSIONS 
Invasive pulmonary aspergillosis is associated with relatively high morbidity 
and mortality (Hope, Kruhlak et al. 2007).  Pathogenic isolates of A. fumigatus that 
are resistant to existing antifungal drugs are emerging (Howard and Arendrup 2011). 
The development of novel antifungal agents is essential in order to improve clinical 
outcomes and meet evolving clinical requirements.  ISA is a novel triazole antifungal 
agent that is administered as the water soluble prodrug, isavuconazonium sulfate 
(BAL8557).  The efficacy of ISA has recently been established in a Phase III clinical 
trial (SECURE), which compared the clinical response and mortality of patients with 
invasive aspergillosis receiving ISA or voriconazole (Ullmann A 2014) . An 
understanding of the PK-PD relationships of ISA is central to the optimal use of this 
agent. These analyses describe the use of in vitro static and dynamic models of early 
invasive pulmonary aspergillosis to define the PK-PD relationships of ISA against 
clinical isolates of A. fumigatus.  
ISA demonstrated a dose- dependent decline in galactomannan release in a 
static model of IPA using the wild-type GFP transformant of A. fumigatus. These 
findings were confirmed in the in vitro dynamic model.  
There were defined differences in the PK-PD relationships between isolates in 
the dynamic model. Both wild-type strains were readily treatable with ISA at trough 
concentrations of approximately 0.1-0.3 mg/L. The isolate expressing an L98H 
substitution in the Cyp51A binding site (F/16216) required a slightly higher 
concentration of ISA in order to eliminate galactomannan release. A trough 
concentration of approximately 0.5 mg/L successfully suppressed galactomannan in 
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this study suggesting these levels may be effective in treating infections with this 
strain. None of the drug concentrations used were efficient in suppressing 
galactomannan release in the strain expressing a G138C substitution mutation. These 
findings are consistent with previous studies to describe the PK-PD of alternative 
triazole agents for the treatment of infection with the four organisms studied here 
(Howard, Lestner et al. 2011, Jeans, Howard et al. 2012). This suggests that these 
isolates may confer pan resistance across the triazole class of agents. 
Again, this pharmacodynamic variability observed between strains may be 
understood and quantified in terms of the MIC and the phenotype of the organism.  
Higher MIC values for ISA are observed against isolates of A. fumigatus carrying 
Cyp51A amino acid substitutions, L98H and G138C (Gregson, Goodwin et al. 2013).  
Relatively more ISA, in terms of the AUC, is required to exert an antifungal effect 
against these strains in this in vitro dynamic model. This suggests that both the MIC 
and the genotype account for a considerable amount of the variance seen. The 
importance of the MIC in this study is demonstrated in Figures 3.8 and 3.9 where an 
improved association between AUC:MIC and antifungal effect can be seen comparted 
to AUC alone. This observation further suggests that the MIC may be a reliable in 
vitro measure to guide antifungal therapy in patients in the setting of invasive 
aspergillosis. Standardized testing methodology for ISA has been developed by both 
CLSI and EUCAST, and epidemiological surveys detailing MICs in medically 
important opportunistic fungal pathogens have been published (Espinel-Ingroff, 
Chowdhary et al. 2013, Gregson, Goodwin et al. 2013).  The MIC value that defines 
the upper limit of the wild-type distribution according to Howard et al, 2013 is 2 mg/L 
for A. fumigatus, A. flavus and A. terreus. For isolates of A. niger it is 4 mg/L. For 
CLSI the ECOFF is 1 mg/L for A. fumigatus, A. flavus and A. terreus. The CLSI 
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ECOFF is 4 mg/L for niger (Espinel-Ingroff, Chowdhary et al. 2013).  The results 
from the Phase III clinical trial (SECURE) suggest that the majority of strains that 
belong to the wild-type distribution are likely to be treatable and using EUCAST 
terminology, wild-type A. fumigatus is likely to be a “good target” for ISA.  There is 
still some uncertainty as to the breakpoint for ISA using either EUCAST or CLSI 
methodology (Marr K 2014, Ullmann A 2014) 
In this model of early invasive pulmonary aspergillosis, total drug AUC:MIC 
values of approximately  19.1 and 12.8 using EUCAST methodology, respectively are 
associated with near maximal antifungal activity for wild-type isolates.  These target 
values are lower than two recently published studies (Lepak, Marchillo et al. 2013, 
Seyedmousavi, Bruggemann et al. 2015).  In the first of these studies, Lepak et al. used 
a profoundly neutropenic murine model of invasive pulmonary aspergillosis, and 
report that a much higher median AUC:MIC target of approximately 500 is associated 
with a static antifungal effect (i.e. prevents net growth or kill as assessed using a qPCR 
endpoint).  This pharmacodynamic target increases almost 2-fold to ~1000 if orders 
of logarithmic killing are used as the pharmacodynamic endpoint (Lepak, Marchillo 
et al. 2013).  A second study by Seyedmousavi et al. suggests that a much lower 
pharmacodynamic AUC:MIC target of 24.73 is reasonable (Seyedmousavi, 
Bruggemann et al. 2015).  This target is closer to the value in our study and was 
estimated using a non-neutropenic model of disseminated aspergillosis.  The 
differences in these estimates of the pharmacodynamic target for ISA may be related 
to the degree in the severity of each model, the stage of disease that is being mimicked 
and the background immunosuppression.  The model of IPA used by Lepak et al. is a 
severe neutropenic model.  In this murine model the progression of disease is rapid 
and terminal without the prompt initiation of therapy.  In contrast, the non-neutropenic 
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model of disseminated aspergillosis has a much longer time-course and estimates of 
drug exposure effect relationships are more complex due to the additional antifungal 
activity of immunological effectors.  The in vitro dynamic model used in this study is 
a model of early invasive disease before there is significant tissue damage. Drug 
exposure-response relationships are estimated before the onset of the haemorrhagic 
infarction and pyogranulomatous inflammation that is characteristic of invasive 
aspergillosis in neutropenic and non-neutropenic hosts, respectively.  The three 
experimental models represent the spectrum of invasive aspergillosis that is observed 
in the clinic, which ranges from very early disease right through to established disease 
in profoundly immunosuppressed hosts.  Therefore the estimates for 
pharmacodynamic targets required for therapeutic efficacy from the three models vary 
accordingly.   
An understanding of the PK-PD of ISA and most relevant pharmacodynamic 
targets is important for decision support in setting in vitro susceptibility breakpoints. 
For phase III clinical trials a loading dose of 200 mg q8h on days 1 and 2 followed by 
200 mg/day was used in order to compare the efficacy and safety of ISA to that of 
VRC. Population pharmacokinetic analysis of this data suggests this regimen produces 
a mean AUC of approximately 100 mg/h/L and is effective for the treatment of the 
majority of wild-type isolates of A. fumigatus. Given this data, a higher AUC:MIC 
target such as that suggested by  the neutropenic mouse model of IPA  may  therefore 
be difficult to achieve for the majority of wild type isolates. An AUC:MIC target of 
500 would likely be achievable for strains with an MIC 0.125 mg/L (i.e. 100 divided 
by 0.125 = 800, which is exceeds the recommended target of 500). However, the 
likelihood of a successful outcome becomes progressively less with strains with MICs 
> 0.125 mg/L).  Using an AUC:MIC target of 500 would therefore mean that the 
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breakpoint would divide the wild-type population. This is not consistent with 
observations from the randomised Phase III clinical trial where there was not a 
tendency for clinical failure with strains with elevated MICs.  In contrast, using a lower 
pharmacodynamic target of 11-25 would enable the wild type population to be 
adequately covered in the majority of patients which would be consistent with clinical 
results.  The most profoundly immunosuppressed patients with a high burden of 
infection may require higher drug exposure for a successful outcome, as suggested by 
Lepak et al.  The determination of this however will require further experience and 
clinical studies with ISA. 
ISA is demonstrated to be a safe and effective agent for the treatment of 
invasive aspergillosis.  The results from this study suggest that the MIC of ISA to 
clinical isolates of A. fumigatus may be an important determinant of the exposure-
response relationships.  The preclinical PK-PD data and analyses from three different 
laboratories are somewhat discordant. This may be due to significant differences in 
the experimental models that are used to characterize these relationships.  The results 
from this study suggest that the majority of wild-type isolates can be treated with the 
currently used regimens.  A definitive breakpoint analysis will require the 
development population PK model, which is currently in progress.  The population 
PK model and PK-PD bridging studies will then help define the highest MIC that can 
be treated with the current ISA regimen and indicate the potential benefit of dosage 
escalation to treat strains that may otherwise be classified as having intermediate 
susceptibility.  
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CHAPTER III 
The pharmacokinetics and 
pharmacodynamics of isavuconazole 
against isolates of Aspergillus terreus 
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3.1 INTRODUCTION 
Invasive pulmonary aspergillosis is a lethal infectious syndrome. Aspergillus 
spp. is the most common mould infection in immunocompromised patients. Due to 
the presence of underlying disease in immunocompromised patient populations and 
inter-species variability in susceptibility to commonly used antifungal agents, the 
treatment of these infections are complex.  
A. terreus is an important human pathogen associated with global morbidity 
and mortality in at risk individuals. The incidence of A. terreus has increased 
significantly over recent years and this species now contributes to approximately 3-
12% of IPA infections (Slesiona, Gressler et al. 2012). Although A. terreus infection 
is less common than that of A. fumigatus clinical outcomes tend to be poor. Mortality 
rates of up to 85% have been described in patients with haematological malignancy. 
A. terreus is intrinsically resistant to amphotericin B meaning there are relatively few 
therapeutic options. Voriconazole is the recommended first-line agent however 
clinical outcome may be variable (Hachem, Kontoyiannis et al. 2004, Steinbach, 
Benjamin et al. 2004, Pastor and Guarro 2014). The development of novel antifungal 
agents effective for the treatment of IPA with A. terreus is essential to provide 
additional therapeutic options. 
Isavuconazole (ISA), administered as prodrug isavuconazonium sulphate, is 
the most recent antifungal agent to obtain licensure from the FDA and EMA for the 
treatment of IPA. ISA demonstrates a favourable safety profile and a broad spectrum 
of antifungal activity that includes medically important yeasts, moulds and species of 
the Mucorales (Rybak, Marx et al. 2015).  ISA exhibits potent in vitro activity 
against most isolates of A. terreus (Pfaller, Messer et al. 2013). 
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Understanding the pharmacokinetics and pharmacodynamics of ISA against 
A. terreus may help determine the best efficacious dosage for the treatment of IPA 
caused by this organism. This chapter describes the preliminary development of a 
previously used in vitro model of IPA for use with isolates of A. terreus. This model 
was then utilised for the definition of in vitro PK-PD parameters for isavuconazole 
against three isolates A. terreus. 
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3.2 METHODS 
Methods for preparation of inoculum, in vitro susceptibility testing, tissue culture, set- 
up of static and dynamic models and analysis of samples are as described in Chapter 
II (Sections 2.21-2.27). 
3.21 Organism preparation 
3.211 Isolates 
All isolates of A. terreus were gifted from the Regional Mycology Reference 
Laboratory, University Hospital of South Manchester and are detailed in Table 3.1. 
Species Isolate 
A. terreus hus1199 
hus1333 
hus7980 
 
 
3.212 Culture 
Isolates of A. terreus were obtained from Wynthenshawe stored at -80⁰C using the 
Microbank ™ preservation system (Pro-lab, Merseyside, UK). Isolates were sub-
cultured onto a potato dextrose agar (PDA) flask (Sigma-Aldrich, Poole, UK), at 37⁰C, 
5 days prior to each experiment.   
3.22 Mathematical modelling 
Data were modelled using the model for isavuconazole described in Chapter II. 
Table 3. 1 Isolates of A. terreus used for static and dynamic studies. 
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3.3 RESULTS 
3.31 Minimum Inhibitory Concentrations 
Minimum inhibitory concentrations (MIC) (mode, range and geometric 
means) for ISA against isolates of A. terreus using EUCAST and CLSI 
methodologies are summarised in Table 4.1.   
3.32 Pharmacokinetics and pharmacodynamics of ISA against isolates of A. 
terreus in static models of invasive aspergillosis 
The exposure-response relationships of ISA against three clinical isolates of A. 
terreus are shown in Figure 4.2. The concentrations of ISA required to achieve 
suppression of galactomannan release were higher for the alveolar compartment than 
the endothelial compartment. No suppression of galactomannan was observed in the 
alveolar compartment for isolates hus1199 and hus7980 at the concentration ranges 
tested. For isolate hus1333 a dose- dependent decline in galactomannan release was 
seen in the alveolar compartment however maximal suppression was not achieved. 
For the endothelial compartment clear differences in the exposure response 
relationships between isolates were observed. Measured concentrations of 
approximately 0.2 mg/L were sufficient to maximally suppress galactomannan 
release for isolates hus1333 and hus7980. Concentrations of ≤1 mg/L were not 
sufficient to maximally suppress galactomannan release for isolate hus1199 (MIC=8) 
although a slight decline can be seen at the highest concentrations tested. 
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  EUCAST CLSI 
Species Isolate Mode Range Mean Mode Range Mean 
A. terreus hus1199 8 4-8 6.06 4 2-4 3.48 
A. terreus hus1333 0.5 0.5-0.5 7.40 4 2-4 3.03 
A. terreus hus7980 1 0.5-1 0.81 2 1-4 1.62 
Table 3. 2 
Minimum inhibitory concentrations were determined in 5 independent experiments. Means displayed above are geometric means. 
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Figure 3. 1 Pharmacokinetics and pharmacodynamics of ISA in a static model against A. terreus isolates.  
hus1199 (A) hus1199 (B), hus1333 and (C) hus7980.  Error bars represent the standard deviation between triplicate samples. 
A 
C 
B 
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3.33 Pharmacokinetics and pharmacodynamics of ISA against isolates of A. 
terreus in dynamic models of invasive aspergillosis 
Human-like plasma concentration-time profiles for ISA were generated using 
the dynamic in vitro model (Figures 4.2- 4.4).  
Preliminary data (not shown) suggested the kinetics of galactomannan release 
may be slower for isolates of A. terreus than A. fumigatus therefore a 72 hour model 
(compared to a 48 hour model for A. fumigatus) was used to ensure the growth of the 
organism in untreated circuits. The kinetics of galactomannan release was different 
between isolates. Concentrations of galactomannan in all untreated circuits started to 
increase at around 48-60 hours post treatment (Figures 3.2-3.4). A maximum 
galactomannan concentration was observed by 72 hours for all strains in untreated 
circuits. In the presence of sub optimal ISA concentrations (Figures 3.2- 3.4 C&D) an 
earlier release of galactomannan is observed for isolates hus1199, hus1333 and 
hus7980. For some isolates an anomalous detection of galactomannan was observed 
at time zero (Figure 3.4H). By 12 hours post treatment galactomannan concentrations 
were below the threshold of detection in all circuits with the exception of isolate 
hus7980 in the circuit treated with 1.5mg ISA (Figure 3.4H). The maximum 
galactomannan concentrations ranged from an index of approximately 7-12.  
Clearly defined exposure-response relationships for ISA against each of the 
isolates were demonstrated. Trough concentrations of approximately 0.2-0.3 mg/L 
resulted in near maximal suppression of galactomannan release for isolates hus1333 
and hus7980. None of the ISA concentrations were able to suppress the release of 
galactomannan for strain hus1199.   
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Figure 3. 2 Pharmacokinetics and pharmacodynamics of ISA against A. terreus 
hus1333. 
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Figure 3. 3 Pharmacokinetics and pharmacodynamics of ISA against A. terreus 
hus1199. 
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Figure 3. 4 Pharmacokinetics and pharmacodynamics of ISA against A. 
terreus hus7980. 
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3.34 Mathematical Modelling of A. terreus pharmacokinetics and 
pharmacodynamics 
 The fit of the mathematical model to the data was highly acceptable (Figure 
3.5).  The fit of the Bayesian posterior estimates for each circuit is shown in Figures 
3.2-3.4. Median posterior parameter estimates for each model can be seen in Table 
3.3. 
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Figure 3. 5 
Observed vs predicted graphs after the Bayesian step, generated using Pmetrics for (A) pharmacokinetics data from 12 individual 
circuits and (B) pharmacodynamics data as measured by absorbance obtained from the Platelia Aspergillus assay from 12 
individual circuits. 
A B 
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Isolate Dosage MIC Cl 
(L/hr) 
V 
(L) 
F Kgmax POPMAX C50 Hg IC1 
hus1333 0 0.5 0.003 0.10 0.03 0.15 7.85 0.03 1.06 0.00 
hus1333 0.1 0.5 0.004 0.10 0.09 1.00 7.15 0.05 7.96 0.04 
hus1333 0.3 0.5 0.003 0.13 0.05 0.17 8.22 0.03 6.16 0.01 
hus1333 1.5 0.5 0.002 0.13 0.05 0.54 8.28 0.02 7.72 0.17 
hus1199 0 8 0.003 0.29 0.06 0.17 11.45 0.07 6.16 0.00 
hus1199 0.1 8 0.004 0.17 0.02 0.43 10.15 0.03 1.59 0.00 
hus1199 0.3 8 0.002 0.13 0.05 0.28 9.25 0.27 2.19 0.03 
hus1199 1.5 8 0.004 0.23 0.10 1.00 10.45 0.03 7.51 0.41 
hus7980 0 1 0.003 0.10 0.03 0.15 7.85 0.03 1.06 0.00 
hus7980 0.1 1 0.002 0.13 0.05 0.55 8.25 0.02 7.74 0.17 
hus7980 0.3 1 0.003 0.12 0.07 1.00 14.95 0.03 7.21 0.01 
hus7980 1.5 1 0.002 0.13 0.05 0.55 8.27 0.02 7.72 0.17 
Table 3. 3 
The median posterior parameter estimates from the mathematical model using data from 12 individual circuits. Cl 
represents the estimated clearance of ISA from the ciruit; V; the estimated volume of the central compartment; Kgmax, 
the predicted rate of growth of A. terreus in the circuit; POPMAX, the maxima obtained from the Platelia Aspergillus 
assay; C50, the concentration of ISA that 50% suppression of galactomannan is obtained; Hg, the slope function to 
describe A. terreus growth in both absence and presence of drug; IC1, the initial conditions for the pharmacodynamic 
dataset, representing background noise of the assay. 
- 111 - 
 
  
Strain Dose (mg/ 
q12) 
Predicted AUC0-72 
isavuconazole(mg.hr/L) 
Predicted 
AUC0-72 
galactomannan 
A. terreus 
hus1333 
0 0 166.92 
0.1 1.96 284.43 
0.3 4.06 0.39 
1.5 26.59 12.37 
A. terreus 
hus1199 
0 0 278.90 
0.1 0.47 543.96 
0.3 5.39 478.29 
1.5 27.68 197.85 
A. terreus 
hus7980 
0 0 166.92 
0.1 1.77 257.07 
0.3 5.80 27.08 
1.5 26.52 12.55 
Table 3. 4 
Model predicted isavuconazole AUC0-72 and galactomannan absorbance values 
for isolates of A. terreus for individual circuits achieved using the dynamic 
model. 
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3.35 Sigmoid Emax analysis 
 The fit of the sigmoidal curve demonstrated little association between the 
AUC0-72 for galatomannan release and the AUC0-72 of ISA (Figure 3.6, R
2= 0.26). This 
link was improved upon the incorporation of the MIC as a pharamcodynamic predictor 
of response (Figure 3.7, R2= 0.618). 
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Figure 3. 6 
Area under the galactomannan curves (0-72hrs) for A. terreus versus the total 
area under the concentration- time curves for ISA (mg.hr/L). R2=  0.26 
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Figure 3. 7 
Area under the galactomannan curves (0-72hrs) for A. terreus versus AUC:MIC 
ISA (0-72hrs). R2= 0.618. 
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3.4 CONCLUSIONS 
 
Invasive pulmonary aspergillosis caused by A. terreus is of emerging clinical 
concern. The resistance of this species to current antifungal agents is increasing. 
Therefore it is essential to develop novel agents for the treatment of these infections.  
Static studies demonstrate clear pharmacodynamic differences between 
isolates of A. terreus upon increasing exposures to ISA.  One isolate demonstrated 
persistent fungal growth in the presence of drug at the highest concentration used 
whereas other isolates demonstrated a clear dose-dependent reduction in 
galactomannan release upon increasing exposure to drug. These results are 
proportional to the MICs obtained for these isolates. A strain with a higher MIC was 
untreatable with ISA in this static model whereas there was a dose-dependent 
antifungal effect against those demonstrating a lower MIC.  This suggests that the 
MIC may make a significant contribution to the pharmacodynamic differences 
observed between isolates and could therefore serve as a predictive parameter 
relating to clinical response. These results are consistent with previous studies that 
have demonstrated the varying susceptibilities of clinical and environmental isolates 
of A. terreus to second generation triazoles such as voriconazole and posaconazole 
(Graybill, Hernandez et al. 2004, Lass-Florl, Griff et al. 2005, Lass-Flörl, Alastruey-
Izquierdo et al. 2009). Whether isolates of A. terreus can ultimately be treated with 
ISA in a clinical setting is yet to be defined. Infections with A. terreus formed 2.8% 
of the total ISA treated patient population in the SECURE phase III trial to establish 
non-inferiority of ISA to voriconazole. However, the stratification of species- 
specific treatment outcomes from this study are yet to be published (Maertens, Raad 
et al. 2016). 
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 A relationship between the MIC and the susceptibility of these isolates to 
ISA in both dynamic and static cellular models can be observed. There was an 
improved correlation between the reduction in galactomannan release and increasing 
AUC:MIC of ISA (R2= 0.614) (Figure 4.7) in dynamic models, compared to that of 
the AUC alone (R2= 0.22) (Figure 4.6). This further supports the potential 
importance of the MIC as a predictor of treatment success for ISA in this model. The 
predicted AUC:MIC values associated with maximal suppression of galactomannan 
were 8.11 and 26.51, comparable to the PD target suggested by Seyedmousavi et al 
(AUC:MIC of 33.4) (Seyedmousavi, Bruggemann et al. 2015). Consistent with PD 
target values obtained for A. fumigatus using this model (Chapter III) (Box, 
Livermore et al. 2016) these estimates are markedly lower than at least one study 
published in the literature (Lepak, Marchillo et al. 2013). However, as detailed in 
Chapter III, key differences in disease severity, and both routes of infection and 
administration between models may account for this variability. Population 
pharmacokinetic models using trough levels predicted that AUC values between 10 
and 343 mg.hr/L were achieved in patients with IFIs (Desai 2014). Probability of 
target attainment (PTA) analyses suggested that at least 90% of this population may 
be able to achieve an AUC:MIC of 33.4 if MIC is ≤1 mg/L. This supports that an 
AUC:MIC of 8-26 may be achievable using clinical regimens and that the two 
susceptible isolates studied in dynamic models may be treatable with ISA without 
dosage escalation. 
Epidemiological surveys performed by EUCAST suggest a clinical 
breakpoint of 1 mg/L for isolates of A. terreus as determined using ECOF values. 
One of the isolates used in this study demonstrates a higher ISA MIC value up to 8 
mg/L and may express potential resistance to azole therapy. Static and dynamic data 
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presented in this study for these isolates further supports that isolates with MICs 
above 1 mg/L may not be treatable with ISA. The underlying mechanisms of azole 
resistance for A. terreus have not been well investigated. Molecular characterisation 
of some azole resistant isolates suggests a potential role for alterations within the 
Cyp51A protein, similar to those seen in A. fumigatus (Arendrup, Jensen et al. 2012). 
However, further characterisation of isolate hus1199 would be necessary to 
determine the molecular mechanisms behind the results observed in this study. 
The results from this study suggest that wild-type isolates of A. terreus may 
be readily treatable with clinically used dosages of ISA. However, isolates with a 
higher MIC may require dosage escalation. The use of population PK models 
described by Desai et al.  may be able to bridge these data to clinical populations to 
derive a susceptibility breakpoint for ISA against A. terreus at which higher dosages 
may be required. 
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CHAPTER IV 
The Pharmacokinetics and 
Pharmacodynamics of Voriconazole 
against isolates of Scedosporium 
apiospermum and Fusarium solani 
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4.1 INTRODUCTION 
Scedosporium apiospermum and closely related organisms within the 
Pseudallescheria- Scedosporium species complex are emerging fungal pathogens that 
can cause disease in both immunocompetent and immunocompromised individuals. 
In neutropenic patients invasive and disseminated infections may develop that can be 
fatal (Cortez, Roilides et al. 2008).  
S. apiospermum exhibits reduced susceptibility to amphotericin B and 
flucytosine, echinocandins and triazole antifungal agents (Cuenca-Estrella, Alastruey-
Izquierdo et al. 2008). Voriconazole is a first-line agent for the treatment of invasive 
scedosporiosis (Tortorano, Richardson et al. 2014). However, the emergence of 
resistant isolates that exhibit reduced in vitro susceptibility are concerning (Tortorano, 
Richardson et al. 2014). The standard regimen of voriconazole for the treatment of 
invasive fungal infections is 6mg/kg intravenously twice-daily on day 1, followed by 
4mg/kg twice daily or 200mg orally. Variable clinical success is seen using this 
regimen for the treatment of scedosporiosis. The clinical response may be as low as 
40-45% in cancer patients and haematopoietic stem cell transplant recipients (Troke, 
Aguirrebengoa et al. 2008). 
A species-specific diagnosis of Scedosporium infection is difficult to achieve. 
The histopathological appearances in tissue are almost identical to those of Aspergillus 
species (Campa-Thompson, West et al. 2014). There are currently no biomarkers that 
are specific for Scedosporium spp. that can be used to establish a diagnosis of invasive 
disease.  A reliable diagnosis therefore depends upon concomitant microbiological 
culture from tissue samples.  
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In 2009, Thornton et al. reported the development of two monoclonal 
antibodies (MAbs), GA3 and HG12, which are directed towards cell wall antigens 
present in species within the Scedosporium- Pseudallescheria complex. The use of 
these MAbs for the detection of species specific antigens in an enzyme-linked 
immunosorbent assay has been used for the identification of these pathogens in 
environment samples. The development of this assay as a clinical product may 
represent a significant advance in the diagnosis of scedosporiosis (Thornton 2009). 
Fusarium spp. are ubiquitous moulds that are emerging as important clinical 
pathogens in immunocompromised patient populations (Boutati and Anaissie 1997, 
Nucci and Anaissie 2007). There are now hundreds of species of Fusarium that have 
been identified.  The majority of these fungi are plant pathogens (Michielse and Rep 
2009). There are approximately eleven known species of Fusarium that are 
pathogenic in humans. F. solani is the predominant species that causes human 
disease, followed by F. oxysporum and F. moniliforme (Dignani and Anaissie 2004). 
The lung is the most common site of primary infection in humans and typically 
affects patients with severe and persistent neutropenia such as those undergoing 
chemotherapy, and transplant recipients (Garnica, Oliveira da Cunha et al. 2015). 
Invasive fusariosis demonstrates mortality rates up to 79% in patients with 
haematological malignancies and 87% in haematological transplant recipients (Nucci 
2003, Campo, Lewis et al. 2010). 
 Imaging and microbiological culture are the main diagnostic techniques used 
for F. solani lung infections. However, these techniques are not species specific. In 
histopathological sections, Fusarium spp. exhibits a morphology similar to that of 
Aspergillus spp. and other filamentous fungi with septate hyphae that exhibit angular 
dichotomous branching.  There are no clinically validated biomarkers available for the 
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detection of these organisms. As a result, the identification of Fusarium spp. to species 
level requires the study of morphological characteristics from organisms recovered 
from cultures. This is a time consuming process that involves considerable 
mycological expertise.   
Al-maqtoofi et al. describe the identification of Fusarium species via the 
detection of a water soluble, surface expressed, carbohydrate antigen present on both 
the conidial spores and hyphae of Fusarium spp. This was done using a genus-specific 
immunoglobulin M (IgM) monoclonal antibody, ED7, directed towards the antigen, 
by ELISA (Al-Maqtoofi and Thornton 2016). The identification of such species-
specific circulatory biomarkers that are indicative of disease state and progression 
provides a platform for the diagnosis of disease using serological techniques.   
There has been much debate on the optimal treatment of invasive fusariosis. 
Traditional treatment regimens were centred upon amphotericin B formulations. 
However, variable in vitro susceptibility profiles, poor clinical response rates and poor 
tolerability all contribute to suboptimal treatment outcomes for fusariosis. With better 
tolerability and improved clinical outcomes, voriconazole has become a first-line 
agent for the treatment of invasive infection (Nucci, Marr et al. 2014). However, in 
vitro susceptibilities of voriconazole against isolates of F. solani are variable 
(Alastruey-Izquierdo, Cuenca-Estrella et al. 2008) and overall response rates to 
voriconazole therapy may be as low as 46% (Perfect, Marr et al. 2003, Stempel, 
Hammond et al. 2015). The commencement of voriconazole therapy without dosage 
optimisation, on the assumption of an invasive disease caused by a more susceptible 
fungi such as Aspergillus spp., may result in the sub-optimal treatment of fusariosis.  
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An understanding of the PD is a first critical step for the optimisation of 
antifungal therapy. There is a lack of understanding of the dose-exposure-response 
relationships for first-line agents such as voriconazole against isolates of 
Scedosporium and Fusarium species. Previous studies are limited to efficacy and do 
not measure drug exposure. Murine models cannot accurately simulate human 
pharmacokinetics of some agents such as voriconazole.  It is clear that the available 
models are far from optimal for the determination of the exposure-response 
relationships in the treatment of these medically important fungi. The development of 
novel models that can mimic a human pathway of disease progression and achieve 
human-like exposures of drug may provide a significant insight into the exposure-
response relationships between current antifungal agents and these lethally infectious 
organisms. The use of these models to further our understanding of the 
pharmacokinetics and pharmacodynamics of novel agents against Scedosporium and 
Fusarium spp. may offer a significant advancement in the development of novel 
treatment strategies for invasive disease.  
In this chapter a previously described model of the human alveolus (Jeans, 
Howard et al. 2012, Box, Livermore et al. 2016) has been used in order to develop 
static and dynamic in vitro models of S. apiospermum and F. solani infection for the 
definition of exposure-response relationships. MAbs, GA3 and HG12, directed 
towards antigens specific to P. boydii and S. apiospermum were used as a measure of 
fungal burden and antifungal drug effect in a model of invasive scedosporiosis. In this 
model of invasive fusariosis, ED7 was used to for the tracking of F. solani. Dynamic 
models for these pathogens were developed using voriconazole against three clinical 
isolates of S. apiospermum and two isolates of F. solani. Once validated these models 
may be used for the assessment of novel antifungal agents against these organisms. 
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4.2 METHODS 
4.21 Organism preparation 
4.211 Pseudallescheria and Scedosporium spp. 
Isolates 
 Isolates of P. boydii , P. ellispoidea and one isolate of S. apiospermum were gifted 
from the Regional Mycology Reference Laboratory, University Hospital of South 
Manchester. Isolates of S. apiospermum were gifted from the Mycology Reference 
Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, 
Spain. Isolates are detailed in Table 4.1. 
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Species Isolate Where obtained 
P. boydii 7935 University Hospital, 
South Manchester 
P. eliipsoidea 13144 University Hospital, 
South Manchester 
S .apiospermum 8353 University Hospital, 
South Manchester 
S. apiospermum CNM-CM6322 Instituto de Salud 
Carlos III, Madrid, 
Spain. 
 
S. apiospermum CNM-CM6386 Instituto de Salud 
Carlos III, Madrid, 
Spain. 
 
 
Table 4. 1 Isolates of P.boydii, P.ellipsoidea and S. apiospermum used for static 
and dynamic studies. 
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Culture 
Isolates of S. apiospermum were stored at -80⁰C using the Microbank ™ preservation 
system.  Isolates were sub-cultured onto an oatmeal agar flask (Sigma-Aldrich, Poole, 
UK), at 30⁰C, 10 days prior to each experiment.   
Inoculum preparation 
Conidial suspensions were prepared by flooding with 20 ml PBS whilst gently 
disturbing the surface of the growth using a sterile swab.  The resulting suspension 
was then filtered through sterile gauze. Washing was performed twice by centrifuging 
the filtrate for 10 minutes at 2500 rpm and re suspending the pellet in 10ml PBS. EBM-
2 was used for the preparation of the final inoculum.  A conidial suspension of 1-2 x 
106 was prepared using a haemocytometer and was confirmed by quantitative cultures 
on SAB-C. 
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4.212 Fusarium spp. 
 Isolates 
All isolates of F. solani used for this thesis were gifted from the Mycology Reference 
Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, 
Spain. Isolates are detailed in Table 4.2. 
 
Species Isolate 
F. solani CNM-CM6951 
F. solani CNM-CM7271 
F. solani CNM-CM7294 
F. solani CNM-CM7328 
 
 
Culture 
Isolates of F. solani were stored at -80⁰C using the Microbank ™ preservation system.  
Isolates were sub-cultured onto a SAB-C, at 30⁰C, 10 days prior to each experiment.   
Inoculum preparation 
Conidial suspensions were prepared by flooding with 20 ml PBS whilst gently 
disturbing the surface of the growth using a sterile swab.  The resulting suspension 
was then filtered through sterile gauze. Washing was performed twice by centrifuging 
the filtrate for 10 minutes at 3500 rpm and re suspending the pellet in 10 ml PBS. 
Table 4. 2 Isolates of F.solani used for static and dynamic studies. 
- 127 - 
 
EBM-2 was used for the preparation of the final inoculum.  A conidial suspension of 
1-2 x 106 was prepared using a haemocytometer and was confirmed by quantitative 
cultures on SAB-C. 
4.22 Sequencing of organisms 
The identification of P.boydii and S. apiospermum was done via sequencing of the 
internal transcribed spacer (ITS) and β-tubulin regions of the fungi. Isolates of P. 
boydii spp. and S. apiospermum detailed in chapter IV were sequenced in the PHE 
Mycology Reference Laboratory, Bristol. Extraction of fungal DNA was performed 
as follows. 20-40 Acid washed glass beads were suspended in 0.5 mL of sterile 
distilled water. 2 mm diameter Flinders Technology Associates (FTA) filters were 
cut from a Whatman FTA classic indicator card (Whatman International) using a 
sterile puncture and placed into 200 µL Ependorfs (where from). Organisms were 
grown on oatmeal agar for five days prior to isolation. Mycelium and spores were 
isolated from the colony by gentle abrasion with a sterile needle. Samples were then 
added to 1.5 mL Ependorfs containing beads and water. Samples were homogenised 
using a FastPrep-24 homogeniser for run twice for 30 seconds at 6.5 m/s. Sterile 
filters were then inoculated with 2 µL of homogenate from each sample for the 
extraction of DNA. Filters were left to dry for 10 minutes then washed twice with 
100 µL sterile distilled water. For amplification, 700 µL of polymerase chain 
reaction (PCR) reaction mix was prepared and consisted of 70 µL buffer (QIAGEN, 
UK), 7 µL dNTPs (2.5mM), 70 µL forward primer, 70 µL reverse primers, 420 µL 
PCR grade H2O, 3.5 µL HotstarTaq (QIAGEN, UK). PCR reaction mixture was then 
vortexed for 1 min. 100 µL of PCR reaction mixture was added to each PCR tube 
containing inoculated filter. PCR reaction conditions were as follows; 15mins 94⁰C 
for one cycle, 40 cycles of 30 sec at 94⁰C, 30 sec 50⁰C, 90 sec 72⁰C, one cycle of 7 
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mins at 72⁰C, 4⁰C for remainder. After the PCR cycle completed, 8 µL was 
transferred to a new PCR tube and 5 µL of the appropriate forward primer was added 
for sequencing of the ITS and β-tubulin regions. Sequencing of the amplicons was 
done by Beckman- Coulter Genomics Inc. Sequences were analysed for 
identification via the FUNCBS.txt database 
(http://www.cbs.knaw.nl/Collections/BioloMICSSequences.aspx).  
4.23 In vitro susceptibility testing 
Minimum inhibitory concentrations (MIC) for voriconazole (VRC) against S. 
apiospermum and F. solani isolates were determined in 5 independent experiments 
using both the European Committee for Antimicrobial Testing (EUCAST) and 
Clinical Laboratories Standards Institute (CLSI) methodologies. Concentrations for 
MIC testing ranged from 0.06 mg/L to 32 mg/L.  The modal value, range and 
geometric mean were determined.  The mode was used in the pharmacodynamic 
analyses for the determination of AUC:MIC values. 
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4.24 Static models of invasive scedosporiosis 
4.241 Inoculum finding for P. boydii/ S. apiospermum 
Cellular bilayers were constructed as described in Chapter II and grown up to 
confluency for five days in a 24-well plate. On the day of experiment, three sets of P. 
boydii 7935 inocula were harvested and adjusted to densities of 5x 104, 2.2x 105 and 
1.5x 106. Inocula were confirmed by quantitative culture after 48 hours incubation. 
Each row of Transwells were inoculated with a 100µL of each inoculum, yielding six 
replicates for each concentration of cells. Transwells were incubated at 37⁰C, 5% C02 
for 48 hours. Samples from the alveolar compartment were then taken by lavage with 
PBS and the endothelial media extracted. Samples were stored at -80⁰C. Antigen 
detection was done at University of Exeter by Dr. Christopher Thornton, using the 
ELISA methodology described for P. boydii/ S. apiospermum in Chapter II without 
the use of goat anti-mouse biotin antibody. 
4.242 Optimisation of inoculation period for P. boydii/ S. apiospermum static 
models 
Cellular bilayers were constructed as described in Chapter II and grown up to 
confluency for five days in a 24-well plate. On the day of experiment, an inoculum of 
1-2 x 106 was harvested from cultures and 100µL of inoculum was pipetted onto the 
alveolar layer of transwells. Inoculated transwells were incubated at 37⁰C, 5% C02 for 
6, 9, 12 and 15 hours post-inoculation. At these time-points the inoculum was removed 
and Transwells were incubated for a further 48 hours post-removal to monitor the 
invasion of the fungi. After 48 hours models were harvested to obtain alveolar and 
endothelial samples. Antigen detection was performed at the University of Exeter in 
collaboration with Dr. Christopher Thornton, using an ELISA methodology described 
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for P. boydii/ S. apiospermum in section 4.27 without the use of goat anti-mouse biotin 
antibody. 
4.25 Dynamic Model of invasive scedosporiosis 
4.251 Bioreactors and Construction  
 
 
 
 
  
A 
B 
Figure 4. 1 Set-up of the dynamic in vitro model of the human alveolus specific 
for voriconazole against Scedosporium apiospermum. 
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B PK sampling PD sampling 
Figure 4. 2 Set-up of the dynamic in vitro model of the human alveolus specific 
for voriconazole against Fusarium solani. 
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4.252 Treatment with Voriconazole and sampling 
Voriconazole pure powder was dissolved in DMSO. Dilutions were prepared 
from known stock concentrations in DMSO in order to achieve the required 
concentrations for each dynamic system. Each regimen was administered directly into 
the central compartment as a 100µL bolus. Dosages were selected from previously 
published data demonstrating the achievement of voriconazole exposures that ranged 
from sub-optimal to successful in treating organisms of similar susceptibilities in this 
model (Jeans, Howard et al. 2012). Dosages of 0mg, 0.1mg, 0.2mg, 1mg and 3mg 
were administered every 12 hours to the central compartments. The pump connected 
to the fresh media and the waste Durans for the clearance of drug was run at a speed 
of 1.9 rpm proportional to a flow rate of 10 mL/hour. This was demonstrated 
previously to generate human-like concentration- time profiles for voriconazole, as 
described by Jeans et al. (Jeans, Howard et al. 2012). 
For each experiment the PK and PD of voriconazole against each isolate of S. 
apiospermum and F. solani were determined in four individual circuits. Each circuit 
was treated with a different dosage of drug.  A fifth untreated circuit was used as a 
control.  Four different dosages were used for each drug. Drugs were administered 
twice-daily. Sampling regimens for both pharmacokinetics and pharmacodynamics 
profiles were optimised using data generated from control circuits (PK alone and PD 
alone). Samples for PK and PD were taken up to 96 hours post treatment. After 
sampling, media taken out of the system was replaced with an equal volume of 
complete DMEM. 
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4.26 Mass Spectrometry 
Mass spectrometry for pharmacokinetic analysis was performed by Joanne 
Goodwin and Sarah Whalley at the University of Liverpool. 
Voriconazole concentrations were determined using a UHPLC/MS-MS triple-
quadrupole 6420 mass spectrometer, (Agilent Technologies, Santa Clara, CA, USA). 
Instrument parameters were optimized for voriconazole (350.0 → 224.0 m/z).  
Voriconazole was extracted from DMEM media using acetonitrile and methanol 
(Fisher Scientific, Loughborough, UK) with IS. 
HPLC separation was achieved using a Zorbax Eclipse Plus Rapid 1.8 µm C18 
50 x 2.1 mm (Agilent Technologies, Santa Clara, CA, USA) column. The mobile 
phase consisted of 0.2% formic acid in water and 0.2% formic acid in acetonitrile at a 
flow rate of 0.5 ml/min for F90318 and 0.1% formic acid in water and 0.1% formic 
acid in acetonitrile at a flow rate of 0.5 ml/min. The column was maintained at 40 °C. 
Phenacetin (Sigma-Aldrich, Poole, UK ) 100 ng/mL in acetonitrile was used as 
internal standard for voriconazole. The chromatographic run time for one sample was 
3 minutes. The lower limit of quantitation of voriconazole was 0.0025 mg/L. Intraday 
and interday coefficients of variation were <8.4% at concentrations ranging from 
0.0025 to 20 mg/L. 
4.27 Enzyme linked immunosorbent assays 
4.271 P. boydii and Scedosporium spp. 
MAbs were developed and cultured as described by Thornton et al. (2009). 50 µL 
volumes of HG12 antibody prepared as previously described (Thornton 2009) were 
used to coat the surface of the wells of Maxisorp microtiter plates (Fisher Scientific, 
Loughborough, UK). After incubation at 4⁰C overnight microtiter plates were washed 
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four times with PBS containing 0.05% (v/v) Tween20 (PBST). Plates were then 
washed once with PBS and once with distilled water then left to dry by air in a drying 
cabinet at 23⁰C for 1 hour. Wells were incubated at 23⁰C for 10 minutes with 100µL 
of PBS containing 1% (w/v) bovine serum albumin (BSA) to prevent non-specific 
protein binding. All following incubations were performed using 50 µL volumes. 
Wells containing samples were incubated for 2 hours, followed by a 1 hour incubation 
with goat anti-mouse biotin antibody (IgM µ chain specific) (Sigma Aldrich, Poole, 
UK)  diluted 1 in 1000 in PBST containing 0.5% (w/v) BSA. A further 1 hr incubation 
with goat anti-mouse polyvalent (IgG, IgA, and IgM) peroxidase conjugate (Sigma-
Aldrich, Poole, UK) diluted 1 in 1000 in PBST containing 0.5% (w/v) BSA was then 
performed. Bound antibody was visualized by incubating wells with tetramethyl 
benzidine (TMB) substrate solution (Sigma- Aldrich, Poole, UK) for 30 minutes.  
Reactions were stopped by the addition of 3M H2SO4. Absorbance values were 
determined using a spectrophotometer at 450 nm. Wells were given three 5 minute 
rinses with PBST between incubations. Control wells were incubated with tissue 
culture medium (EBM-2) containing 10% (vol/vol) FBS. All incubation steps were 
performed at 23°C in sealed plastic bags. The threshold for detection of antigen in 
ELISA was determined previously from control means (2 TCM absorbance values) 
(Thornton 2001, Thornton 2009). These values were consistently in the range of 0.050 
to 0.100. Consequently, absorbance values of >0.100 were considered positive for the 
detection of antigen. 
4.272 Fusarium  spp. 
MAbs were developed and cultured as described by Thornton et al. (2001). 50 µL 
volumes of antigen contraining samples were used to coat the surface of the wells of 
Maxisorp microtiter plates and incubated at 4⁰C overnight. Microtiter plates were then 
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washed four times with PBST. Plates were then washed once with PBS and once with 
distilled water then left to dry by air in a drying cabinet at 23⁰C for 1 hour. Wells were 
incubated at 23⁰C for 10 minutes with 100µL of PBS containing 1% (w/v) BSA to 
prevent non-specific protein binding. All following incubations were performed using 
50µL volumes. A 1 hour incubation with Anti-Mouse Polyvalent Immunoglobulins 
(G,A,M)−Peroxidase solution (Sigma Aldrich, Poole, UK)  diluted 1 in 1000 in PBST 
was then performed. Bound antibody was visualized by incubating wells with TMB 
substrate solution for 30 minutes.  Reactions were stopped by the addition of 3M 
H2SO4. Absorbance values were determined using a spectrophotometer at 450 nm. 
Wells were given three 5 minute rinses with PBST between incubations. Control wells 
were incubated with tissue culture medium (EBM-2) containing 10% (vol/vol) FBS. 
All incubation steps were performed at 23°C in sealed plastic bags. 
 
4.28 Histology 
Cell culture inserts were transferred to a 12 well plate containing 1.5 mL per well of 
EBM-2 media supplemented with 2% FBS. A conidial suspension of 4-8 x 105 was 
prepared as described earlier and warmed to 37⁰C for 20 minutes. 400 µL of conidial 
suspension was then pipetted into the top compartment of each cell culture insert. Cell 
culture inserts were serially sacrificed in triplicate until 84 hours post inoculation. 
Samples from the endothelial compartment were taken and stored at -80⁰C for PK and 
PD analysis. Membranes/inserts/bilayers were formalin-fixed, routinely processed, 
trimmed, and embedded in paraffin. Care was taken to ensure appropriate tissue 
orientation for evaluation of cross-sectional and endothelial surfaces. Approximately 
5 µm thick, serial sections were cut, mounted on glass slides and stained with Grocott 
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methenamine silver stain (Newcomer Supply, Middleton, WI) at Charles River 
Laboratories, Pathology Associates Division, Frederick, MD. All slides were 
evaluated microscopically by a board-certified anatomic veterinary pathologist (J. 
Schwartz).  Slides were digitally scanned at 40 x and 400 x magnification using an 
Aperio ScanScope CS (Leica Biosystems) and images captured using Spectrum 
10.1.5.2029 software (Leica Biosystems).  High magnification cross-section images 
were acquired using an Olympus BH-2 microscope. 
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4.25 Mathematical Modelling  
A population methodology was used throughout. Version 1.2.9 of the 
population PK- PD program Pmetrics was used for all fitting.  For the estimation of 
pharmacokinetic polynomial error, the intercept and slope values from a polynomial 
equation derived using trough, median and Cmax values from circuits treated with 3mg 
dosages were used. A one compartmental model was used in order to represent the 
experimentally simulated bloodstream infection and its subsequent treatment with 
voriconazole. For pharmacodynamic datasets, data were normalised to a maxima of 1 
due to variability in maximum absorbance obtained in control circuits between 
isolates. Initially a Tlag was used to account for the delayed observation of Cmax in the 
model. However, as voriconazole is also given as an oral formulation the delayed Cmax 
may be better described using an absorption parameter to represent oral dosing of the 
drug. Therefore, a parameter to define absorption (Ka) was used to improve the fit of 
the model as used by Hope et al. in a previous model of orally dosed voriconazole 
(Hope, VanGuilder et al. 2013). Initial conditions for pharmacodynamic data were set 
to describe PD values obtained at T0 due to background noise from the assay. The 
structural mathematical model consisted of the following two inhomogeneous 
ordinary differential equations: 
dX1/dt=B(1)-(SCL/Vc)*X1    Equation 1 
dN/dt=Kgmax*(1-(N/POPMAX))*N   Equation 2a 
*(1-(X1/Vc)Hg/(X1/Vc)Hg+C50Hg))    Equation 2b 
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Where: B(1) is the bolus input of is the bolus input of VRC, SCL is the 
clearance of drug  from the circuit, Vc  is the volume of the circuit, N is the antigen 
concentration, Kgmax is the maximal rate of growth; POPMAX is the theoretical 
maximal density within the circuit; Hg is the slope function for the suppression of 
growth; and, C50 is the concentration of drug in the circuit where there is half-maximal 
suppression of growth. 
Equation 1 describes the rate of change of drug concentrations in the circuit.  
Equation 2 describes the rate of change of antigen in the circuit and contains terms 
that describe fungal growth in the absence of drug (Equation 2a) and the drug induced 
suppression of growth (Equation 2b). 
The model was fitted to the dataset of untreated and treated circuits obtained 
from each isolate.  Each circuit was treated as an “individual”.  The fit of the model 
was assessed using the coefficient of determination (r2 ) from a linear regression of the 
observed vs. predicted plots for both population and individual predictions, the mean 
and median values of parameters predicted by the model compared to those observed 
experimentally and the log likelihood. The Bayesian posterior estimates for each of 
the parameters in the model were then used to define the concentration-time profile of 
voriconazole and the resultant effect on antigen concentrations.  As the AUC:MIC has 
been shown to be the pharmacodynamic indices best associated with maximal 
antifungal effect (REF), parameter estimates were used to estimate the AUC that 
developed in each circuit and consequently the AUC:MIC ratio. 
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4.3 RESULTS 
 
4.31 Minimum Inhibitory Concentrations 
The minimum inhibitory concentrations (mode, range and geometric mean) for 
voriconazole against isolates of S. apiospermum, P. boydii and F. solani are 
summarised in Table 4.3. 
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EUCAST CLSI 
Drug Species Isolate Mode Range Mean Mode Range Mean 
Voriconazole S. apiospermum 8353 0.5 0.5-1 0.57 0.25 0.25-0.25 0.25 
Voriconazole S. apiospermum 6322 1 1-1 1 0.25 0.25-0.25 0.25 
Voriconazole S. apiospermum 6386 1 0.5-1 0.71 0.5 0.25-0.5 0.44 
Voriconazole P. boydii 7935 0.5 0.5-0.5 0.5 2 2-8 3.48 
Voriconazole P. ellipsoidea 13144 8 8-8 8 4 0.5-4 1.74 
Voriconazole F. solani CNM-6951 16 8-16 12.12 4 2-4 3.03 
Voriconazole F. solani CNM-7328 16 8-32 16 16 8-16 10.56 
Table 4. 3 
Minimum inhibitory concentrations were determined in 5 independent experiments. Means displayed above are geometric means. 
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4.32 Pseudallescheria boydii- Scedosporium apiospermum models 
4.321 Growth and inocula investigation 
Preliminary experiments using P. boydii 7935 demonstrated that an inoculum 
of 1-2x 106 and an initial incubation period of 12 hours preceding a 48 hour model 
post- removal of inoculum yielded the highest absorbance values using ELISA 
methodology for the detection of antigen in both alveolar and endothelial samples 
(Figures 4.3 and 4.4). These conditions were therefore used for subsequent 
experiments using drug. The maximum absorbance value obtained from these 
preliminary finding experiments was approximately 0.17. Therefore, for further 
analysis of pharmacodynamic samples the use of a goat anti-mouse biotin antibody 
(IgM µ chain specific) (Sigma Aldrich, Poole, UK) was incorporated into the ELISA 
methodology for the amplification of signal and improvement of dynamic range.  
Figure 4. 3 
Mean absorbance values from static models to determine optimal inoculcum 
density of of P. boydii for invasion through the cellular bilayer and detection of 
antigen. All samples were obtained after 48 hours post-removal of inocula.  Data 
presented are the mean absorbance values obtained from six transwells. Error bars 
represent the standard deviations between transwells for each time-point.  
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Figure 4. 4 
Mean absorbance values from static models to determine optimum time for conidial 
germination of P. boydii 7935.  Data presented are the mean absorption of six 
transwells. Error bars represent the standard deviations between transwells for each 
time-point.  
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4.322 In vitro Histopathology model 
Germination and invasion of S. apiospermum conidia through the cellular bilayer was 
observed over 84 hours as seen in Figure 4.5 and 4.6. Antigen levels increased over 
time to a maximum absorbance of approximately 1.5 (absorbance at 450nm). There 
was little variation in antigen detection between experiments at the same time-point, 
with relatively low standard deviation values between cellular models (0.0006-0.12) 
(Figure 4.5). After 12 hours the conidia had begun to germinate into hyphae, invade 
through the cell layers and were able to colonise the endothelial layer (Figure 4.6). By 
72 hours post inoculation complete invasion, biofilm development and destruction of 
the cell layers were observed (Figure 4.6).
Figure 4. 5 
Detection of antigen in the endothelial compartment of transwells infected with 
S. apiospermum isolate 8353 over 84 hours measured using HG12 and GA3 
antibodies. Error bars represent the standard deviation between triplicate samples 
for each time-point. 
 
144 
 
400x 40x 40x 
40x 40x 400x 
Figure 4. 6 Histopathology of the growth and biofilm development of S. apiospermum on the endothelial side of the cellular 
bilayer over 84 hours.  
Arrows point to S. apiospermum conidia (36hr) and hyphae (84hr) on the endothelial cell layer. 
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4.333 Static models of the human alveolus 
The exposure-response relationships for voriconazole are described in Figure 4.7. 
Antigen detection was consistent for samples obtained from untreated controls in static models. 
Variability between antigen levels measured in samples exposed to the same concentration of 
drug was apparent in those obtained from the alveolar compartment. A maximum absorbance 
value of approximately 1 -1.5 for isolates of S. apiospermum, P.boydii and P. ellipsoidea were 
achieved as opposed to 0.17 in growth experiments suggesting the use of biotin antibody 
successfully boosts the range of this ELISA. Voriconazole concentrations of approximately 8 
mg/L, 4 mg/L and 2 mg/L were sufficient for maximal suppression of antigen release for S. 
apiospermum isolates 8353, 6322 and 6386 respectively. For isolates of P.boydii and P. 
ellipsoidea concentrations of approximately 4 mg/L and 1 mg/L were sufficient for the 
maximal suppression of growth. 
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Figure 4. 7 
Pharmacokinetics and pharmacodynamics of voriconazole in a static model against S. apiospermum isolates (A) 8353, 
(B) 6322, (C) 6386, P. boydii 7935(D)  and P. ellipsoidea 13144 (E).   
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5.333 Dynamic models of the human alveolus 
Human like concentration-time profiles for VRC were generated using a twice-daily 
dosing regimen in this model (Table 4.4, Figures 4.8-4.10). Clinically relevant exposures were 
achieved within the circuits (Table 4.5) however there was a delay in the detection of maximal 
concentrations within the system of 2-4 hours post dose. This was due to PK sampling after the 
bioreactor as opposed to straight out of the central compartment. For all isolates there were 
dose response relationships using a twice-daily dosing regimen. Model- predicted AUC72-96 
values of 66.6, 65.5 and 64.5 mg.hr/L for isolates 8353, 6322 and 6386 respectively, were 
associated with maximal suppression of antigen, using a minimum threshold absorbance of 0.1 
measured at 450nm.  Subsequently, AUC72-96: MIC ratios calculated using EUCAST 
methodology generated MIC values that were associated with maximum effect were 133.3, 
65.5 and 64.5 for isolates 8353, 6322 and 6386 respectively. The antigen was detected 
consistently under the flow and clearance conditions set by the model. The kinetics of antigen 
expression in the untreated circuits was different between isolates. Antigen concentrations for 
isolates 8353 and 6386 began to increase at around 60-72 hours post-inoculation. Isolate 6322 
was slightly slower growing and may be less virulent as antigen levels only began to increase 
at 84-96 hours post- inoculation. 
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Figure 4. 8 Pharmacokinetics and pharmacodynamics of voriconazole against S. 
apiospermum isolate 8353. 
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Figure 4. 9 Pharmacokinetics and pharmacodynamics of voriconazole against S. 
apiospermum isolate 6322. 
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Figure 4. 10 Pharmacokinetics and pharmacodynamics of voriconazole against 
S. apiospermum isolate 6386. 
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4.334 Mathematical Modelling 
The fit of the mathematical models to the data were acceptable. Bayesian R2 values were 0.715 
and 0.73 for pharmacokinetic and pharmacodynamic data respectively (Figure 4.11). The use 
of Ka as a parameter improved the fit of the model. Despite this, the delay in Cmax levels due 
to the late sampling point in the system reduced the r2.  The fits of the Bayesian posterior 
estimates for each circuit is shown in Figures 4.8-4.10. The posterior median parameter values 
can be seen in Table 4.4. Predicted AUC72-96 values (mg.hr/L) for voriconazole and total AUC 
for the antigen are displayed in Table 4.5. 
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Figure 4. 11 
Observed vs predicted graphs after the Bayesian step, generated using Pmetrics for (A) pharmacokinetics data from 15 
individual circuits and (B) pharmacodynamics data as measured by antigen from 15 individual circuits. 
A 
B 
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Isolate Dose 
(mg) 
Ka Cl V Kgmax POPMAX C50 Hg IC1 
8353 0 0.90 0.04 0.30 0.03 1.49 1.13 4.84 0.061 
8353 0.1 0.88 0.05 0.30 0.03 1.49 1.14 4.83 0.061 
8353 0.2 4.03 0.03 0.30 0.02 1.49 0.58 6.03 0.07 
8353 1 4.01 0.03 0.30 0.02 1.49 0.59 6.00 0.07 
8353 3 4.01 0.02 0.30 0.02 1.49 0.59 6.00 0.07 
6322 0 4.01 0.03 0.30 0.02 1.49 0.59 6.00 0.07 
6322 0.1 0.88 0.05 0.30 0.03 1.49 1.14 4.83 0.06 
6322 0.2 4.03 0.03 0.30 0.02 1.49 0.58 6.03 0.07 
6322 1 2.55 0.03 0.30 0.03 1.49 1.13 4.85 0.06 
6322 3 4.02 0.03 0.30 0.02 1.49 0.58 6.01 0.07 
6386 0 2.54 0.03 0.30 0.03 1.49 1.13 4.85 0.06 
6386 0.1 4.02 0.03 0.30 0.02 1.49 0.58 6.01 0.07 
6386 0.2 0.88 0.05 0.30 0.03 1.49 1.14 4.83 0.06 
6386 1 2.53 0.03 0.30 0.03 1.49 1.13 4.85 0.06 
6386 3 4.01 0.03 0.30 0.02 1.49 0.59 6.00 0.07 
Table 4. 4 
The median posterior parameter estimates from the mathematical model using data from 15 individual circuits. Ka is a description of 
absorption and describes the estimated time taken for Cmax concentrations to be reached at the sampling point in the circuit. Cl represents 
the estimated clearance of VRC from the ciruit; V; the estimated volume of the central compartment; Kgmax, the predicted rate of 
growth of S. apiospermum in the circuit; POPMAX, the maxima obtained from the ELISA assay; C50, the concentration of voriconazole 
that 50% suppression of antigen is obtained; Hg, the slope function to describe S. apiospermum growth in both absence and presence 
of drug; IC1, the initial conditions for the pharmacodynamic dataset, representing background noise of the assay. 
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Strain Dose (mg/ q12) Predicted AUC72-96 
voriconazole 
(mg.hr/L) 
Predicted AUC0-
96 antigen 
S. apiospermum 8353 0 0 25.70 
0.1 4.39 25.48 
0.2 15.42 12.98 
1 66.64 6.79 
3 254.91 6.78 
S. apiospermum 6322 0 0 22.72 
0.1 4.38 25.48 
0.2 15.42 12.98 
1 65.55 6.69 
3 206.27 6.81 
S. apiospermum 6386 0 0 25.76 
0.1 6.95 21.92 
0.2 8.71 24.89 
1 64.46 6.73 
3 197.12 6.78 
 
Table 4. 5 
Model predicted voriconazole AUC72-96 and antigen AUC0-96 for isolates of S. apiospermum 
for individual circuits achieved using the dynamic model. 
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Figure 4. 12 
Total AUC for Scedosporium specific antigen detected at 450nm, versus AUC72-96 for 
voriconazole (mg.hr/L). Equations were generated in ADAPT 5 using the maximum 
likelihood estimator.  
AUCantigen=  24.67-(17.92*(AUC)^7.9)/((AUC)^7.9+14.23^7.9).  
R2=  0.986. 
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Figure 4. 13 
Total AUC for Scedosporium specific antigen detected at 450nm, versus AUC72-96 : MIC 
(EUCAST methodology). Equations were generated in ADAPT 5 using the maximum 
likelihood estimator. 
AUCantigen =  24.89-(18.42*(AUC)^2.455)/((AUC)^2.455+19.77^2.455) 
R2=  0.986 
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5.34 Fusarium solani models 
5.341 Static models of the human alveolus 
The exposure-response relationships for voriconazole are described in Figure 4.14 (A 
& B). Antigen detection was consistent for samples obtained from the model and seemed to be 
in proportion to fungal burden seen by eye. Maximum absorbance values of approximately 1 -
1.5 measured at 450nm were obtained for untreated inserts infected with isolates of F. solani. 
Voriconazole concentrations of approximately 8 mg/L were sufficient for maximal suppression 
of antigen release for isolate 7328. For isolate 6951, antigen was not sufficiently suppressed 
even at the highest concentration of 16 mg/L.  
  
Figure 4. 14 Pharmacokinetics and pharmacodynamics of voriconazole in a static model 
against F. solani isolates. 
CNM-6951 (A) and CNM-7328 (B).  
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5.342 Dynamic models of the human alveolus 
The exposure-response relationships for voriconazole against F. solani were similar for 
both isolates studied (Figures 4.15-4.16). Sampling for PK was taken before the bioreactor and 
Cmax levels of drug were detected within an hour of dosing in these experiments. Trough 
concentrations of approximately 1.5 mg/Lwere sufficient in suppressing the release of antigen 
for all isolate using a cut off value of 0.1. These concentrations are proportional to the MICs 
obtained for voriconazole against these isolates. Model- predicted AUC24-48 values of 64.9- and 
85.2 mg.hr/L corresponding to AUC24-48; MIC ratios of 4 and 5 were associated with minimal 
detection of antigen using a cut-off absorbance value at 450nm of 0.1 for isolates CNM-6951 
and CNM-7328 respectively. 
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Figure 4. 15 Pharmacokinetics and pharmacodynamics of voriconazole against F. solani CNM-
6951. 
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Figure 4. 16 Pharmacokinetics and pharmacodynamics of voriconazole against F. solani 
CMM-7328. 
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5.343 Mathematical Modelling 
The fit of the mathematical models to the data were acceptable. Bayesian R2 values were 0.958 
and 0.691 for pharmacokinetic and pharmacodynamic data respectively (Figure 4.17). The use 
of absorption (Ka) as a parameter improved the fit of the pharmacokinetic model.  The fits of 
the Bayesian posterior estimates for each circuit is shown in Figures 4.15-4.16. The posterior 
median parameter values can be seen in Table 4.6. Predicted AUC48-72 values (mg.hr/L) for 
voriconazole and total AUC for the antigen are displayed in Table 4.7. 
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 Figure 4. 17 
Observed vs predicted graphs after the Bayesian step, generated using Pmetrics for (A) pharmacokinetics data from 10 individual 
circuits and (B) pharmacodynamics data as measured by absorbance at 450nm from 10 individual circuits. 
A B 
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Isolate Dose 
(mg) 
Cl 
(L/hr_) 
V (L) Kgmax POPMAX C50 Hg IC1 
CNM-6951 0 0.03 0.47 0.03 2.98 0.42 5.72 0.033 
CNM-6951 0.1 0.03 0.31 0.03 2.48 0.85 3.59 0.042 
CNM-6951 0.2 0.04 0.29 0.005 0.55 0.25 7.96 0.070 
CNM-6951 1 0.02 0.31 0.01 2.99 1.77 5.68 0.062 
CNM-6951 3 0.02 0.19 0.02 0.86 1.99 0.83 0.054 
CNM-7328 0 0.03 0.47 0.03 2.98 0.422 6.87 0.033 
CNM-7328 0.1 0.04 0.50 0.05 2.99 0.41 8.91 0.009 
CNM-7328 0.2 0.04 0.50 0.05 2.99 0.41 8.91 0.009 
CNM-7328 1 0.03 0.50 0.03 2.99 0.37 5.20 0.024 
CNM-7328 3 0.03 0.50 0.03 2.99 1.95 6.91 0.033 
Table 4. 6 
The median posterior parameter estimates from the mathematical model using data from 10 individual circuits. Cl represents 
the estimated clearance of VRC from the ciruit; V; the estimated volume of the central compartment; Kgmax, the predicted 
rate of growth of F. solani in the circuit; POPMAX, the maxima obtained from the ELISA assay; C50, the concentration of 
voriconazole that 50% suppression of antigen is obtained; Hg, the slope function to describe F. solani growth in both absence 
and presence of drug; IC1, the initial conditions for the pharmacodynamic dataset, representing background noise of the 
assay. 
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Strain Dose (mg/ q12) Predicted AUC48-72 
voriconazole 
(mg.hr/L) 
Predicted AUC0-
72 antigen 
F. solani CNM- 
6951 
0 0 15.0.2 
0.1 5.07 21.63 
0.2 10.15 7.99 
1 68.80 2.29 
3 230.63 3.13 
F. solani CNM- 
7328 
0 0 14.97 
0.1 5.98 17.48 
0.2 9.27 7.42 
1 86.17 6.71 
3 348.93 6.17 
Table 4. 7 
Model predicted voriconazole AUC48-72  and area under antigen curves (0-72) for 
individual circuits achieved using the dynamic model. 
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Figure 4. 18 
Total AUC for Fusarium specific antigen detected at 450nm, versus AUC48-72 for 
voriconazole (mg.hr/L). Equations were generated in ADAPT 5 using the maximum 
likelihood estimator. 
AUCantigen  = 17.41-(12.78*(AUC)^10.53)/((AUC)^10.53+8.387^10.53) 
R2=  0.879 
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Figure 4. 19 
Total AUC for Fusarium specific antigen detected at 450nm, versus area under the 
AUC48-72: MIC (EUCAST methodology). Equations were generated in ADAPT 5 using 
the maximum likelihood estimator. 
AUCantigen = 17.40-(12.74*(AUC)^10.42)/((AUC)^10.42+0.5237^10.42) 
R2=  0.879 
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4.4 CONCLUSIONS 
Scedosporium and Fusarium spp. are emerging fungal pathogens. The treatment 
of these infections is problematic owing to primary resistance to several agents used 
in first-line therapy. Voriconazole is a first-line agent for the treatment of invasive 
scedosporiosis; however, the clinical outcome using this agent is variable. Due to the 
scarcity of randomised comparative data from clinical studies to compare the 
antifungal efficacy of agents for the treatment of disseminated F. solani infection, the 
optimal treatment strategy for this disease remains unclear. With a favourable toxicity 
profile to amphotericin B, voriconazole has become a first-line treatment option for 
invasive fusariosis despite demonstrating high minimum inhibitory concentrations and 
variable clinical success (Alastruey-Izquierdo, Cuenca-Estrella et al. 2008, Lortholary, 
Obenga et al. 2010).  
The pharmacokinetics and pharmacodynamics (PK-PD) of a drug are central for 
an understanding of the relationship between dose, exposure and the subsequent 
antifungal effect of an agent. An understanding of these key relationships may provide 
insight into the exposures of drug that are best associated with optimal antifungal 
efficacy. To date, the PK-PD of currently used agents for the treatment of invasive S. 
apiospermum and F, solani infections has not been extensively studied. Current 
animal models are limited to tail-vein models of fungaemia. No models of invasive 
pulmonary disease for these fungi have been described. The pharmacokinetics of 
voriconazole in mice are characterised by a rapid clearance of drug. Therefore, 
clinically relevant exposures cannot be achieved. This chapter describes the 
development of novel in vitro models of early invasive pulmonary disease with S. 
apiospermum and F. solani that are able to simulate human-like voriconazole PK.  
These models were used to define the PK-PD relationships of voriconazole against 
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clinical isolates of S. apiospermum and F. solani, using novel antigens directed 
towards these pathogens as a measure of disease progression. 
4.41 Models of P. boydii and S. apiospermum  
4.411Static models of the human alveolus  
The detection of the Scedosporium/Pseudallescheria boydii specific antigen in 
both alveolar and endothelial compartments of untreated static models was consistent 
(Figures 4.5 and 4.7). Maximum absorbance values of approximately 1-1.5 were 
detected in endothelial samples from these models. These values are comparable to 
maxima achieved by Thornton et al. and suggest that the fungi were able to invade 
through the cellular bilayer effectively (Thornton 2009).  Upon histological 
examination of transwells over time, an association between the detection of antigen 
in the endothelial compartments and fungal burden was seen, indicating that the 
antigen may be a good marker for disease progression in this model (Figures 4.5 and 
4.6).    
For drug treated models, voriconazole demonstrated a dose dependent reduction 
in antigen for all isolates. The concentrations at which maximal antifungal effect was 
observed in static models were consistent with the respective MIC values, with the 
exception of two isolates (Figure 4.7, A and B). Here, we must consider the effect of 
starting inoculum on the observed antifungal effect. The starting inoculum used in 
these preliminary studies is markedly higher than those used in standardised 
methodologies set by EUCAST and CLSI which may explain the difference in 
exposures needed to achieve antifungal effect for a “susceptible” isolate in this model 
(CLSI 2008, Arendrup, Cuenca-Estrella et al. 2012).  For isolates that demonstrated 
slightly lower absorbance values in untreated controls, exposure- response 
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relationships can be seen at levels of drug comparable to those seen in the clinic 
(Pascual, Calandra et al. 2008). It is also important to note that some models 
demonstrate variable antigen measurement in samples taken from the alveolar 
compartments. This may be due to the variable amount of fungi that is extracted when 
flooding the surface of the alveolar layer.   
5.412 Dynamic models of the human alveolus 
S. apiospermum was markedly slower growing than other filamentous fungi used 
in this model such as Aspergillus spp (Box, Livermore et al. 2016). Little to no growth 
was seen in the first 48 hours of these experiments. The maximum absorbance values 
detected in untreated circuits varied between isolates, largely with isolate 6386. This 
isolate also observed a low maximum absorbance in static studies. A difference in 
virulence between clinical isolates of S. prolificans has previously been documented 
in murine investigations, despite demonstrating pathogenicity in humans (Ortoneda, 
Pastor et al. 2002). It may be that some isolates of S. apiospermum demonstrate lesser 
virulence in this cell associated model to others which may account for the differences 
in antigen detected between models.   
 When PK samples were taken after the bioreactor, Cmax levels were reached within 
2-4 hours. This is not representative of the bolus dose administered, which may be a 
limitation of this particular dataset and may be why the model fit is not optimal (R2= 
0.715). However, the pharmacokinetics generated using this model are comparable to 
those seen in orally dosed patients where peak plasma concentrations are achieved up 
to 2 hours post-administration (Wang, Xie et al. 2015). 
In clinical populations, voriconazole displays a marked variability in drug 
exposure that is due in part to its non-linear pharmacokinetic behaviour. It is difficult 
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to predict a dosage that will yield exposures within a therapeutic window without the 
use of therapeutic drug monitoring (Trifilio, Pennick et al. 2007, Moriyama, Kadri et 
al. 2015). A number of studies have investigated the importance of voriconazole serum 
concentrations in relation to both clinical outcome and toxicity in patients at risk or 
with IFI (Table 4.8). The area under curve: MIC (AUC: MIC) has been described as 
the pharmacodynamic parameter best associated with therapeutic success in 
preclinical models of Aspergillus spp. (Andes, Marchillo et al. 2003, Mavridou, 
Bruggemann et al. 2010, Jeans, Howard et al. 2012)..  
Clinical data from haematopoietic stem cell transplant patients suggest that 
AUC0-24 values of around 70 mg.hr/L were achieved using standard dosages of 
voriconazole. These values are comparable to AUCs associated with maximum 
suppression of antigen in this model of around 65 mg/L (Table 4.5) (Bruggemann, 
Blijlevens et al. 2010). This suggests that with currently used regimens, the 
voriconazole exposures associated with treatment success in this model may be 
suitable for the treatment of scedosporiosis with these isolates.  
The MICs from this study correlate well with the reported MIC90 of 1 mg/L
 for 
voriconazole against clinical isolates of S. apiospermum (Troke, Aguirrebengoa et al. 
2008).  The concentrations relative to maximal suppression of the antigen in the 
dynamic model are consistent with the respective MICs suggesting that clinically used 
regimens may be effective in treating the isolates used in dynamic models. 
Predicted AUC: MIC values of 133.3, 65.5 and 64.5 (Figure 4.14) were 
associated with maximal antifungal effect in this model.  These values are similar to 
those obtained for voriconazole against isolates of A. fumigatus in a similar 
experimental model of aspergillosis where an AUC:MIC value of 45.59 was 
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associated with a 90% probability of treatment success (Jeans, Howard et al. 2012). 
Furthermore, a strong association between the AUC:MIC and antigen suppression was 
demonstrated (Figure 4.14, R2= 0.986)  indicating that the MIC may be predictive of 
antifungal efficacy for voriconazole in this model. 
Although AUC:MIC has been derived as the best pharmacodynamic parameter 
associated with treatment success, the number of clinical samples required for the 
determination of AUC is often difficult to obtain from patients. Therefore many 
clinical studies use trough levels of voriconazole as a surrogate for AUC to predict 
treatment outcome (Table 4.8). However, a small change in dose based on reported 
trough levels of drug may have a disproportionate effect on serum levels due to the 
non-linear pharmacokinetic profile seen with voriconazole. Studies have reported that 
nonparametric population models may be able to predict voriconazole AUC from 
clinically obtained Cmin values. There is the potential here to predict target exposures 
from as little as one pharmacokinetic sample, for the individualisation of therapy 
(Hope, VanGuilder et al. 2013, Neely, Margol et al. 2015, Huurneman, Neely et al. 
2016) 
Troke et al. reported a relationship between increasing trough/ MIC ratio and 
the probability of clinical success for the treatment of IFI. These analyses estimated a 
trough/ MIC ratio between 2 and 5 to be associated with maximal clinical outcome in 
the treatment of IFIs (Troke, Hockey et al. 2011). This correlates well with trough/ 
MIC ratios calculated from dynamic model data for voriconazole against isolates of S. 
apiospermum which are 5.2, 2.7 and 2 for strains 8353, 6322 and 6386 respectively. 
The largest study to date, described by Dolton et al., retrospectively analysed 
voriconazole TDM data collected from 201 patients from centres across Australia. 
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Plasma levels of drug were shown to be a significant determinant of clinical success. 
It was suggested that trough concentrations of ≥ 1.17 mg/L significantly minimised 
the risk of treatment failure, whilst levels ≥ 5 mg/L saw an increase in the incidence 
of neurological adverse events (Dolton, Ray et al. 2012). A similar therapeutic window 
was suggested by Pascual et al. In this cohort, 46% of patients with trough levels ≤ 
1mg/ L failed to respond to therapy and all patients experiencing neurological adverse 
events demonstrated trough levels ≥ 5.5mg/ L (Pascual, Calandra et al. 2008). Troke 
et al. also performed a retrospective analysis on data from 9 clinical trials confirming 
low response rates outside of the range of 0.5 mg/L- 5 mg/L (Troke, Hockey et al. 
2011).  
In this in vitro model of scedosporiosis, median trough concentrations of 
approximately 2.45 mg/L were associated with maximal antifungal effect against all 
isolates, well within the therapeutic range suggested by these clinical studies for the 
treatment of IFIs. Although, it is important to note that analyses performed by Troke 
et al. did not distinguish between the pathogenic causes of IFIs, which may be a key 
determinant of patient response to voriconazole therapy. 
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Indication Lower Limit 
(mg/L) 
Upper Limit 
(mg/L) 
Reference 
Treatment ≤ 1.17 ≥ 5 (Dolton, Ray et al. 
2012) 
Treatment ≤ 1 ≥ 5.5 (Pascual, Calandra 
et al. 2008) 
Treatment ≤2 ≥5 (Troke, Hockey et 
al. 2011) 
Treatment ≤2 ≥10 (Denning, Ribaud 
et al. 2002) 
Treatment ≤2 ≥6 (Ueda, Nannya et 
al. 2009) 
Table 4. 8 
Table to describe the upper and lower limits of plasma trough levels best associated with 
efficacy and toxicity for voriconazole derived from clinical datasets for the treatment of 
IFIs. 
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Due to the scarcity of both preclinical and clinical PK-PD datasets available 
for voriconazole therapy against S. apiospermum there are no clinical breakpoints set 
(Tortorano, Richardson et al. 2014). Therefore little is known about the optimum 
treatment of resistant infections within this species.  This model is able to generate 
voriconazole exposures comparable to those seen in the clinic, a marked limitation of 
murine studies (Andes, Marchillo et al. 2003, Mavridou, Bruggemann et al. 2010). 
The ability of this model to link clinically relevant drug levels to disease progression 
using a novel biomarker as a measure of disease progression is a clear advancement 
in the study of PK-PD relationships for agents against S. apiospermum. Although there 
is no defined association between dosage and plasma voriconazole concentrations in 
humans, a knowledge of the optimal AUC and trough levels associated with the 
successful treatment of these infections may guide clinicians in predicting therapeutic 
failure and the need for dosage escalation. This may be particularly helpful for the 
definition of PK-PD relationships between voriconazole and resistant isolates of S. 
apiospermum, to further our understanding of the potential susceptibility breakpoints 
for these organisms. 
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5.42 Models of F. solani 
5.421 Static models of the human alveolus  
For the treatment of F. solani infection, static studies demonstrated that 
concentrations of ≥16 mg/L were insufficient for the complete suppression of antigen 
using a cut off value of 0.1. Maximum absorbency values in untreated transwells for 
each of these experiments were all around 1.5 suggesting that in a static setting these 
isolates of F. solani were able to invade through the cellular bilayer, consistent with 
the in vivo pathogenicity of invasive fusariosis. This similarity in maxima also 
suggests that each fungal isolate may exhibit a similar release of antigen. A relatively 
small dynamic range is observed for this assay, more so than the assay used for the 
tracking of Scedosporium spp. This may be due to the lack of a biotin amplification 
step for this assay leading to a decreased sensitivity for the detection of antigen. 
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5.422 Dynamic models of the human alveolus 
Throughout dynamic experiments the kinetics of antigen release in untreated 
circuits by ELISA were variable. For isolate CNM-6951 increasing absorbance values 
were obtained in both experiments up to 60 hours suggesting an accumulation of 
antigen up to this time point. However, antigen levels seem to decline from this time 
onwards. This may be due to a number of factors. This isolate of F. solani may cease 
to produce antigen over prolonged periods of time or degradation of the antigen may 
occur, causing a decline in antigen through the clearance mechanism set by the model. 
Alternatively, this may be related to a decline in fungal burden within the system, in 
which case the fungi may have entered a stationary phase of growth similar to that 
seen in bacterial cultures and existing cultures are cleared. For isolate CNM-7328 a 
noticeably lower maxima is observed in untreated circuits, whilst drug exposed 
circuits followed a similar dose-response pattern to CNM-6951. It has been 
demonstrated with F. oxysporum that a large amount of glucose is necessary for 
maximum efficiency of the initial growth phase to occur. It also is known that glucose 
consumption of fungi varies between both species and strains through the expression 
of glucose transporters (Srivastava, Pathak et al. 2011). It may be that the medium 
used in this model was not suitably glucose-rich or that replenishment was not 
sufficient in order to support the optimal growth of this isolate under flow conditions.   
Clinically relevant exposures of voriconazole were achieved. Predicted 
AUC48-72 values of approximately 64.9 and 85.2 and median trough values of 
approximately 2.41 mg/L were required to maximally suppress the antigen for isolates 
CNM-6951 and CNM-7328 respectively. These exposures are consistent with those 
achieved in experiments using S. apiospermum demonstrating the reproducibility of 
this model for the assessment of voriconazole pharmacokinetics. TDM studies suggest 
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that median trough concentrations of approximately 2- 5.5 mg/L are associated with 
maximal clinical outcome suggesting that the currently derived upper and lower limits 
associated with maximal voriconazole efficacy for the treatment of general IFIs may 
be encompassing of F. solani. (Pascual, Calandra et al. 2008, Myrianthefs, 
Markantonis et al. 2010, Dolton, Ray et al. 2012).  
Isolate CNM-7328 appeared to be more susceptible to voriconazole at lower 
concentrations in this dynamic model compared to values obtained for MIC and static 
experiments. This supports the argument that the growth of this isolate in a dynamic 
setting may not have been fully representable of a severe invasive infection. This is 
further demonstrated by the low predicted AUC:MIC values associated with treatment 
success in this model of 14.3 compared to those predicted for S. apiospermum. 
The work presented in this chapter describes the development of novel in 
vitro models of invasive scedosporiosis and fusariosis using the detection of surface 
antigens as a measure of disease progression and response to therapy. This model 
achieves clinically relevant drug exposures of voriconazole and can be sampled 
frequently to obtain a detailed pharmacokinetic dataset, a clear advantage over 
murine models. This, alongside the establishment of a model of invasive disease for 
which eradication can be directly linked to drug exposure represents a potential 
platform for the investigation of the PK-PD relationships for novel antifungal agents 
against these rare and under-studied organisms. In turn, PK-PD datasets generated 
using this system may help to develop optimal dosing strategies that may be taken 
forward to clinical trial. 
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CHAPTER V 
The Pharmacokinetics and 
Pharmacodynamics of Novel Orotomide, 
F901318, against isolates of Scedosporium 
apiospermum and Fusarium solani 
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5.1 INTRODUCTION 
The discovery and development of novel classes of antifungal agents has been 
a great challenge over the past decades. The interest from big pharma in the 
development of antimicrobials with novel targets has diminished due to lack of 
financial incentive. Therefore, small biotechnology companies have become the main 
contributors towards the discovery of novel antimicrobial agents. The orotomide class 
of agents are a novel class of antifungals. F901318 is the first and most advanced agent 
of the orotomides and is currently in Phase I of clinical development with F2G Ltd. 
F901318 was discovered via the screening of a 370,000 compound library for 
antifungal activity against A. fumigatus. Its primary target was determined to be the 
dihydroorotate dehydrogenase (DHODH) enzyme. The role of DHODH in the de novo 
biosynthesis of pyrimidines is well characterised in both humans and fungi. It is 
responsible for the conversion of dihydroorotate to orotate. As fungi such as 
Aspergillus spp. cannot salvage pyrimidines from their environment, the de novo 
biosynthesis pathway is the sole source of pyrimidines for these pathogens (Figure 
1.7). Specificity of F901318 for fungal DHODH has been demonstrated and the agent 
exhibits a very poor inhibition of the human enzyme. The mechanism of F901318 is 
reversed in the presence of pyrimidine compounds however this is only at high 
concentrations of >5mM of which only a small fraction is present in human serum 
(Oliver, Law et al. 2015). F901318 also demonstrates in vitro activity against S. 
apiospermum and other species within its species complex (Fothergill, Wiederhold et 
al. 2015). 
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F901318 demonstrates in vitro activity against S. apiospermum and other species 
within the Scedosporium- Pseudallescheria species complex, as well as F. solani 
(Fothergill, Wiederhold et al. 2015, Fothergill, Law et al. 2016). Phase I data also 
suggests F901318 is safe and well tolerated at the dosages given in its first single 
ascending dose study in humans (Kennedy, Allen et al. 2015). An understanding of 
the pharmacokinetics and pharmacodynamics of novel agents such as F901318 may 
provide a valuable insight into the effective dosages and regimens to further study in 
clinical trials. The use of PK-PD is now a mandatory component of regulatory 
portfolios, and a critical tool that enables more streamlined approaches to the 
development of new antimicrobial agents (Rex, Eisenstein et al. 2013). 
This chapter describes the use of previously described static and dynamic in 
vitro models of invasive scedosporiosis and fusariosis to facilitate an understanding 
of the exposure- response relationships for F901318 against isolates of S. 
apiospermum and F. solani. 
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5.2 METHODS 
The isolates of Pseudallescheria, Scedosporium and Fusarium spp. used are detailed 
in Chapter IV (Section 4.21). Methods for the culture of organisms, inoculum preparation, the 
set -up of static and dynamic models of invasive scedosporiosis and fusariosis and the 
analysis of pharmacodynamics samples by ELISA are described in Chapter IV (Sections 
4.21, 4.23, 4.24, 4.27 respectively). 
5.21 In vitro susceptibility testing 
Minimum inhibitory concentrations (MIC) for F901318 against S. apiospermum and F. 
solani isolates were determined in 5 independent experiments using both the European 
Committee for Antimicrobial Testing (EUCAST) and Clinical Laboratories Standards Institute 
(CLSI) methodologies. Concentrations for MIC testing ranged from 0.006 mg/L to 4 mg/L for 
F901318.  The modal value, range and geometric mean were determined.  The mode was used 
in the pharmacodynamic analyses for the determination of AUC:MIC values. 
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5.21 Construction of the dynamic model 
The construction of the circuitry comprising the dynamic model is described in 
Chapter II (Section 2.251). The locations of sampling ports are detailed below (Figure 5.2). 
 
 
  
F901318 
Cap of bioreactor 
Transwell 
O- ring 
Media in Media out 
Central 
reservoir 
Drug-free 
media 
Waste 
A 
B PK sampling PD sampling 
Figure 5. 1 The set-up of the dynamic in vitro model of the human alveolus 
specific for F901318 against S. apiospermum and F. solani. 
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5.22 Treatment with F901318 
F901318 pure powder was dissolved in DMSO. Dilutions were prepared from known 
stock concentrations in DMSO in order to achieve the required concentrations for each dynamic 
system. For Scedosporium experiments, the drugs were administered directly into the central 
compartment as a 100 µL bolus. F901318 dosages were selected in order to obtain exposures 
of sub-MIC level (0.00025 mg, 0.0005 mg), the approximate MIC for isolate 8353 (0.001mg) 
and approximately 4 x supra- MIC (0.05 mg) as multiples of the MIC are routinely used in the 
assessment of antimicrobial activity (Pfaller, Sheehan et al. 2004). Dosages of 0 mg, 0.00025 
mg, 0.0005 mg, 0.001 mg and 0.05 mg were administered every 12 hours to the central 
compartment of each corresponding circuit. For Fusarium experiments, dosages of 0 mg, 0.1 
mg, 0.2 mg, 1 mg and 3 mg were administered as four hour infusions every 12 hours to the 
central compartment of each corresponding circuit. F901318 was administered directly to the 
central compartment of the relevant circuits. Pump speeds for controlling the clearance of drug 
were set in order to simulate a half-life of approximately 4-5 hours, similar to that observed in 
monkey PK studies.  The pump connected to the fresh media and the waste Durans was run at 
a speed of 4.5rpm corresponding to a flow rate of approximately 24mL/hour. Pump speeds 
were calculated using clearance data published by the pump manufacturer. Pharmacokinetic 
sampling regimens were optimised using data obtained from preliminary dynamic 
pharmacokinetic models (data not shown).  
5.23 Mass spectrometry 
Mass spectrometry for pharmacokinetic analysis was performed by Joanne Goodwin 
and Sarah Whalley at the University of Liverpool. 
F901318 concentrations were determined using a UHPLC/MS-MS triple-quadrupole 
6420 mass spectrometer, (Agilent Technologies, Santa Clara, CA, USA). Instrument 
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parameters were optimized for F901318 (499.1 → 172.0 m/z).  F901318 were extracted from 
DMEM media using acetonitrile and methanol (Fisher Scientific, Loughborough, UK) with IS. 
HPLC separation was achieved using a Zorbax Eclipse Plus Rapid 1.8 µm C18 50 x 2.1 mm 
(Agilent Technologies, Santa Clara, CA, USA) column. The mobile phase consisted of 0.2% 
formic acid in water and 0.2% formic acid in acetonitrile at a flow rate of 0.5 ml/min, the 
column was maintained at 40 °C. 6, 7-Dimethyl-2,3-di(2-pyridyl) Quinoxaline (Sigma Aldrich, 
Dorset, UK ) 100 ng/ml in methanol:acetonitrile (50:50) was used as an internal standard. The 
chromatographic run time for one sample was 2.5 minutes. The lower limit of quantitation of 
F901318 was 0.0005 mg/L. Intraday and interday coefficients of variation were <14.7% at 
concentrations ranging from 0.0005 to 5 mg/L. 
5.24 Mathematical Modelling 
A population methodology was used in order to fit a mathematical model to the data 
from each isolate.  Version 1.2.9 of Pmetrics PK-PD analytical software was used. For 
pharmacodynamic datasets, data were normalised to a maxima of 1 due to variability in 
maximum PD values obtained in control circuits between isolates. For Scedosporium datasets 
the structural mathematical model consisted of the following two inhomogeneous ordinary 
differential equations: 
 
dX1/dt= B(1)-(SCL/Vc)*X1    Equation 1 
dN/dt=Kgmax*(1-(N/POPMAX))*N  Equation 2a 
*(1-(X1/Vc)Hg/(X1/Vc)Hg+C50gHg))    Equation 2b 
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Where: B(1) is the bolus input of is the bolus input of F901318, SCL is the clearance of drug  
from the circuit, Vc  is the volume of the circuit, N is the antigen concentration, Kgmax is the 
maximal rate of growth; POPMAX is the theoretical maximal density within the circuit; Hg is 
the slope function for the suppression of growth; and, C50g is the concentration of drug in the 
circuit where there is half-maximal suppression of growth. 
Equation 1 describes the rate of change of drug concentrations in the circuit.  Equation 2 
describes the rate of change of antigen in the circuit and contains terms that describe fungal 
growth in the absence of drug (Equation 2a) and the drug induced suppression of growth 
(Equation 2b). 
 The structural model for the analysis of Fusarium datasets was identical to that 
described earlier, with the exception that in Equation 1. a RATEIV expression is used to 
describe the infusion of drug as opposed to a bolus input (Equation 1b).  
dX1/dt= -RATEIV(1)-(SCL/VC)*X1    Equation 1(b) 
 
The models were fitted to the dataset of untreated and treated circuits obtained from 
each isolate.  Each circuit was treated as an “individual”. The fit of the model was assessed 
using the coefficient of determination (r2) from a linear regression of the observed vs. predicted 
plots for both population and individual predictions, the mean and median values of parameters 
predicted by the model compared to those observed experimentally and the log likelihood.    
The Bayesian posterior estimate for each of the parameters in the model was then used to define 
the concentration-time profile of F901318 and the resultant effect on antigen concentrations. 
As no data on the PD indices best associated with antifungal efficacy were available at the 
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time, these parameter estimates were used to estimate the AUC that developed in each circuit 
and the AUC:MIC ratios. 
  
187 
 
5.3 RESULTS 
5.31 Minimum Inhibitory Concentrations 
The minimum inhibitory concentrations (mode, range and geometric mean) for voriconazole 
against isolates of S. apiospermum, P. boydii and F. solani are presented in Table 5.1. 
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EUCAST CLSI 
Drug Species Isolate Mode Range Mean Mode Range Mean 
F901318 S. apiospermum 8353 0.06 0.06-0.06  0.06 0.03 0.03-0.03 0.03 
F901318 S. apiospermum 6322 0.125 0.06-0.125  0.107 0.06 0.06-0.06 0.06 
F901318 S. apiospermum 6386 0.125 0.125-0.125  0.125 0.06 0.06-0.06 0.06 
F901318 P. boydii 7935 0.5 0.5-0.5 0.5 0.015 0.015-
0.015 
0.015 
F901318 P. ellipsoidea 13144 0.03  0.03-0.03 0.03 0.015 0.015-
0.015 
0.015 
F901318 F. solani CNM-
6951 
8 4-8 6.06 2 1-2 1.5 
F901318 F. solani CNM-
7328 
0.12 0.06-0.125 0.09 0.015 0.015-0.03 0.019 
Table 5. 1 
Minimum inhibitory concentrations were determined in 5 independent experiments. Means displayed above are geometric means. 
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5.32 Scedosporium apiospermum models 
5.321 Static models of the human alveolus 
The exposure- response relationships for F901318 are described in Figures 5.2. Antigen 
detection was consistent for samples obtained from the static models however some variability 
is observed between both species and strain. Maximum absorbance values of 1-1.5 were 
obtained from inserts infected with S. apiospermum and P. boydii that were untreated or 
exposed to low doses of drug. A slightly lower maximum of approximately 0.8 was achieved 
for the isolate of P. ellipsoidea. For S. apiospermum 6322 and 6386 variability in data obtained 
from the alveolar compartment can be seen. For F901318 a concentration-dependent inhibition 
of antigen release was observed for isolates of S. apiospermum, P. boydii and P. ellipsoidea. 
For the endothelial compartments a clear exposure response relationships are defined. 
Concentrations of 0.5 mg/L and 0.125 mg/L were sufficient to achieve maximal suppression 
of antigen for S. apiospermum strains 8353 and 6386 respectively. For isolate 6322 maximal 
suppression of antigen was not achieved even at the highest concentration. Concentrations of 
0.5 mg/L and 0.0125 mg/L were sufficient to suppress antigen release for isolates of P. boydii 
and P. ellipsoidea. The concentrations required to suppress antigen release were higher for the 
alveolar compartment than for the endothelial compartment in all experiments. 
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Figure 5. 2 
Pharmacokinetics and pharmacodynamics of F901318 in a static model against S. apiospermum 8353 (A), 6322 (B), 
6386 (C) , P. boydii 7935 (D) and P. ellipsoidea 13144 (E).  
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5.322 Dynamic models of the human alveolus 
The exposure-response relationships of F901318 and S. apiospermum were defined for 
all three clinical isolates (Figures 5.3-5.5). There were differences in the PK-PD relationships 
between isolates. Trough concentrations within the range of 0.02 mg/L- 0.05 mg/L were 
sufficient to maximally suppress antigen release for isolates 8353 and 6322 using a cut-off 
value of 0.1. These concentrations are consistent with the MICs obtained in this study using 
CLSI methodology. Much lower concentrations of 0.0006 mg/L were able to successfully 
suppress the breakthrough of antigen for strain 6386. A minimal amount of breakthrough was 
observed at 108 hours post inoculation when exposed to these concentrations for strains 8353 
and 6322. 
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Figure 5. 3 Pharmacokinetics and pharmacodynamics of F901318 against S. 
apiospermum isolate 8353. 
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Figure 5. 4 Pharmacokinetics and pharmacodynamics of F901318 against S. apiospermum 
isolate 6322. 
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Figure 5. 5 Pharmacokinetics and pharmacodynamics of F901318 against S. 
apiospermum isolate 6386. 
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6.323 Mathematical modelling 
 
The fit of the mathematical model to the data was acceptable (Figure 5.6).  The fit of 
the Bayesian posterior estimates for each circuit is shown in Figures 5.3-5.5. Median posterior 
parameter estimates for each model can be seen in Table 5.2. Predicted AUC72-96 values 
(mg.hr/L) for F901318 and total AUC for the antigen are displayed in Table 5.3. 
 
 
196 
 
 
  
Figure 5. 6 
Observed vs predicted graphs after the Bayesian step, generated using Pmetrics for (A) pharmacokinetics data from 15 individual 
circuits and (B) pharmacodynamics data as measured by antigen from 15 individual circuits. 
A B 
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Isolate Dosage 
(mg) 
Cl 
(L/hr) 
V (L) Kgmax POPMAX C50 Hg IC1 
8353 0 0.04 0.30 0.03 1.99 0.00 7.26 0.05 
8353 0.00025 0.03 0.30 0.06 1.99 0.00 5.31 0.00 
8353 0.0005 0.04 0.30 0.03 1.99 0.00 7.32 0.06 
8353 0.001 0.04 0.30 0.03 1.99 0.00 7.32 0.06 
8353 0.05 0.04 0.30 0.03 1.99 0.00 7.31 0.06 
6322 0 0.03 0.30 0.06 1.99 0.00 5.28 0.00 
6322 0.00025 0.03 0.30 0.06 1.99 0.00 5.31 0.00 
6322 0.0005 0.03 0.30 0.03 1.99 0.00 5.32 0.02 
6322 0.001 0.04 0.30 0.03 1.99 0.00 7.32 0.05 
6322 0.05 0.04 0.28 0.03 1.99 0.00 7.34 0.05 
6386 0 0.04 0.30 0.03 1.99 0.00 7.27 0.05 
6386 0.00025 0.04 0.30 0.03 1.99 0.00 7.33 0.06 
6386 0.0005 0.04 0.30 0.03 1.99 0.00 7.30 0.05 
6386 0.001 0.04 0.30 0.03 1.99 0.00 7.32 0.06 
6386 0.05 0.04 0.30 0.03 1.99 0.00 7.31 0.06 
Table 5. 2 
The median posterior parameter estimates from the mathematical model using data from 15 individual circuits. Cl represents the 
estimated clearance of F901318 from the ciruit; V; the estimated volume of the central compartment; Kgmax, the predicted rate of 
growth of S. apiospermum in the circuit; POPMAX, the maxima obtained from the ELISA assay; C50, the concentration of F901318 
that 50% suppression of antigen is obtained; Hg, the slope function to describe S. apiospermum growth in both absence and presence of 
drug; IC1, the initial conditions for the pharmacodynamic dataset, representing background noise of the assay. 
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Strain Dose (mg/ q12) Predicted AUC72-96 
F901318 
 (mg.hr/L) 
Predicted AUC0-
96 antigen 
S. apiospermum 8353 0 0 23.59 
0.00025 0.019 13.78 
0.0005 0.026 13.34 
0.001 0.051 6.97 
0.05 2.559 5.64 
S. apiospermum 6322 0 0 15.69 
0.00025 0.019 13.84 
0.0005 0.030 9.25 
0.001 0.051 6.69 
0.05 2.560 6.28 
S. apiospermum 6386 0 0 23.61 
0.00025 0.013 24.75 
0.0005 0.026 12.40 
0.001 0.051 6.97 
0.05 2.559 5.64 
 
 
 
Table 5. 3 
Model predicted F901318 AUC72-96 for isolates of S. apiospermum for individual circuits 
achieved using the dynamic model. 
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Figure 5. 7 
Total AUC for Scedosporium specific antigen detected at 450nm, versus AUC72-96 for 
F901318 (mg.hr/L). Equations were generated in ADAPT 5 using the maximum 
likelihood estimator. 
AUCantigen = 22.58-(17.30*(AUC)^2.912)/((AUC)^2.912+0.02177^2.912) 
R2= 0.872 
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Figure 5. 8 
Total AUC for Scedosporium specific antigen detected at 450nm, versus F901318 AUC72-
96: MIC (EUCAST methodology). Equations were generated in ADAPT 5 using the 
maximum likelihood estimator. 
AUCantigen = 20.99-(15.89*(AUC:MIC)^1.862)/((AUC:MIC)^1.862+0.2405^1.862) 
R2= 0.780 
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5.33 Fusarium solani models 
5.331 Static models of invasive fusariosis 
The exposure- response relationships for F901318 are described in Figures 5.9. Antigen 
detection was consistent for samples obtained from the static model. Maximum absorbance 
values of approximately 1.5 were obtained from the alveolar compartments of inserts infected 
with F. solani that were untreated or exposed to low doses of drug. Slightly lower maximum 
absorbencies of approximately 0.8-1 were achieved from samples obtained from the 
endothelial compartment. F901318 demonstrated a similar concentration-dependent inhibition 
of antigen release was observed for both isolates of F. solani. For the endothelial compartments 
clear exposure response relationships are defined however only the top concentrations of 5 
mg/L were sufficient to maximally suppress antigen release for both strains. The concentrations 
required to suppress antigen release were higher for the alveolar compartment than for the 
endothelial compartment in all experiments. 
Figure 5. 9 
Pharmacokinetics and pharmacodynamics of F901318 in a static model against F. solani 
isolates 6951 (A) & 7328 (B).   
A B 
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5.332 Dynamic models of invasive fusariosis 
The exposure-response relationships of F901318 against F. solani were defined for both 
clinical isolates. There were differences in the PK-PD relationships between isolates. In this 
dynamic model, trough concentrations within the range of 1 mg/L- 2 mg/L and Cmax 
concentrations of around 4 mg/L, estimating an AUC0-24-:MIC ratio of approximately 14 
(Figure 5.10 I&J, Table 5.5) is sufficient to maximally suppress antigen release for isolate 
CNM-6951 using a cut-off value of 0.1 to describe complete antigen suppression. Cmax and 
trough concentrations of approximately 1.2 mg/L and 0.2 mg/L- 0.4 mg/L respectively equating 
to an AUC:MIC value of approximately 3 (Figure 5.11 G-H, Table 5.5) were sufficient to 
maximally suppress antigen release for isolate CNM-7328 in this model. A minimal amount of 
breakthrough was observed at 96 hours post inoculation when exposed to these concentrations 
for both strains. 
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Figure 5. 10 Pharmacokinetics and pharmacodynamics of F901318 against F. solani 
CNM-6951. 
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Figure 5. 11 Pharmacokinetics and pharmacodynamics of F901318 against F. solani 
CNM-7328. 
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6.333 Mathematical modelling 
The fit of the mathematical model to the data was acceptable (Figure 5.12).  The fit of the 
Bayesian posterior estimates for each circuit is shown in Figures 5.10-5.11. Median posterior 
parameter estimates for each model can be seen in Table 5.4. Predicted AUC48-72 values 
(mg.hr/L) for F901318 and total AUC for the antigen are displayed in Table 5.6. 
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Figure 5. 12 
Observed vs predicted graphs for F901318 versus F. solani after the Bayesian step, generated using Pmetrics for (A) 
pharmacokinetics data from 10 individual circuits and (B) pharmacodynamics data as measured by antigen from 10 individual 
circuits. 
A B 
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Isolate Dosage 
(mg) 
Cl 
(L/hr) 
V (L) Kgmax POPMAX C50 Hg IC1 
CNM-6951 0 0.09 0.75 0.06 1.59 0.02 24.09 0.02 
CNM-6951 0.1 0.14 1.81 0.05 1.39 0.09 3.01 0.05 
CNM-6951 0.2 0.09 0.38 0.06 6.97 0.22 14.81 0.01 
CNM-6951 1 0.12 0.86 0.06 1.60 0.01 29.84 0.02 
CNM-6951 3 0.09 0.74 0.06 1.59 0.02 23.95 0.02 
CNM-7328 0 0.14 0.92 0.03 6.97 0.10 22.04 0.01 
CNM-7328 0.1 0.28 1.67 0.04 6.97 0.86 11.86 0.01 
CNM-7328 0.2 0.14 0.91 0.03 6.96 0.10 22.19 0.01 
CNM-7328 1 0.14 0.92 0.03 6.97 0.10 22.18 0.01 
CNM-7328 3 0.28 1.67 0.04 6.97 0.86 11.86 0.01 
Table 5. 4 
The median posterior parameter estimates from the mathematical model using data from 10 individual 
circuits.. Cl represents the estimated clearance of F901318 from the circuit; V; the estimated volume of the 
central compartment; Kgmax, the predicted rate of growth of F. solani in the circuit; POPMAX, the maxima 
obtained from the ELISA assay; C50, the concentration of F901318 that 50% suppression of antigen is 
obtained; Hg, the slope function to describe F. solani growth in both absence and presence of drug; IC1, the 
initial conditions for the pharmacodynamics dataset, representing background noise of the assay. 
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Strain Dose (mg/ q12) Predicted AUC48-72 
F901318 
 (mg.hr/L) 
Predicted AUC0-
72 antigen 
F. solani CNM- 
6951 
0 0 3.275 
0.1 0.73 2.90 
0.2 2.96 1.50 
1 14.74 0.95 
3 21.78 1.20 
F. solani CNM- 
7328 
0 0 17.81 
0.1 1.36 17.90 
0.2 4.67 2.79 
1 17.20 1.52 
3 69.86 1.45 
Table 5. 5 
Model predicted F901318 AUC48-72  and area under antigen curves (0-72) for individual 
circuits achieved using the dynamic model. 
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Figure 5. 13 
Total AUC for Fusarium specific antigen detected at 450nm, versus AUC48-72  for 
F901318 (mg.hr/L). Equations were generated in ADAPT 5 using the maximum 
likelihood estimator. 
AUCantigen= 17.68-(16.69*(AUC)^3.645)/((AUC)^3.645+2.263^3.645) 
R2= 0.353 
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Figure 5. 14 
Total AUC for Fusarium specific antigen detected at 450nm, versus F901318 AUC48-
72:MIC (EUCAST methodology). Equations were generated in ADAPT 5 using the 
maximum likelihood estimator. 
AUCantigen = 17.8-(16.69*(AUC:MIC)^3.280)/((AUC:MIC)^3.280+16.74^3.280) 
R2= 0.055 
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5.4 CONCLUSIONS 
Scedosporium spp. and Fusarium spp. are emerging fungal pathogens. Invasive 
diseases with these organisms have high mortality rates owing to a lack of treatment options. 
The development pipeline for novel antifungal agents targeting novel molecular mechanisms 
is severely lagging the clinical need for new drugs to treat these infections.   
F901318 is a novel antifungal agent and is the most advanced member of the orotomide 
class of agents. F901318 demonstrates in vitro and in vivo efficacy against both wild-type and 
triazole resistant isolates of A. fumigatus (Beckmann, Binder et al. 2015, Fothergill, 
Wiederhold et al. 2015, Law, Oliver et al. 2015). The preclinical and clinical pharmacokinetic 
data from phase I studies suggest a favourable ADME profile for this agent and the agent 
appears well tolerated (Kennedy, Allen et al. 2015). Although primarily developed for the 
treatment of invasive aspergillosis, F901318 also demonstrates potent in vitro activity against 
isolates of S. apiospermum and F. solani (Fothergill, Wiederhold et al. 2015, Fothergill, Law 
et al. 2016). The diagnosis of invasive scedosporiosis and fusariosis is challenging. The 
histopathological and morphological characteristics of these fungi are often indistinguishable 
from those of other moulds such as Aspergillus spp. There are currently no clinically validated 
biomarkers for the diagnosis of these fatal diseases. The development of novel platforms for a 
quick and accurate diagnosis alongside an optimised portfolio of therapeutics could greatly 
improve the clinical outcomes of invasive infections with these rare species.  
This investigation presents an in vitro PK-PD dataset for novel antifungal agent, 
F901318 against three isolates of S. apiospermum and two isolates of F. solani. Novel 
methodologies for the detection of membrane- expressed antigens specific to Scedosporium 
and Fusairum spp. were used as a measure of disease progression. 
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5.41 F901318 against isolates of S. apiospermum 
 Static studies demonstrate defined dose-response relationships for F901318 and isolates 
of S. apiospermum, P. boydii and P. ellipsoidea. There are pharmacodynamic differences 
between the isolates. One isolate of S. apiospermum demonstrated persistent growth even in 
the presence of the highest concentration of drug used. This is not in proportion to the MIC of 
0.125 mg/L or data obtained from dynamic studies for this isolate. This is also the case for S. 
apiospermum 8353 for which an MIC of 0.006 mg/L is reported however maximal suppression 
of antigen is not achieved at dosages <0.5 mg/L in the static model. 
The pharmacodynamic behaviour of S. apiospermum in untreated controls is similar to 
that seen in in voriconazole experiments demonstrating the reproducibility of this model in the 
assessment of novel antifungals. Isolates exhibit similar patterns of growth and a decreased 
susceptibility regardless of the agent used. As discussed in Chapter IV, starting inoculum is an 
important consideration when determining the severity of this model. A disease state too severe 
may counteract the antifungal effect of the agent used.  It is also important to note that in some 
experiments there is a variation in the antigen concentrations measured from the alveolar 
compartment of the models. This may again be due to the variable amount of fungi that is 
extracted when flooding the surface of the alveolar layer with PBS. Another explanation may 
be that a destruction of the cell layer in some transwells may have allowed the antigen to pass 
through the porous membrane into the endothelial compartment causing variable antigen 
concentrations in lavage samples. 
 Dynamic studies present a concentration dependent reduction in antigen when treated 
with F901318. Phase I single ascending dose trials demonstrate that F901318 is well tolerated 
in healthy volunteers receiving up to 4mg/kg of drug. This dosage corresponded to total AUCs 
of 38.04mg.hr/L over a 120 hour period in the clinic. In this dynamic model of scedosporiosis 
AUC72-96 values of approximately 2.55mg.hr/L were associated with a maximal antifungal 
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effect against all isolates of S. apiospermum, using a twice-daily dosing regimen of 0.05mg. 
Clinical exposures of F901318 may therefore have the potential to treat an invasive disease 
with these isolates. Hope et al. described the pharmacodynamics of F901318 in a murine model 
of aspergillosis. F901318 demonstrated time-dependent killing in this investigation. It is 
suggested that either T>MIC or Cmin: MIC may be the pharmacodynamic parameters that best 
predict in vivo efficacy. Cmin: MIC ratios of 10-30, corresponding to Cmin values of 
approximately 1 mg/L were associated with near maximal reduction in galactomannan in this 
study (Hope, Livermore et al. 2015). Dynamic studies suggest that isolates of S. apiospermum 
were readily treatable with F901318 trough levels of 0.02 mg/L- 0.05 mg/L. These estimates 
are markedly lower than those suggested for the treatment of aspergillosis from murine studies. 
This dynamic model simulates an early invasive disease and provides direct exposure of fungi 
to drug in the absence of immunological effectors which may explain the augmented antifungal 
effect seen here. It is also important to note that the pharmacodynamic study by Hope et al. 
used isolates of A. fumigatus that demonstrated a range of susceptibilities. Whereas the isolates 
of S. apiospermum studied here are largely representative of a susceptible population (Table 
5.1). There was a lesser correlation between the decline in antigen (total AUC) and the AUC 
of F901318 (R2 = 0.872) compared to that seen with voriconazole (R2 = 0.986), a known AUC 
driven drug. This association became weaker when the MIC was incorporated ie. the AUC:MIC 
(R2 = 0.78) suggesting that this pharmacodynamic parameter may not be predictive of 
antifungal effect in this model. This further supports that, consistent with PK-PD studies done 
in animals F901318 may exhibit time-dependent killing in this model. 
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6.42 F901318 against isolates of F.  solani 
Static studies demonstrated a clear concentration dependent decline in antigen upon 
exposure to F901318 against both isolates of F. solani. Concentrations of approximately 5 
mg/L were sufficient to suppress the antigen in this model. These findings in contrast to ≥16 
mg/L for voriconazole are encouraging for the potential use of F901318 to treat infections with 
isolates that are not susceptible to voriconazole using current dosing strategies. Maximum 
absorbency values in untreated transwells for each of these experiments were all around 1.5 
indicating successful invasion of F. solani through the cellular bilayer.  
In a dynamic setting, low absorbance values were obtained from untreated circuits using 
isolate CNM-7328. The low antigen levels detected in a dynamic setting using this isolate were 
consistent with voriconazole data and may be due to the incapacity of this isolate to grow in 
the absence of high amounts of glucose (Srivastava, Pathak et al. 2011). CNM-6951 antigen 
concentrations decline after 60 hours consistently between models. This may due to a reduced 
expression of the antigen at high fungal densities or clearance of the fungi by the model during 
a stationary phase of growth. 
As F901318 progressed from preclinical to clinical evaluation, data relating to the 
clinical dosing regimen had become available. In this model of fusariosis, F901318 was 
administered as a four-hour infusion twice-daily. Predicted AUC48-72 values of 14.74 and 17.20 
mg.hr/L, corresponding to total AUCs of 44.22 and 51.60 mg.hr/L, were associated with 
maximal antifungal effect against isolates 6951 and 7328 respectively in this model. These 
values are slightly higher than exposures seen in single ascending dose trials (38.04 mg.hr/L) 
at the highest dose administered suggesting that higher dosages or a different dosing regimen 
may be necessary for the treatment of F. solani invasive disease in the clinic.  
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The pharmacodynamic association between the AUC48-72 of F901318 and antifungal 
efficacy in this model was poor. Cmin values within the range of the respective MIC values were 
observed to suppress antigen release for both isolates suggesting the MIC may be a good 
predictor of dose response in these experiments. However, upon further analysis there was no 
relationship between the AUC:MIC and efficacy in this model (Figure 5.15, R2= 0.055) and a 
noticeably weakened association was seen compared to AUC alone (Figure 5.14, R2= 0.353). 
These pharmacodynamic analyses support that the AUC: MIC may not be an important 
predictor of antifungal effect for this agent. 
These analyses represent the first in vitro PK-PD dataset for novel antifungal agent, 
F901318, against isolates of S. apiospermum and F. solani. These models are able to link 
clinically relevant exposures to the pharmacodynamic behaviour of fungi whilst accounting for 
key interactions such as protein binding (eg. the use of 2% protein). Their use for the 
delineation of PK-PD relationships may be an important advancement in the assessment of 
novel antifungal agents and may provide a basis for the further investigation into the 
development of F901318 for the treatment of these rare and emerging mycoses.  This work 
also contributes towards a further understanding into the presentation and detection of the 
antigens described by Thornton et al. under flow conditions and may assist in their efforts to 
develop these assays as a clinical product. 
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CHAPTER VI 
General conclusions 
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The general aims of this thesis were comprised of two key components. Firstly, 
to develop in vitro models of invasive fungal infections that can successfully mimic the 
human PK of antifungal agents. Secondly, to refine these models for the establishment 
of key PK-PD relationships of new and existing agents that may guide the use of 
antifungal therapy in the clinic. 
The models simulated human-like PK of isavuconazole and voriconazole, a 
marked advantage over animal models using these agents. Furthermore, mathematical 
modelling provided a link between the dose-exposure (PK) and suppression of antigen 
(PD) in these models. This allowed for the estimation of the PD indexes associated with 
maximal antifungal efficacy, in terms of the AUC: MIC.  
PK-PD investigations for novel agents should be carried out in in vitro models 
such as those described, animal models and in patient populations. Datasets should be 
cross-validated for the recommendation of accurate PD targets. The bridging of 
experimental data to clinical populations using PK-PD simulation may help to delineate 
patient response to therapy to specific organisms provided the clinical datasets are 
sufficiently empowered. Clinical datasets describing the use of isavuconazole in patient 
populations are now available. The bridging of these experimental data may help to 
guide antifungal dosing for the potential individualisation of isavuconazole therapy in 
the future. A key limitation to these studies is the absence of immune- mediated 
suppression of organism. Therefore, the physiological response to disease and the 
resultant clearance of organism seen in humans is not accounted for. However, the 
absence of immune function allows for the direct estimation of antifungal suppression 
that can be attributed to drug. Another important consideration is the difference in 
protein levels that were used in the models compared to those present in humans (2% 
vs ~40. It would be necessary to incorporate the effect of protein binding into the 
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models when bridging to humans in order to properly translate the experimental 
findings into a clinical context. 
Limited data on the human PK of F901318 were available at the time of this 
study. It is therefore undetermined whether the exposures of drug achieved using these 
models are clinically relevant. The exposure-response relationships were defined at the 
dosages tested and contribute to our understanding of the minimum exposures that may 
be necessary to achieve in the treatment of invasive disease with S. apiospermum and 
F. solani. Whether these levels are exceeded in the clinic is yet to be determined. As 
only the highest dose of F901318 generated levels of drug that were above the MIC for 
any significant amount of time, dose- fractionation studies for the further investigation 
into the PD targets, in terms of the T>MIC, would be necessary. 
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